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ABSTRACT
IMPEDIMENTS TO THE HISTORICAL DEVELOPMENT OF THE CLINICAL PAP
TEST IN THE UNITED STATES: THEIR RELEVANCE IN OPTIMIZING CERVICAL
CANCER SCREENING IN THE STATE OF QATAR
Nikolaos Chantziantoniou, Ph.D.
University of Nebraska Medical Center, 2019
Supervisor: Amber D. Donnelly, Ph.D.
Three hundred surveys listing 31 questions were distributed amongst women
and men at Sidra Medicine, Doha, State of Qatar, to assess knowledge and perceptions
of: Cervical cancer (CxCa); preventive Pap test screening; Human Papilloma Virus
(HPV) vaccination; and, need for population-based screening. Survey questions
captured categorical statistical data through four categories: (1) Socio-demographic; (2)
Healthcare Services; (3) Health Literacy; and, (4) Self-efficacy and Perceptions.
Hypothesis 1: 12 survey questions pertaining to CxCa and Pap testing revealed 8
statistically-significant dependencies; notably, 70% of respondents were aware of CxCa;
however, 31.8% were unaware that CxCa may be curable; 33.7% were unaware of the
Pap test; and, 35.2% were unaware that HPV vaccination may protect against CxCa.
Hypothesis 2: Two survey questions pertaining to screening practice revealed no
statistically-significant dependencies; however, 67.4% of respondents strongly agreed for
establishment of population-based screening in Qatar. Hypothesis 3: Three salient
parallels were revealed between the Qatar and US clinical experiences: (1) Greater than
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60% of symptomatic women in Qatar presented with Stage II/III CxCa in 2014, relative to
60% of women in the US with inoperable disease before 1957; (2) Estimated CxCa death
rates in Qatar are 26.7%, relative to 32.2% in the US; and, (3) The burden of CxCa was
under-estimated prior to emergence of death registries and epidemiologic data in the US
in 1914 and 1952 respectively, relative to 2014 in Qatar.
Impediments to Pap test development and application in the US stemmed from
macro-dynamics (i.e., societal, economic, political situations); and, reactive microdynamics (i.e., professional conflicts, skepticism, conceptualization of cervical
precancer). Pap test screening practices in the State of Qatar may be optimized through:
(1) Tumor Registry for inclusion of precancer cases to ascertain actual CxCa incidence; (2)
Organized screening with initial call to screening for asymptomatic women deemed at risk; and,
(3) Reallocation of financial resources to support expanded screening for all women.

viii

TABLE OF CONTENTS
ACKNOWLEDGMENTS ............................................................................................................ i
ABSTRACT ..................................................................................................................................vi
TABLE OF CONTENTS.......................................................................................................... viii
LIST OF FIGURES ....................................................................................................................xvi
LIST OF TABLES ................................................................................................................... xviii
LIST OF ABBREVIATIONS .................................................................................................... xx
CHAPTER 1: INTRODUCTION AND DISSERTATION FUNDAMENTALS ............... 1
Introduction ............................................................................................................................... 1
Dissertation Fundamentals - Presumptions .......................................................................... 6
Dissertation Fundamentals - Literature Review ................................................................... 7
Dissertation Fundamentals - Aims And Hypotheses .......................................................... 7
Overarching Hypothesis ...................................................................................................... 8
Dissertation Aim 1 .................................................................................................................... 8
Hypothesis ............................................................................................................................. 9
Dissertation Aim 2 .................................................................................................................... 9
Hypothesis ............................................................................................................................. 9
Dissertation Aim 3 .................................................................................................................... 9
Hypothesis ........................................................................................................................... 10
CHAPTER 2: HISTORICAL IMPEDIMENTS TO THE DEVELOPMENT OF THE
CLINICAL PAP TEST ARISING FROM MACRO- AND MICRO-DYNAMICS IN
THE US ........................................................................................................................................ 11
Knowledge Of Foundational Events In Diagnostic Cytopathology ................................ 12
Impediments To The Development Of The Clinical Pap Test Arising From Historical
Macro-Dynamics ..................................................................................................................... 12
Cervical Cancer In The US In The Early-1900s ............................................................... 13
Detection Of Cervical Cancer In The Early-1900s .......................................................... 14
Establishment Of The American Society For The Control Of Cancer ......................... 16
Linear Model Of Cervical Carcinogenesis ....................................................................... 17

ix

Mortality From Cancer And Other Malignant Tumors - In The Registration Area Of
The United States 1914 ....................................................................................................... 18
Cancer In The US And Impact Of The Great Depression.............................................. 20
Cervical Cancer Burden In The US In The 1930s ............................................................ 22
The Women’s Field Army .................................................................................................. 25
The National Cancer Act Of 1937 ..................................................................................... 29
Rebranding Of The American Society For The Control Of Cancer Into The American
Cancer Society ..................................................................................................................... 31
Death Of Henrietta Lacks To Cervical Cancer: The HeLa Cell Line ............................ 34
The Memphis And Shelby County, Tennessee, Trial For Cervical Carcinoma In Situ
............................................................................................................................................... 37
The American Cancer Society At 75: Despair To Hopefulness, And Cancer
Prevention ............................................................................................................................ 40
The American Cancer Society At 100: Increasing Life Expectancy In The US, And
Burden Of Cervical Cancer ................................................................................................ 40
Impediments To The Development Of The Clinical Pap Test Arising From Historical
Micro-Dynamics ...................................................................................................................... 42
Dr. George N. Papanicolaou: PhD Research, Employment At Cornell Medical
College, New York .............................................................................................................. 42
Development Of The Experimental Vaginal Fluid Smear Method In Lower
Mammals (1915-1920) ......................................................................................................... 46
Transformation Of The Experimental Vaginal Fluid Smear Method Into The Clinical
VFSM In Women (1920-1948) ............................................................................................ 48
The Clinical Pap Test (1948 Henceforth).......................................................................... 62
Screening Principles And World Health Organization Targets ................................... 72
Sequential (Two-Stage) Testing Model For Cervical Cancer Prevention Through
Screening .............................................................................................................................. 74
Promotion And Endorsement Of Pap Test Screening In The US ................................. 76
Dr. George N. Papanicolaou: Personal Letters, Character, Aspirations, And
Professional Conflicts ......................................................................................................... 78
Dr. George N. Papanicolaou: Dyskaryotic Cells Pathognomonic Of Cervical
Precancer .............................................................................................................................. 81
Divides Of Authority Between Papanicolaou’s Experimental Work And Clinical
Practice.................................................................................................................................. 82
Salient Impediments To The Development Of The Clinical Pap Test In The US,
Categorized And Stratified For Two Salient Timeframes: 1928-1941 And 1941-1957... 86
Evolutionary Timeframes Of Pap Test Development .................................................... 86

x

Tables Summarizing The Salient Historical Impediments ............................................ 87
CHAPTER 3: CERVICAL CANCER BURDEN, EPIDEMIOLOGICAL EXPERIENCE,
CLINICAL PAP TEST UPTAKES, AND HEALTH PROMOTION IN THE STATE OF
QATAR ........................................................................................................................................ 97
Pap Test Uptakes In The Extended Middle East And North Africa Region .................. 97
Global Cervical Cancer Burden............................................................................................. 99
Cervical Cancer Burden In Resource-Poor, Developing Global Regions ................... 99
Cervical Cancer Burden In The US ................................................................................. 100
Cervical Cancer Burden And Management In The State Of Qatar ................................ 100
Accessing Pap Test Sampling In The State Of Qatar ................................................... 102
Current Pap Test Uptake Practice In The State Of Qatar ............................................ 103
Cervical Cancer Epidemiology In The State Of Qatar ..................................................... 104
Cervical Cancer Rates In The State Of Qatar................................................................. 104
Cervical Cancer Registry, Presentation, And Diagnosis In The State Of Qatar ....... 104
Cervical Cancer Health Literacy And Healthcare Promotion In The State Of Qatar .. 106
Sidra Medicine Symposium: The 1st Century Of Gynecological Cytopathology, The
Pap Test – Then, Now And The Future ......................................................................... 106
Guidelines For Cervical Cancer Screening In The State Of Qatar .............................. 106
Guideline For Suspected Cancer Referral In The State Of Qatar ............................... 107
Qatar Cancer Society Awareness Campaign For Cervical Cancer: “Be Well” ......... 109
National Health Strategy 2018-2022 ............................................................................... 110
National Clinical Guidelines For The State Of Qatar (2nd Edition) ............................ 110
Qatar Ministry Of Public Health Infographic: “What Is Cervical Cancer?” ............. 111
HPV Vaccination Protection In The State Of Qatar...................................................... 111
Opportunities For Healthcare Promotion Research ..................................................... 112
CHAPTER 4: NEEDS-ASSESSMENT SURVEY MATERIALS AND METHODS...... 114
Preceding Survey-Based Research In The State Of Qatar ............................................... 114
Needs-Assessment Survey Design ..................................................................................... 115
Needs-Assessment Survey Questions, Responses, And Rationale ............................ 116
Needs-Assessment Survey Questions And Data Categories ...................................... 116
Needs-Assessment Survey Questions ............................................................................ 117
Question 1 .......................................................................................................................... 118
Question 2 .......................................................................................................................... 118
Question 3 .......................................................................................................................... 119

xi

Question 4 .......................................................................................................................... 119
Question 5 .......................................................................................................................... 120
Question 6 .......................................................................................................................... 120
Question 7 .......................................................................................................................... 120
Question 8 .......................................................................................................................... 121
Question 9 .......................................................................................................................... 121
Question 10 ........................................................................................................................ 121
Question 11 ........................................................................................................................ 122
Question 12 ........................................................................................................................ 122
Question 13 ........................................................................................................................ 122
Question 14 ........................................................................................................................ 123
Question 15 ........................................................................................................................ 123
Question 16 ........................................................................................................................ 124
Question 17 ........................................................................................................................ 124
Question 18 ........................................................................................................................ 125
Question 19 ........................................................................................................................ 125
Question 20 ........................................................................................................................ 126
Question 21 ........................................................................................................................ 126
Question 22 ........................................................................................................................ 127
Question 23 ........................................................................................................................ 127
Question 24 ........................................................................................................................ 128
Question 25 ........................................................................................................................ 128
Question 26 ........................................................................................................................ 129
Question 27 ........................................................................................................................ 129
Question 28 ........................................................................................................................ 130
Question 29 ........................................................................................................................ 130
Question 30 ........................................................................................................................ 131
Question 31 ........................................................................................................................ 131
CHAPTER 5: NEEDS-ASSESSMENT SURVEY RESULTS ............................................. 132
Needs-Assessment Survey Data Set ................................................................................... 132
Needs-Assessment Survey Data Set Analysis............................................................... 132
Needs-Assessment Survey Data Set Organization....................................................... 134
Needs-Assessment Survey Limitations ......................................................................... 134
Needs-Assessment Survey Tables For Categorical Data And Statistical
Dependencies Analyses.................................................................................................... 137
Needs-Assessment Survey Data Set Representation ................................................... 152
Needs-Assessment Survey Data Set Figures ................................................................. 152

xii

CHAPTER 6: DISCUSSION AND CONCLUSIONS ........................................................ 169
Insights Brought Forward From The Historical Development Of The Clinical Pap Test
In The United States.............................................................................................................. 170
Significance Of Cervical Cancer Definition Through Carcinoma In Situ ................. 170
Significance Of Organizational Policy, Promotion, And Advocacy .......................... 172
Significance Of Method Framing .................................................................................... 173
Significance Of Political Commitment And Financial Resources .............................. 174
Significance Of Field Testing And Method Modeling ................................................. 174
Significance Of Professional Collaboration And Perception ...................................... 175
Significance Of Adequate Health Literacy And Sense Of Disease Susceptibility.... 176
Low Incidence Of Cervical Cancer And Screening Policy In The State Of Qatar ........ 177
Data Analyses, Remarks, And Interpretations ................................................................. 179
Interpretation Of Socio-Demographic Research Data (Questions: 1-8, 31)................... 180
Q1 Nationality. .................................................................................................................. 180
Q2 Gender. ......................................................................................................................... 183
Q3 Age group (Years). ...................................................................................................... 184
Q4 Highest education level.............................................................................................. 186
Q5 Marital status. .............................................................................................................. 188
Q6 Marriage duration. ...................................................................................................... 189
Q7 Employment status. .................................................................................................... 191
Q8 You have health insurance coverage? ...................................................................... 192
Q31 If employed, are you employed in the healthcare sector?................................... 193
Interpretation Of Healthcare Services Research Data (Questions: 9-11) ....................... 195
Q9 You had a Pap test before?......................................................................................... 195
Q10 If you had a Pap test before, when was it performed? ........................................ 197
Q11 Did you, or any member of your family have cervical cancer before? ............. 199
Interpretation Of Health Literacy Research Data (Questions: 12-20) ............................ 200
Q12 Cervical cancer may be preventable....................................................................... 200
Q13 You are aware of the Pap test smear cytologic method....................................... 201
Q14 Where did you hear of the Pap test smear cytologic method for the first time?
............................................................................................................................................. 202
Q15 You have knowledge of cervical cancer................................................................. 204
Q16 Early detection of cervical cancer is important for effective treatment............. 205
Q17 Regular Pap tests may protect you from cervical cancer. ................................... 206
Q18 Cervical cancer may be curable. ............................................................................. 207

xiii

Q19 Vaccination for the Human Papilloma Virus protects against cervical cancer
and other HPV-associated cancers. ................................................................................ 208
Q20 Menopausal women need a Pap test. ..................................................................... 212
Interpretation Of Self-Efficacy And Perceptions Research Data (Questions: 21-30) ... 213
Q21 More information is needed to improve your knowledge of cervical cancer. . 213
Q22 Regular Pap tests are a good health practice. ....................................................... 214
Q23 Getting a Pap test performed is too difficult. ........................................................ 215
Q24 You would recommend a Pap test to your family, friends, and colleagues. .... 216
Q25 Getting a Pap test is a valued investment for good healthcare. ......................... 217
Q26 You would support a Pap test screening program for cervical cancer. ............ 218
Q27 A formal Pap test screening program for cervical cancer should be established
for all women in the State of Qatar. ................................................................................ 219
Q28 You know where to go to get a Pap test performed. ........................................... 220
Q29 A Pap test has no value for you. ............................................................................. 221
Q30 If a self-test for cervical cancer was available you would prefer it? .................. 222
Particular Consideration: Sub-Set Of Married Women In The State Of Qatar Never
Before Having A Pap Test.................................................................................................... 224
Conclusions Arising From Dissertation Aims .................................................................. 229
Dissertation Aim 1 ................................................................................................................ 229
Health Literacy Of Cervical Cancer:............................................................................... 229
Health Literacy Of Pap Test Screening: ......................................................................... 230
Health Literacy Of HPV Vaccination: ............................................................................ 231
Dissertation Aim 2 ................................................................................................................ 233
Support For Population-Based Cervical Cancer Screening In The State Of Qatar: . 233
Dissertation Aim 3 ................................................................................................................ 234
Opportunistic Cervical Sampling: .................................................................................. 235
Advanced-Stage Cervical Cancer At Presentation: ...................................................... 235
Death Rates Due To Cervical Cancer: ............................................................................ 236
Cervical Cancer Case Registries: ..................................................................................... 236
Opportunities For Improvement ........................................................................................ 237
Tumor Registry:................................................................................................................. 238
Implementation Of Population-Based Screening For All Women: ............................ 239
Managing Reallocation Of Financial Resources: .......................................................... 241
CHAPTER 7: EPILOGUE ........................................................................................................ 243

xiv

BIBLIOGRAPHY...................................................................................................................... 247
APPENDICIES.......................................................................................................................... 268
Appendix A: National Cancer Program, Qatar National Cancer Registry 2014 report
published by the Qatar Ministry of Public Health. [http://www.sidra.org/sidra-marksinternational-pathology-day/] ............................................................................................. 268
Appendix B: Needs-Assessment Survey (English version) [Protocol: MoPH-Sidra-IRB099]. ......................................................................................................................................... 269
Appendix C: Symposium Compendium (The 1st Century Of Gynecological
Cytopathology, The Pap test – Then, Now And The Future), conducted December 7,
2014. [https://www.sidra.org/media/news-room/2014/december/sidra-medical-andresearch-center-hosts-symposiu/] ....................................................................................... 276
Appendix D: Symposium Goals and Objectives (The 1st Century Of Gynecological
Cytopathology, The Pap test – Then, Now And The Future), conducted December 7,
2014. [https://www.sidra.org/media/news-room/2014/december/sidra-medical-andresearch-center-hosts-symposiu/] ....................................................................................... 277
Appendix E: Symposium Program Schedule (The 1st Century Of Gynecological
Cytopathology, The Pap test – Then, Now And The Future), conducted December 7,
2014. [https://www.sidra.org/media/news-room/2014/december/sidra-medical-andresearch-center-hosts-symposiu/] ....................................................................................... 278
Appendix F: National Cancer Program, Guidelines For Cervical Cancer Screening In
The State Of Qatar report (2016) published by the Qatar Ministry of Public Health. . 279
Appendix G: National Cancer Program, Guideline For Suspected Cancer Referral In
The State Of Qatar report (2016) published by the Qatar Ministry of Public Health.
[https://www.moph.gov.qa/healthstrategies/Documents/MOPH_%20Suspected%20Cancer%20Referral%20Guideline%2
0for%20the%20State%20of%20Qatar_V1_2016.pdf] ........................................................ 280
Appendix H: Cervical cancer health literacy campaign: “Be Well”, produced by the
Qatar Cancer Society (2017). [http://www.qatarisbooming.com/article/qcs-urgeswomen-go-cervical-cancer-screening] ............................................................................... 281
Appendix I: The National Health Strategy 2018-2022; Our Health Our Future (2018),
published by the Qatar Ministry of Public Health.
[https://www.moph.gov.qa/HSF/Documents/short%20report%20eng%2020.03.2018.pd
f] ............................................................................................................................................... 282

xv

Appendix J: The National Clinical Guidelines For The State Of Qatar (2nd Edition,
2017), published by the Qatar Ministry of Public Health.
[https://www.moph.gov.qa/healthstrategies/Documents/April%202017%20clinical%20guidline%20en.pdf] ................... 283
Appendix K(a): Infographic, What Is Cervical Cancer; a 2-page fold-out brochure
produced by the Ministry of Public Health, State of Qatar (Front and Back covers).
[www.moph.gov.qa] ............................................................................................................ 284
Appendix K(b): Infographic, What Is Cervical Cancer; a 2-page fold-out brochure
produced by the Ministry of Public Health, State of Qatar (Pages 2 and 3).
[www.moph.gov.qa] ............................................................................................................ 285
Appendix L: The National Cancer Framework – Achieving Excellence In Cancer Care:
A Vision for 2022, published by the Qatar Ministry of Public Health.
[https://www.moph.gov.qa/publications/Documents/Health%20Publications/National
%20Cancer%20Framework%20English.pdf] ..................................................................... 286
Appendix M: Abstract/ePoster, International Academy of Cytology Congress, Sydney,
Australia, May 5-9, 2019 ....................................................................................................... 287

xvi

LIST OF FIGURES

FIGURE 1: Two bar plots representing Socio-demographic survey data captured for
Questions 1 and 2 reflecting the breakdown of response counts; all respondents, for
Nationality and Gender. ............................................................................................................. 153
FIGURE 2: Composite figure of 2 bar plots representing Socio-demographic survey data
captured for Questions 1 and 3 reflecting the breakdown of response counts; all
respondents, for Nationality and Age Group respectively stratified by Gender. ................ 154
FIGURE 3: Composite figure of 2 bar plots representing Socio-demographic survey data
captured for Questions 4 and 5 reflecting the breakdown of response counts; all
respondents, for Highest Education Level and Marital Status respectively stratified by
Gender.......................................................................................................................................... 155
FIGURE 4: Composite figure of 2 bar plots representing Socio-demographic survey data
captured for Questions 6 and 7 reflecting the breakdown of response counts; all
respondents, for Marriage Duration and Employment Status respectively stratified by
Gender.......................................................................................................................................... 156
FIGURE 5: Composite figure of 2 bar plots representing Socio-demographic and
Healthcare Services survey data captured for Questions 8 and 9 reflecting the
breakdown of response counts; all respondents, for Health Insurance Coverage and Pap test
Uptake respectively stratified by Gender................................................................................. 157
FIGURE 6: Composite figure of 2 bar plots representing Healthcare Services survey data
captured for Questions 10 and 11 reflecting the breakdown of response counts; all
respondents, for Preceding Pap test and Family history of Cervical Cancer respectively
stratified by Gender. .................................................................................................................. 158
FIGURE 7: Composite figure of 2 bar plots representing Health Literacy survey data
captured for Questions 12 and 13 reflecting the breakdown of response counts; all
respondents, for Cervical cancer preventability and Pap test smear awareness respectively
stratified by Gender. .................................................................................................................. 159
FIGURE 8: Composite figure of 2 bar plots representing Health Literacy survey data
captured for Questions 14 and 15 reflecting the breakdown of response counts; all
respondents, for Initial Pap test knowledge and Knowledge of cervical cancer respectively
stratified by Gender. .................................................................................................................. 160

xvii

FIGURE 9: Composite figure of 2 bar plots representing Health Literacy survey data
captured for Questions 16 and 17 reflecting the breakdown of response counts; all
respondents, for perceived Importance of early cervical cancer detection and Protection
through regular Pap tests respectively stratified by Gender. .................................................. 161
FIGURE 10: Composite figure of 2 bar plots representing Health Literacy survey data
captured for Questions 18 and 19 reflecting the breakdown of response counts; all
respondents, for perceived Cervical cancer curability and HPV vaccination protection
respectively stratified by Gender. ............................................................................................ 162
FIGURE 11: Composite figure of 2 bar plots representing Health Literacy and Selfefficacy & Perceptions survey data captured for Questions 20 and 21 reflecting the
breakdown of response counts; all respondents, for perceived Need of Pap testing for
menopausal women and Need for additional information regarding cervical cancer respectively
stratified by Gender. .................................................................................................................. 163
FIGURE 12: Composite figure of 2 bar plots representing Self-efficacy & Perceptions
survey data captured for Questions 22 and 23 reflecting the breakdown of response
counts; all respondents, for perceived Value of Pap testing and Difficulty in getting a Pap
test performed respectively stratified by Gender. .................................................................... 164
FIGURE 13: Composite figure of 2 bar plots representing Self-efficacy & Perceptions
survey data captured for Questions 24 and 25 reflecting the breakdown of response
counts; all respondents, for Willingness to recommend the Pap test to others and Perceived
healthcare value of a Pap test respectively stratified by Gender. ............................................. 165
FIGURE 14: Composite figure of 2 bar plots representing Self-efficacy & Perceptions
survey data captured for Questions 26 and 27 reflecting the breakdown of response
counts; all respondents, for Support for a Pap test screening program and Support for a formal
Pap test screening program for all resident women in the State of Qatar respectively stratified
by Gender. ................................................................................................................................... 166
FIGURE 15: Composite figure of 2 bar plots representing Self-efficacy & Perceptions
survey data captured for Questions 28 and 29 reflecting the breakdown of response
counts; all respondents, for Knowledge of where to go to get a Pap test performed and
Perceived personal value of a Pap test respectively stratified by Gender. ............................... 167
FIGURE 16: Composite figure of 2 bar plots representing Self-efficacy & Perceptions and
Socio-demographic survey data captured for Questions 30 and 31 reflecting the
breakdown of response counts; all respondents, for Support and preference for possible selftesting for cervical cancer and for Employment in the healthcare sector respectively stratified
by Gender. ................................................................................................................................... 168

xviii

LIST OF TABLES
TABLE 1: Salient impediments to the development of the clinical Pap test in the United
States due to socio-economic factors, stratified before and after 1941. .................................. 88
TABLE 2: Salient impediments to the development of the clinical Pap test in the United
States due to socio-political factors, stratified before and after 1941. .................................... 89
TABLE 3: Salient impediments to the development of the clinical Pap test in the United
States due to socio-behavioral factors, stratified before and after 1941. ................................. 90
TABLE 4: Salient impediments to the development of the clinical Pap test in the United
States due to cervical cancer burden: diagnosis, treatment, and prognosis, stratified before and
after 1941. ..................................................................................................................................... 91
TABLE 5: Salient impediments to the development of the clinical Pap test in the United
States due to VFSM imperfections, and interruptions, stratified before and after 1941. ....... 92
TABLE 6: Salient impediments to the development of the clinical Pap test in the United
States due to VFSM method framing, public awareness, and advocacy, stratified before and
after 1941. ..................................................................................................................................... 93
TABLE 7: Salient impediments to the development of the clinical Pap test in the United
States due to VFSM clinical application, and validation, stratified before and after 1941. .... 94
TABLE 8: Salient impediments to the development of the clinical Pap test in the United
States due to infrastructure, and human resources, stratified before and after 1941. ............ 95
TABLE 9: Salient impediments to the development of the clinical Pap test in the United
States due to Dr. Papanicolaou’s vulnerabilities, professional qualifications, and conflicts
stratified before and after 1941. ................................................................................................. 96
TABLE 10: Categorical data from the survey data set for Questions 1-4 including
Response Rates. Data presented as counts (n) with corresponding frequencies (%)
stratified by Gender. .................................................................................................................. 138
TABLE 11: Categorical data from the survey data set for Questions 5-9 including
Response Rates. Data presented as counts (n) with corresponding percentages (%)
stratified by Gender. .................................................................................................................. 139
TABLE 12: Categorical data from the survey data set for Questions 10-13 including
Response Rates. Data presented as counts (n) with corresponding percentages (%)
stratified by Gender. .................................................................................................................. 140

xix

TABLE 13: Categorical data from the survey data set for Questions 14-16 including
Response Rates. Data presented as counts (n) with corresponding percentages (%)
stratified by Gender. .................................................................................................................. 141
TABLE 14: Categorical data from the survey data set for Questions 17-19 including
Response Rates. Data presented as counts (n) with corresponding percentages (%)
stratified by Gender. .................................................................................................................. 142
TABLE 15: Categorical data from the survey data set for Questions 20-22 including
Response Rates. Data presented as counts (n) with corresponding percentages (%)
stratified by Gender. .................................................................................................................. 143
TABLE 16: Categorical data from the survey data set for Questions 23-25 including
Response Rates. Data presented as counts (n) with corresponding percentages (%)
stratified by Gender. .................................................................................................................. 144
TABLE 17: Categorical data from the survey data set for Questions 26-28 including
Response Rates. Data presented as counts (n) with corresponding percentages (%)
stratified by Gender. .................................................................................................................. 145
TABLE 18: Categorical data from the survey data set for Questions 29-31 including
Response Rates. Data presented as counts (n) with corresponding frequencies (%)
stratified by Gender. .................................................................................................................. 146
TABLE 19: Bivariate analysis matrix revealing dependencies expressed through p-values
between Socio-demographic variables (Q1-8, 31) in Category 1, and Health Services
variables (Q9-11) in Category 2 (significant p-values in bold font). .................................. 147
TABLE 20: Bivariate analysis matrix revealing dependencies expressed through p-values
between Socio-demographic variables (Q1-8, 31) in Category 1, and Health Literacy
variables (Q12-16) in Category 3 (significant p-values in bold font). ................................ 148
TABLE 21: Bivariate analysis matrix revealing dependencies expressed through p-values
between Socio-demographic variables (Q1-8, 31) in Category 1, and Health Literacy
variables (Q17-20) in Category 3 (significant p-values in bold font). ................................ 149
TABLE 22: Bivariate analysis matrix revealing dependencies expressed through p-values
between Socio-demographic variables (Q1-8, 31) in Category 1, and Self-efficacy &
Perceptions variables (Q21-25) in Category 4 (significant p-values in bold font). .......... 150
TABLE 23: Bivariate analysis matrix revealing dependencies expressed through p-values
between Socio-demographic variables (Q1-8, 31) in Category 1, and Self-efficacy &
Perceptions variables (Q26-30) in Category 4 (significant p-values in bold font). .......... 151

xx

LIST OF ABBREVIATIONS

ACS

American Cancer Society

AGC

Atypical glandular cells

ASCC

American Society for the Control of Cancer

ASC-H

Atypical squamous cells – cannot rule out HSIL

CAP

College of American Pathologists

CDC

Centers for Disease Control and Prevention

CIS

Carcinoma in situ

CMC-NY

Cornell Medical College, New York

CxCa

Cervical cancer

DC

Diagnostic Cytopathology

EMENA

Extended Middle East and North Africa

HMC

Hamad Medical Corporation

H&E

Hematoxylin and Eosin

HPV

Human Papilloma Virus

HSIL

High-grade squamous intraepithelial lesion

ICO

Institut Catala d’Oncologica

IRB

Institutional Review Board

xxi

KFSH&RC

King Faisal Specialist Hospital & Research Center

LSIL

Low-grade squamous intraepithelial lesion

NCI

National Cancer Institute

NIH

National Institutes of Health

Pap

‘Papanicolaou’

PHCC

Primary Health Care Corporation

QCS

Qatar Cancer Society

QID

Qatar Identification Number

QMoPH

Qatar Ministry of Public Health

US

United States of America

VFSM

Vaginal Fluid Smear Method

WFA

Women’s Field Army

WHO

World Health Organization

1

CHAPTER 1: INTRODUCTION AND DISSERTATION
FUNDAMENTALS
Introduction
The clinical (morphology-based) Papanicolaou (Pap) test is a medical procedure
applied to ideally detect precancerous (i.e., precursor) lesions of the uterine cervix
through cytological grading of abnormal epithelial cells. A plethora of literature in the
cytopathology and public health bibliographies establish the clinical Pap test as being
the first effective cancer prevention tool in the history of medicine (Chang, 1999; Austin
& Chantziantoniou, 2014; El-Mazny, 2014). However, the global impact of the Pap test in
preventive medicine varies depending on its availability, accessibility, promotion,
endorsement, and uptake.
Since the early experimental work conducted by Dr. George Nicholas
Papanicolaou at Cornell Medical College, New York (CMC-NY) that ultimately
conceived gynecological cytopathology starting in 1917, and more formally since 1928,
29 years transpired before the clinical Pap test was understood, optimized and field
tested, and deployed in screening service in the United States of America (US) by 1957
(Christopherson & Scott, 1977; Chantziantoniou, 20141; Cibas & Ducatman, 2014;
Chantziantoniou, 2017). In those intervening 29 years various scientific and nonscientific factors disrupted or utterly impeded the evolutionary course of the Pap test
from the experimental setting through to population-based clinical practice in the US.
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It is impractical to speculate upon the ramifications to society or to public health
that may have compounded over time due to those impediments disrupting progress to
effective cervical cancer (CxCa) management. Nevertheless, detailed knowledge of those
impediments, of their impact, and how they were overcome, may hold relevance when
considered to optimize contemporary Pap test screening systems that may be
underperforming.
The efficacy of the Pap test remains a testament to a favorable balance between
its technical and procedural simplicity, and its far-reaching clinical benefits. Historically,
during specific timeframes in the US, system imbalances led to conflicts that were
gradually overcome with advancing knowledge of the disease’s preinvasive phases, and
the Pap test’s potential in differentiating them from frank carcinoma. Despite advanced
automation in modern cytopathology, the Pap test remains a simple medical procedure
whereby cells from ecto- and endo-cervical epithelia may be salvaged and processed to
facilitate methodical, cytological grading. In stark contrast to its simplicity, however,
was a complex evolutionary warren that continues to elicit speculation in society and in
diagnostic medicine (Foltz & Kelsey, 1978; Reagan, 1997; Dickey, 2001; Lowy, 2010). The
collective dynamics remain in a state of transition. They also continue to influence the
Pap test’s scope of practice both in the US and in other nations. As a result, the Pap test’s
scope of practice globally is inconsistent, as also are the public health ramifications
arising from its varied application to manage CxCa (Gustafsson, Ponten, Zack, & Adami,
1997).
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Since its promotion by the American Cancer Society (ACS) starting in 1948, the
Pap test has steadily and significantly reduced the incidence and mortality rates of CxCa
in the US by revealing occult, eradicable precancerous lesions (Koss, 1993; Casper &
Clarke, 1998; Michalas, 2000; American Cancer Society, 20171). The impact of the Pap test
globally has been similarly favorable, but typically in developed nations deploying
systematic, population-based Pap test screening programs with adequate patient call
and recall as dictated through enforced rescreening guidelines and robust patient-case
registries (Christopherson & Scott, 1977; Koss, 1989; Habbema, De Kok, & Brown, 2012;
Vaccarella, Lortet-Tieulent, Plummer, Franceschi, & Bray, 2013; Cibas & Ducatman,
2014). In contrast, in developing and in resource-poor regions, where Pap test uptakes
may be inaccessible, opportunistic or utterly unavailable, advanced CxCa at diagnosis
continues to pose major public health priorities associated with disparaging clinical and
societal outcomes (Garner, 2003; Lowy, 2010).

As CxCa is currently regarded a preventable disease in adequately-screened
women, cases presenting with advanced-stage malignancy at diagnosis may serve as
surrogates reflecting screening disparities or system underperformances (Chang, 1999;
Garner, 2003; Gorin, Gauthier, Hay, Miles, & Wardle, 2008). Therefore, system
underperformance may be appraisable through such cases as the natural progression of
asymptomatic precursor lesions through to infiltrating disease may span numerous
years (Garner, 2003). Hence, with optimal population-based Pap test screening coupled
with strategic patient call and recall and colposcopy, sufficient opportunities may be
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exploited to identify and ablate lesions when still precancerous. Hallmarks of effective
screening are therefore repeated Pap test sampling and timely ablation of intraepithelial
lesions. However, opportunistic screening systems are typically reactive to suspicious
symptomatology and not governed by initial patient call to screening or surveillance
strategies (Seoud, 2013; Alemrayat, Abu-Abbas, Al-Naemi, AlTwaisi, Saibi, Zaheer,
Khattab, & Adnan, 2018).

Despite the success of CxCa prevention through Pap test screening in the US and
in other industrialized nations, not all global regions deploy like practices for the
surveillance of precancer in asymptomatic women deemed at risk for developing this
disease (Gustafsson, Ponten, Zack, & Adami, 1997).
As discussed in Chapter 3, at the time of this writing, the State of Qatar has not
implemented a formal, organized, national population-based Pap test screening
program for CxCa prevention for all resident women inclusive of strategic patient call
and recall. Although, Pap test sampling is available through various public and private
medical providers in Qatar. Creditably, through the Qatar Ministry of Public Health
(QMoPH), the Primary Health Care Corporation (PHCC), and the Qatar Cancer Society
(QCS), the State has recently invested extensively to support remarkable campaigns to
increase public awareness of CxCa, and to encourage women to actively seek Pap test
sampling opportunities. Nevertheless, Pap test uptakes in the State of Qatar remain
opportunistic following guidance based on the low prevalence of CxCa in this clinical
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setting (QMoPH National Cancer Framework, 2017; Sancho-Garnier, Khazraji, Cherif,
Mahnane, Hsairi, El Shalakamy, Osgul, Tuncer, Jumaan, & Seoud, 2013; Seoud, 2013).
The State of Qatar is a member country of the Extended Middle East and North
Africa (EMENA) region (Seoud, 2013). According to Sancho-Garnier et al. (2013),
essentially all member territories and countries of the EMENA region deploy
opportunistic Pap test screening in public and private medicine, mainly reactive to
presenting symptoms. Consequently, according to Sancho-Garnier et al. (2013), and
more recently to Alemrayat et al. (2018), the majority of cervical cancers in the EMENA
countries are initially diagnosed when clinically advanced.
Cervical cancer ranks as the 5th most common malignancy in women in the State
of Qatar according to the Institut Catala d’Oncologica (ICO) (Institut Catala
d’Oncologica, 20172). The ICO has also published an estimated annual CxCa burden of
15 cases for Qatar; whereas, four cases would prove fatal, reflecting an estimated annual
death rate of 26.7% (Institut Catala d’Oncologica, 20172). In line with these estimates, the
Qatar National Cancer Registry 2014 report (Appendix A) published by the National Cancer
Program, QMoPH, revealed that of the 18 cases of CxCa registered in 2014, greater than
60% of those cases harbored Stage II/III disease at presentation (QMoPH National
Cancer Program, 2014).
As the contemporary experience in Qatar is not unlike the historical experience
of CxCa presentation and diagnosis in the US prior to expansion of Pap test screening by
1957, this parallel runs central throughout this dissertation. This parallel also poses an
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opportunity for detailed study of its public health and epidemiologic elements. The State
of Qatar is a relatively small country with a small female clinical population deemed at
risk for developing CxCa; and, is serviced by premier tertiary medical institutions with
accredited Diagnostic Cytopathology (DC) operations. The State is modern and
developed (Institut Catala d’Oncologica, 20172).
The parallels between the historical-US and contemporary-Qatar experiences
pertaining to CxCa presentation and diagnosis led to the presumptions, research aims,
and hypotheses herein considered.

Dissertation Fundamentals - Presumptions
The intents and purposes of this dissertation are conceptually based upon the
overarching epidemiological dictum that disease in general, and CxCa notwithstanding,
is not randomly distributed throughout humanity (Gordis, 2014). It is presumed,
therefore, that prevalence and clustering of CxCa globally may manifest specific
commonalities. Commonalities may involve risk factors; Human Papilloma Virus (HPV)
subtypes and potential co-infections; CxCa etiology and pathobiology; symptoms at
presentation; behavioral attitudes reflecting perceived etiology and likely prevention
and cure; women’s perceptions of barriers to screening; cultural norms and prohibitions;
and, ultimately, the organizational infrastructures that either promote or compromise
availability, access, or uptake of Pap test sampling (Chang, 1999; Garner, 2003).
It is from these core presumptions that a detailed understanding of the historical
impediments in the US experience may indeed provide insights to guide the designing
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of CxCa screening practices in non-US regions. Insights from the US model may guide
optimization of existing screening practices by facilitating identification of shortcomings
or inadequacies. Likewise, historical insights may address modern public health
challenges stemming from rapid technological change, life-style and societal attitudes,
financial disparities, and the cultural norms typifying conservative societies, as those
characteristic of the EMENA region.

Dissertation Fundamentals - Literature Review
A methodical review of the pertinent cytopathology and public health literature
was conducted to support an analysis and categorization of the factors that impeded the
historical development, acceptance, and application of the clinical Pap test in the US
(Chapter 2).
The literature review also involved a supplementary analysis of chronologicallyrelevant personal correspondences of Dr. George N. Papanicolaou. It also included a
review of pertinent literature in the Greek bibliography to glean obscure perspectives
that may embellish the overall understanding of impediments to the development of the
clinical Pap test (Diamantis & Magiorkinis, 2012 – translated from Greek).

Dissertation Fundamentals - Aims And Hypotheses
The principal aim of this dissertation involved the generation of original,
relevant health promotion data to facilitate transformation of existing opportunistic
screening practices into more effective population-based Pap test screening programs for
CxCa in the State of Qatar.
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Overarching Hypothesis
It is hypothesized that women and men in the State of Qatar have adequate
health literacy of CxCa; however, they may lack commensurate awareness of disease
prevention possible through Pap test screening and HPV vaccination; and, that they
would support the establishment of a formal Pap test screening program for all resident
women in this nation. It is also hypothesized that, based on likely similarities of CxCa
extent at presentation and diagnosis between the contemporary Qatar experience and
the historical US experience prior to clinical Pap test screening, insights gained from the
US model may provide actionable considerations to facilitate optimization of Pap test
screening practices in the State of Qatar, and potentially in other countries in the
EMENA region.

Dissertation Aim 1
Evaluate the degree of health literacy in women and men in the State of Qatar of
CxCa; of Pap test screening, and of its benefits and uptakes; and, of HPV vaccination.
To evaluate the degree of health literacy in women and men pertaining to CxCa,
the disease prevention benefits possible through Pap test screening, and those through
HPV vaccination in the State of Qatar, specific questions are incorporated in a needsassessment survey to generate supporting Socio-demographics, Healthcare Services,
Health Literacy, and, Self-efficacy & Perceptions data (Appendix B).
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Hypothesis
It is hypothesized that the majority of women and men in the State of Qatar have
adequate health literacy of CxCa; however, they lack commensurate awareness of the
disease prevention benefits possible through Pap test screening and HPV vaccination.

Dissertation Aim 2
Evaluate the degree of support in women and men in the State of Qatar for the
establishment of a formal Pap test screening program for all women.
To evaluate the degree of support by women and men in the State of Qatar for
the establishment of a formal Pap test screening program for all women, specific
questions are incorporated in a needs-assessment survey to generate supporting sociodemographic and self-efficacy & perceptions statistical data (Appendix B).

Hypothesis
It is hypothesized that the establishment of a formal Pap test screening program
for CxCa for all women in the State of Qatar is strongly supported by women and men.

Dissertation Aim 3
Evaluate possible similarities of extent of CxCa at presentation and diagnosis
between the contemporary Qatar experience and the historical experience in the US
prior to the introduction of clinical population-based Pap test screening in 1957.
To evaluate possible similarities of extent of CxCa at presentation and diagnosis
between the contemporary Qatar experience and the historical US experience prior to
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Pap test screening, pertinent literature reviews were conducted to ascertain historical
information. To facilitate comparisons, equivalent epidemiological data for CxCa arising
from the State of Qatar was researched and correlated.

Hypothesis
It is hypothesized that the extent of CxCa at presentation and diagnosis in the
historical US experience, prior to the introduction of clinical population-based Pap test
screening in 1957, bears similarities with the current experience of CxCa presentation in
the State of Qatar mainly due to opportunistic Pap test uptakes.
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CHAPTER 2: HISTORICAL IMPEDIMENTS TO THE
DEVELOPMENT OF THE CLINICAL PAP TEST ARISING FROM
MACRO- AND MICRO-DYNAMICS IN THE US

Chapter 2 details the salient macro- and micro-dynamics that historically
impacted upon the evolution of the clinical Pap test in 20th century US. The literature
reviews revealed a wide range of factors that influenced the development of the clinical
Pap test. This Chapter describes events occurring primarily between 1900 and 1957. This
period represents the experience arising from the detection and diagnosis of CxCa prior
to robust Pap test screening in the US starting in 1957. The salient impediments revealed
through this period were stratified through specific categories and timeframes, and
summarized in subsequent sub-sections and tables in this Chapter (Tables 1-9).
The literature revealed that establishment of the clinical Pap test, and by
extension gynecological DC, was not a phenomenon occurring in isolation of major
historical milestones. These entities were rooted in various facets of history, in the
emerging burden of cancer, and in the societal and public health apprehensions and
priorities that ensued. They also stemmed from the changing cultural fabric of the US
along with prevailing economic and political situations since 1900. They were likewise
influenced by events occurring during and immediately following the two World Wars.
The overall saga was complex. For the purposes of this dissertation, the following subsections were structured to elucidate the most impactful events in an effort to sustain
historical and scientific coherence.
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Knowledge Of Foundational Events In Diagnostic Cytopathology
Knowledge of the foundational events in DC was formed from information
collated from a wide array of literary sources. Pertinent information in the DC and
public health bibliographies was reviewed, as were relevant narratives in the medical
and political history bibliographies. Accounts from individuals being either confidantes
of Dr. Papanicolaou, close professional associates, relatives, moderate or staunch critics
of him or of the cytologic method were also reviewed. In addition, Papanicolaou’s
statements through his personal correspondences in English and Greek were correlated.
All materials were cross-checked to build the overall experience through utmost
contextual and chronological relevance.

Impediments To The Development Of The Clinical Pap Test Arising From
Historical Macro-Dynamics
Macro-dynamics reflected greater forces that either directly or indirectly
influenced the inception, development, and application of the clinical Pap test in the US.
These dynamics were primarily due to societal, economical, and political developments
over the course of time. Although they revolved outside the realm of DC, they
predisposed reactive micro-dynamics within the discipline. From a practical perspective,
macro-dynamics were inevitable. They were external forces that characterized an
evolving American society; hence, may be regarded historical milestones.
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Cervical Cancer In The US In The Early-1900s
Epidemiological data pertaining to CxCa incidence per se from the early-1900s is
practically unavailable. From information referring to death registries, it became evident
that mortality due to CxCa changed remarkably between 1900 and 1957, when Pap test
screening practices started to make an impact in disease prevention throughout the US.
Accounts referring to the burden of CxCa in the early-1900s appear mainly in
secondary-source works by medical historians. Although devoid of specific
epidemiological detail, these works described the impact of CxCa, and the attitudes and
fears elicited in both women and clinicians. These works underscored the sensitivities
and stigmatization associated with this disease throughout the wider dimensions of
American society. Such accounts also referred to racial differences seen in CxCa
mortality at the turn of the 20th century.
Remarkable descriptions of the overall impact of cancer in the US were
organized in a book, entitled The Secret History Of The War On Cancer (2007), by Devra
Davis. One poignant statement in Davis’ book notably embodied the essence of CxCa at
the start of the 20th century. According to Davis (2007):
“At the start of the twentieth century, cervical cancer was a death sentence, and
often a secret one. It was not unusual for women to go to their graves never
knowing what was wrong.”
In the early-1900s, CxCa posed particular challenges that tried the patient and
her clinician equally. Amid the most prominent of difficulties was its detection. And,
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this was hampered by human attitudes and sensitivities at a time when the disease was
regarded a societal menace that inexorably led to silent, painful deaths in relatively
young women indiscriminately (Gardner, 2006; Skloot, 2010).

Detection Of Cervical Cancer In The Early-1900s
Research by Lowy (2010) revealed that the vaginal speculum was developed in
the early 19th century. Using the speculum, gynecologists gained visual access to the
uterine cervix and, after shining light upon it, assessed its gross anatomy with the naked
eye. This practice allowed gynecologists to raise clinical suspicions and target
exploratory biopsies. This in turn helped anatomical pathologists correlate the ensuing
histopathologic findings with the gross, clinical cervical features (Lowy, 2010). Based on
such correlations, in 1908, a German physician, Dr. Walther Schauenstein, advocated
that the naked eye may adequately inspect the cervix to distinguish a healthy cervix
from one that may be cancerous. The healthy cervix “looks soft, pink and rosy”, whereas
the diseased cervix appears “gray and full of pus” (Davis, 2007).
Visual inspection of the cervix with clinical correlation of its gross appearance
thus became the standard-of-practice in the US. This practice led to early speculations of
the disease’s genesis. At the turn of the 20th century, doctors associated CxCa with sexual
habits as Jewish women and nuns demonstrated the lowest rates of the disease. They
also related the disease to multi-parity and, likely, to cervical trauma during childbirth
(Olson, 1989). But unlike other human ailments, the perceptions of CxCa and of its likely
etiology transposed the disease onto broader societal contexts in the early-1900s.
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Collectively, these dynamics had a profound effect upon clinicians required to not only
discover the disease, but to also understand it, and to deliver effective care to all women
impartially. According to Davis (2007):
“Doctors had long known that cervical cancer did not arise overnight. But it was
accepted as an inevitable result of some poorly understood deficiency, perhaps a
moral one. Disease of any kind was seen as a result of not trying hard enough to
be good enough. Then, as now, far more black women got the disease and died
of it. The fact that this ailment was uniquely a women’s disease that
disproportionately affected those then called “coloreds” combined to make
cervical cancer less than a high priority for doctors.”
Cervical cancer posed additional barriers for both patients and clinicians given
its anatomical origin. The intimacies arising from this disease along with its outcomes
relative to other malignancies in women made CxCa a unique clinical challenge, and one
often avoided leading to grave consequences. Both the disease in women and its
detection by doctors were embedded within a web of societal attitudes, mutuallyperceived taboos and embarrassment, and both implicit and explicit prohibitions
(Gardner, 2006; Skloot, 2010). According to Davis (2007):
“More accessible forms of cancer might produce visible or palpable lesions,
lumps and bumps that, once found and recognized, gave doctors a fighting
chance to cut out the growth and arrest the disease. But the cervix, the most
common locus of cancer at the beginning of the last century, was a private place
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whose means of access was closed to all eyes. At a time when women felt shame
at the mere mention of their genitals, the topic of cancer of their private parts was
not considered appropriate for public discussion.”
Yet, CxCa could not remain overlooked. The clinical detection of the disease and
its treatment posed foremost dilemmas in society and in medicine. These priorities
obliged gynecologists to nonetheless align their efforts against the disease applying the
standard practice: Advocating visual inspections of the uterine cervix in search of
obvious lesions in women. In the early-1900s radical hysterectomy was the mainstay
procedure for treatment of CxCa with an associated surgical mortality rate of 20%
(Olson, 1989).
The overall problem of CxCa was neither trivial in society, nor in medicine. The
predecessor organization to the modern ACS, the American Society for the Control of
Cancer (ASCC), was formed precisely in response to these emerging priorities.

Establishment Of The American Society For The Control Of Cancer
The ASCC was established in 1913 in response to the problems arising from the
management of CxCa when initially diagnosed in advanced stages (Greenwald, Cullen,
& McKenna, 1987; American Cancer Society, 20172).
The ASCC was formed by a group of businessmen and gynecologists in New
York City with the founding mission to: “Fight Cancer With Knowledge” (Holleb, 1988;
Davis, 2007; American Cancer Society, 20172). The ASCC promoted the then standard-ofpractice: CxCa may be visually detected with the naked eye, confirmed through biopsy,
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and managed through hysterectomy (Holleb, 1988; Davis, 2007). However, the founding
members of the ASCC had no illusions of the imminent challenge pertaining to cervical
visualization. Dr. James S. Ewing served the founding committee of the ASCC.
According to Davis (2007), in an effort to promote the principles of CxCa detection and
diagnosis, the ASCC had a “simple aim”:
“…to persuade physicians to learn how to look at the cervix and persuade
women to allow regular exams... It never has been easy to get women to take
their clothes off and lie…with their feet in cold metal stirrups. A leading ASCC
pathologist, James Ewing, ruefully conceded in 1926 that even if doctors became
convinced of its value, the prospects for persuading women to undergo this
exam twice a year were slim and daunting. It was not clear at the time whether it
was harder to find physicians who understood the value of performing the exam
or to persuade women of its value.”

Linear Model Of Cervical Carcinogenesis
In the early 20th century in the US, it was surmised that malignant disease
progressed linearly starting from a physiological normal (Croswell, Ransohoff, &
Kramer, 2010). The linear model of carcinogenesis thus emerged. Based on this theory,
CxCa developed incrementally through progressive pathobiological phases. Therefore,
CxCa could be hypothetically eliminated through periodic inspections of the cervix for
apparent symptomatology however trivial (Croswell, Ransohoff, & Kramer, 2010; Olson,
1989). Throughout the 1920s, the American Medical Association recommended periodic
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health examinations in search for subtle anatomical changes in the uterine cervix
(Croswell, Ransohoff, & Kramer, 2010). The ASCC, and its descendant organization the
ACS, adopted authoritative roles in promoting such practices. The development of the
colposcope in 1924 by Dr. Hans Von Hinselmann produced additional tools to support
this clinical model (Olson, 1989). The early rationalization of medical screening for
apparent CxCa thus emerged in the US.

Mortality From Cancer And Other Malignant Tumors - In The Registration Area Of The
United States 1914
Within the first year of its mandate, in 1914, in its inaugural attempt to generate
knowledge of cancer, the ASCC collaborated with the Department Of Commerce, United
States of America, Bureau Of The Census, to produce a detailed registry of deaths
throughout the US based on estimated population growth; cancer type; patient age
group; gender; and, State of residence. In the mammoth publication that ensued under
the directorship of Sam L. Rogers in 1916, entitled Mortality From Cancer And Other
Malignant Tumors - In The Registration Area Of The United States 1914, death rate statistics
were organized spanning the years 1900 through 1914 (Department Of Commerce,
Bureau Of The Census, 1916). From the data published, when comparing figures
specifically from the terminal-end years of 1900 and 1914; for: (a) the estimated
population growth; (b) the crude deaths due to all cancer types in women and men; and
(c) the deaths specifically due to cancer of the ‘female genital organs’, the differences in
magnitude over the course of the 14 registration years were: 2.14 fold; 2.70 fold; and, 3.02
fold respectively.
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The trend in the number of deaths due to all cancer types in those 14 years outpaced estimated US population growth. Meanwhile, the trend in deaths specifically due
to gynecological cancer out-paced the trends of all cancers combined for the same
period.
As it were, during the first 14 years of the 20th century in the US, CxCa posed an
anomaly evidently set upon an unnerving, perhaps geometric trajectory.
Enigmatic problems like CxCa along with other undesirable human ailments
formed the bedrock fundamentals of the Eugenics movement in the US. It was during
World War I, and thereafter, that the Eugenics movement flourished across the nation
(Davis, 2007). The impact of the Eugenics movement in the US was extensively
researched in a book, entitled War Against The Weak – Eugenics And America’s Campaign
To Create A Master Race (2003), by Edwin Black. According to Black (2003):
“During the war years, eugenic organizations proliferated in America. Likeminded citizens found ethnic solace and self-vindication in the idea of biological
superiority. The Race Betterment Foundation was among the leading eugenic
organizations that sprouted around the country…In 1914, Dr. Kellogg organized
the First Race Betterment Conference in Battle Creek, Michigan. The conference’s
purpose was to lay the foundations for the creation of a super race…”
Coincidentally, it was also in September 1914 that Dr. George N. Papanicolaou
took employment at CMC-NY, starting the research work that ultimately led to the
establishment of the clinical Pap test and its application in CxCa screening (Carmichael,
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1973; Chantziantoniou, 20141). The reactive micro-dynamics and the ensuing
impediments specific to Papanicolaou’s work at CMC-NY are described in subsequent
sub-sections in this Chapter.

Cancer In The US And Impact Of The Great Depression
The literature likewise revealed that the historical juxtaposition between the
development of the clinical Pap test and specific events occurring during the Great
Depression was not coincidental.
The Great Depression, spanning a 12-year period from 1929 to 1941, was
undoubtedly the most challenging period in US history nested economically and
politically between two major World Wars (Amadeo, 2018). It was during the Great
Depression that extraordinary shifts emerged in epidemiology and in public health, and,
consequently in ensuing societal attitudes (Turnock, 2012). These shifts were widely
impactful, not just within the realms of science and medicine, and public health (Tapia
Granados & Diez Roux, 2009; Amadeo, 2018).
Since the beginning of the 20th century, and throughout the Great Depression, life
expectancy in the US was gradually increasing in pace with incrementally-efficacious
treatment for infectious diseases (Armstrong, Conn, & Pinner, 1999). The threat of death
from cancer eventually surpassed that likely from communicable disease by the time the
Depression started dissipating in 1941. Cancer usurped all other ailments, becoming the
foremost public health priority coupled with societal distress; casting a profound sense
of despair and hopelessness upon patients and clinicians alike.
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In 1928, against the backdrop of mounting economical and societal decline, and
increasing burden due to advanced CxCa, Papanicolaou introduced the vaginal fluid
smear method (VFSM) as being an effective diagnostic test to detect the disease.
Conclusions drawn from his research at CMC-NY were reported through a presentation,
entitled New Cancer Diagnosis, delivered in the 3rd Race Betterment Conference organized
for eugenicists (Papanicolaou, 1928). As Papanicolaou’s discoveries clashed with then
standard-of-practice for CxCa detection, his proposals were dismissed by the medical
community as being clinically unnecessary (Papanicolaou-Kokkori, 2008; Naylor, 1988).
This setback was highly adverse and most unfortunate throughout Papanicolaou’s
career, but also for the detection and management of CxCa at the start of the Depression.
Due to this failure, Papanicolaou ceased working towards refining the diagnosis of CxCa
through the cytologic method, and this disruption led to the ‘lost decade of
cytopathology’ (Chantziantoniou, Donnelly, Mukherjee, Boon, & Austin, 2017). The
significance of these events in the overall evolution of the clinical Pap test is detailed in
subsequent sub-sections in this Chapter.
In 1929, as the Depression deepened, Dr. Clarence Cook Little directed the ASCC
(Davis, 2007). Due to the widespread economic decline, the ASCC faced financial
difficulties alongside dismal fundraising campaigns and unable to sustain its objective:
To manage the control of cancer. Nonetheless, the intensifying impact of CxCa in the US
by 1930 exerted considerable pressure upon the organization to act and to project
servant leadership command. According to Davis (2007):
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“By then more than 140,000 Americans were dying of cancer each year, and the
disease had become the nation’s second leading cause of death after heart
disease. The sobering fact was that more women than men were dying of cancer
and usually from cancers of the cervix, stomach and breast.”

Cervical Cancer Burden In The US In The 1930s
Knowledge of the incidence and burden of CxCa in the 1930s was mainly
ascertained retrospectively from cross-referenced information appearing in the more
recent DC bibliography proper, mainly in publications after 1941.
In the 1930s, cervical and uterine cancers in the US caused the highest death
burden of all cancers in women exerting a heavy societal toll of life-years-lost (Casper &
Clarke, 1998; Cibas & Ducatman, 2014). Prior to cytologic screening, CxCa was
conventionally discovered through opportunistic biopsy, as classical symptoms
secondary to advancing disease (i.e., pelvic pain, abnormal bleeding, and discharge)
prompted women to seek the care of a gynecologist. Epidemiological and biographical
research by Olson (1989) revealed that in 1931, CxCa was predominantly seen in poorer
women during the Depression years. Coupled with unfavorable surgical success rates, a
key parameter that emerged in the 1930s was time, exemplifying a sense of urgency
posed by presenting symptoms and the need for prompt medical intervention to
facilitate relief and treatment. Time became the essence for CxCa control. As well, time
became the ASCC’s signature political edict (Davis, 2007).
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By 1931, time was relatable with CxCa cure outcomes. This relationship was
reflected in 1945 by Meigs, Graham, Fremont-Smith, Janzen, & Nelson (1945):
“Early, accurate diagnosis of cancer of the female genital tract has long been the
goal of gynecologists. Ewing states that in 1931, 14,464 women died of cancer of
the uterus or 12 per cent of all cancer deaths were due to this type…Ewing
arrived at figures of an average of 10 per cent approximate 5 year cures for
uterine cancer. He calculated that the possible cure under ideal conditions, i.e.,
intelligent public, skillful and experienced specialists, and modern equipment,
would be 40 per cent. The discrepancy between the possible rate of cure and of
actual cure bears a direct relationship to the time at which diagnosis is
established and treatment instituted.”
To simplify the apparent relationship between timely intervention and possible
cure for CxCa, with extent of disease at time of intervention, Meigs, Graham, FremontSmith, Kapnick, & Rawson (1943) stated:
“Cancer of the cervix and body of the uterus is a curable condition. Early
diagnosis and treatment are prerequisites for cure…Approximately the same
statement is given for carcinoma of the cervix by Todd who reports that from the
onset of abnormal bleeding the chance of cure decreases 3.24 per cent a week.
The average time from the onset of symptoms to operation is stated to be 7.5
months. Eleven of a hundred women with cancer of the cervix reach the surgeon
in the early (operable) stage; 29 in the stage of so called “border-line operability”;
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60 are totally inoperable when treatment is begun…Delay is thus responsible for
a majority of deaths from cervical cancer, a delay to which both patient and
physician contribute.”
An understanding of the shared contributions and impact of advanced CxCa at
presentation and diagnosis in the 1930s, and how this disease tormented patients and
clinicians alike, is herein relevant. But given the aims of this dissertation, these
associations ought to be viewed from broader perspectives to reveal their influence
throughout the wider dimensions of societal medicine. These perspectives included yet
another parameter: The extent of disease at presentation. According to Davis (2007):
“By the time its physical tracks could be felt, the illness had often been brewing
for more than a decade. The warning signs of bleeding, shortness of breath and
pain – then touted as the indications of cancer – were not at all clear in the
disease’s early stages. After all, women have been bleeding, sometimes
uncomfortably, for as long as the species has existed. By the time the strange
discharges, unstoppable cramps, and relentless full-belly feeling were evident,
the cancer was unstoppable.”
The evolution of gynecological DC was thus inextricable from two enduring
parameters: Time and Bleeding. The clinical significance of these factors became
gradually apparent alongside incremental scientific advancements that led, ultimately,
to an understanding of the disease’s natural progression and pathobiology, and how
best to manage them depending on available tools. Indeed, it ought to be emphasized
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that the association of HPV in cervical carcinogenesis was not known until 1978
(Syrjanen, 2017). In the 1930s, the importance of Time and Bleeding likewise stemmed
from greater historical and societal situations. Abundant scientific and lay literature
substantiated the revolutionary advances that characterized the 20th century in North
America and elsewhere. In the US particularly, significant technological innovations
rapidly transformed medicine and the methods applied to diagnose and treat disease
against a backdrop of unprecedented scientific, political, and socio-economical changes.
Amid these dynamics, the extent of public knowledge of the classical symptoms
of CxCa became another important variable in an effort to discover cancer as early as
possible. The ASCC took these challenges seriously in order to defend the touted
urgency for timely disease detection. For the ASCC, sufficient public literacy became a
governing organizational objective.
The health literacy campaigns developed in the US to disseminate knowledge of
cancer and of its symptoms were researched in a book, entitled Early Detection – Women,
Cancer, And Awareness Campaigns In The Twentieth-Century United States (2006), by
Kirsten E. Gardner.

The Women’s Field Army
In an effort to deliver on the expectations posed upon the ASCC, Dr. Clarence C.
Little considered an unprecedented idea in 1933. He wanted to disseminate knowledge
of cancer to the general public to gain its allegiance in the effort to discover the disease
early and, by doing so, raise needed funds. He approached the General Women’s
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Federation seeking assistance. Dr. Marjorie B. Illig, a radiologist, was the serving Chair
of the Federation’s Public Health Division. Little’s proposal to her was the formation
and mobilization of a women’s group to spread knowledge of cancer (Gardner, 2006;
Davis, 2007).
The General Women’s Federation was then active in spreading public health
information throughout the US. The organization encouraged its members to educate
the public of medical services still available throughout the Depression years, but to also
protest the ongoing budget cuts to healthcare (Gardner, 2006).
Little’s proposal gained Illig’s support and materialized in 1936. It led to a robust
public health awareness expedition: The Women’s Field Army (WFA) (American Cancer
Society, 20172). The women’s movement adopted para-military hierarchies and marched
strategically under the motto: ‘Cancer Thrives On Ignorance. Fight It With Knowledge’.
According to Davis (2007):
“At its peak the army numbered over 2 million. Set up as the ASCC’s public
education arm and fielding battalions in every State, WFA members marched
door-to-door collecting money and handing out pamphlets. They organized
public events…to raise money and generally spread the word about cancer…”
Dr. Illig supported the WFA given her professional experiences and convictions
pertaining to CxCa in the mid-1930s. According to Davis (2007):
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“As a radiologist, she had seen dozens of young women whose x-rays revealed
abdomens riddled with spreading white blotches of disease. Illig explained to
her colleagues at the federation that doctors could identify subtle abnormalities
of the cervix long before cancer showed up on x-rays. Women’s lives could be
saved if they would show up for regular physical exams. The suggestion that
early detection could prevent deaths provided a radical and hopeful solution for
a problem that had come to be fatalistically accepted. If women could be
mobilized against this devastating disease, the world would be better off.”
The WFA was established in the mid-west States by 1937 (Gardner, 2006). Based
in Cedar Rapids, the Iowa WFA phalanx organized various projects relying on the
prominence of Dr. Arthur Wright Erskine, a local physician. Collaborating with Erskine,
the Iowa WFA produced various educational materials for dissemination throughout the
mid-west States. As radio was the mainstay technology by which to reach the public
widely, their initiatives included live broadcasts in an effort to reach households
dispersed throughout the rural farming landscapes. And it was through these initiatives
that Erskine uncovered another impediment to the timely detection of CxCa: The
geographic vastness of the mid-west US, and the varied urban and rural population
clustering throughout the heartland States. According to Gardner (2006):
“The Iowa WFA, female activists, and Erskine expressed concern about teaching
female cancer awareness in rural areas, with scattered populations of women.
Unlike urban areas, Erskine argued, “there are geographic, economic, and
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perhaps psychological conditions in our state, and in other rural states” that
might interfere with early detection efforts. Iowa cancer activists recognized that
many people would not want to travel to remote urban cancer centers for
treatment: “They get homesick and discouraged and abandon treatment before
they should. In practice, therefore, the great majority of patients with cancer
must now, and for some time to come, be treated in or near their communities.
We must do the best we can with what we have.” Through the medical lens,
Erskine realized that local treatment facilities might be inferior to centralized,
better-equipped urban centers, but he also considered the unique behavioral
tendencies of his target population. Less superior treatment was better than no
treatment.”
Nevertheless, with increased public awareness of cancer because of the WFA,
with expanded organizational exposure, and with the imperative to fight the disease as
early as possible, the ASCC faced potent public relations predicaments. Davis (2007)
stated:
“Folks began to believe the claim that early detection was the key to treating the
disease, but such claims raised serious questions. Why were cancer rates
increasing when more people were seeing their doctors sooner? Why was so little
real progress being made against finding and treating the disease? Why were
more and more women dying of cervical cancer? Significant numbers were
beginning to question what “cancer control” really meant.”

29

The National Cancer Act Of 1937
Despite the expanded general awareness of cancer, the worsening patterns
between population growth and mortality trends due to cancer became profoundly
alarming throughout the late-1930s.
In response, US Congress was compelled to enact the National Cancer Act of
1937 (Holleb, 1988; National Cancer Institute, 2016). The Act, signed into law by
President Franklin D. Roosevelt, created the National Cancer Institute (NCI) from an
allocation of $750,000 accompanied by ambitious aims during a period in US history
marked by devastating economic and societal setbacks. The NCI became the foremost
research organization in the US Public Health Service (Habbema, De Kok, & Brown,
2012). Amongst the initial mandates of the NCI was the redistribution of an additional
$700,000 in the form of research grants cascaded to scientists through affiliated
governmental organizations (Holleb, 1988; National Cancer Institute, 2016). The
underlying intent of the Act was to stimulate research and development and training, to
unravel the causes of cancer, its diagnosis, its effective treatment, and eradication.
The National Cancer Act of 1937 was enacted in the depths of the Great
Depression (Amadeo, 2018). The Act therefore symbolized a stark paradox between the
magnitude of the public health urgency posed by increasing burdens of cancer, and the
funding seemingly necessary to rein in this plight upon humanity during the severest
financial recession in US history.
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In 1939, following a change in prospects at CMC-NY, the ‘lost decade’ of DC
ended. Papanicolaou was then encouraged to revive his work on CxCa working in
collaboration with Dr. Herbert F. Traut, a gynecological oncologist at CMC-NY.
By 1941, as the Depression ended, Papanicolaou and Traut had transformed the
previously-dismissed VFSM from a diagnostic test into a screening test accompanied by an
awareness of its secondary disease-prevention potential (Papanicolaou & Traut, 1941).
However, the method’s resurrection and transformation through to the clinical Pap test
in 1948 occurred following specific events stemming, in large part, from the National
Cancer Act of 1937, and bold advocacy demonstrated by the ACS. These events are
detailed in dedicated subsequent sub-sections in this Chapter.
What facilitated this shift in prospects was primarily the urgency posed by
increasing deaths due to CxCa and, secondarily, by the conceptualization of cervical
precancer arising from Papanicolaou’s and Traut’s work in 1941. As such, another
worrisome paradox began to emerge for the ASCC that contrasted increasing deaths due
to invasive CxCa with the possible cures for precancer through VFSM detection.
However, the screening test remained under scrutiny; notably, it lacked a characteristic,
unambiguous diagnostic nomenclature to allow alignment with the diagnostic language
of anatomical pathology. But perhaps more importantly in 1941, the VFSM lacked
widespread consensus as to what would be its true role in the burgeoning medicine of
CxCa detection and control (Koss, 1989).
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Despite the imperfections, the cytologic method offered promising clinical
advantages at a most opportune time. The VFSM offered an alternative by which to
detect and ablate precancerous lesions through timely intervention; an alternative that
may arrest the natural biology of the disease towards invasive cancer. Papanicolaou’s
simple procedure thus offered far-reaching clinical benefits, not merely the detection of
advanced disease through vaginal secretion analysis. The cytologic method lessened the
detriments of time, the urgency due to presenting symptoms, and the grave
consequences typical of delayed surgery. This alternative appealed to gynecologists
facing the sensitivities and therapeutic challenges of advanced, oftentimes inoperable
CxCa in their patients in the early-1940s.
Against a background of escalating enthusiasm in gynecological DC,
Papanicolaou and Traut’s monograph, entitled Diagnosis Of Uterine Cancer By The Vaginal
Smear (1943), published by The Commonwealth Fund, became a cornerstone for the
subsequent events that led towards the establishment of the clinical Pap test
(Papanicolaou & Traut, 1943). Their monograph formed the catalyst for ongoing
technical and procedural advancements, but also for the realization of population-based
cytologic screening for cervical precancer in asymptomatic women (Boon &
Chantziantoniou, 2013).

Rebranding Of The American Society For The Control Of Cancer Into The American
Cancer Society
One year after Papanicolaou and Traut’s epic monograph in 1943, the ASCC was
obliged to respond to pressing developments. It was rebranded as the American Cancer
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Society in 1944 because of the initiatives commanded by Mrs. Mary Woodard Lasker,
and of her convictions and political influence.
Mary W. Lasker was a wealthy, prominent philanthropist dismayed by the lack
of progress in research and apparent inaction by the ASCC to address the growing
threat of cancer. Noting the ASCC’s limited cash flow and chronic inability to uphold its
mission, she actively raised $4 million for the organization demanding, in return, major
restructuring of its constitution (Holleb, 1988).
Mary Lasker transformed the ASCC into an authoritative, agile organization
supported by astonishing financial leverage during the depths of World War II. She thus
became an influential member on the ACS Board. Following her command, ACS
policymakers espoused funding for cancer research as so dictated by Mary Lasker: That,
“…out of every $4 raised the organization would spend $1 on research” (Davis, 2007;
American Cancer Society, 20172).
Due to Mary Lasker’s enterprises the ASCC reemerged in 1944 as the
emboldened ACS, poised to tackle the mounting problem of ineffective cancer control in
the US. The re-profiling of the ASCC coincided favorably with Papanicolaou’s work at
CMC-NY and with the ongoing developments in the cytologic methods (Hinsey, 1962).
It was following these specific dynamics that barriers impeding the acceptance and use
of the VFSM started to weaken following the extensive research work in DC funded by
the ACS. The ACS honored the National Cancer Act’s intents and purposes, and became
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a staunch supporter of Papanicolaou’s work (Hinsey, 1962; Koss, 1993; PapanicolaouKokkori, 2008).
Amid growing interest in the VFSM in 1945, the ACS was compelled to review its
public awareness and advocacy policies to assess organizational alignment with the
rapidly changing societal and medical developments in the US as World War II ended.
Its Board then deemed the WFA as being utterly unfitting in a post-war period. Being a
quasi-military operation predominantly made up of amateurs and activists with little
formal education in medicine or cancer, the ACS Board decided the WFA be disbanded
to mitigate likely bruising public relations quandaries (Davis, 2007).
Alternatively, in 1946, to disseminate scientific knowledge formally, the ACS
inaugurated its intramural program for epidemiological research responding to a 5-fold
increase in lung cancer in the US during the Great Depression years (Thun, Calle,
Rodriguez, & Wingo, 2000). The intramural program was designed to track cancer
incidence trends, risk factors, screening methods, and treatment statistics. However, it
was not until 1952, and henceforth, that the ACS published Cancer Facts And Figures
annually to include data for CxCa (Thun, Calle, Rodriguez, & Wingo, 2000).
The timing of the ACS’s Cancer Facts And Figures for CxCa in 1952 was not
immaterial. It followed two significant events in the evolutionary timeline of the clinical
Pap test, both occurring in 1951: The death of Mrs. Henrietta Lacks to CxCa; and,
auspicious preliminary outcomes arising from the Memphis and Shelby County,
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Tennessee, trial sponsored by the NCI - a direct consequence of the National Cancer Act
of 1937.

Death Of Henrietta Lacks To Cervical Cancer: The HeLa Cell Line
The story of Henrietta Lacks was detailed in a remarkable book, entitled The
Immortal Life Of Henrietta Lacks (2010), by Rebecca Skloot.
Henrietta Lacks was an African-American woman that died from advanced
CxCa at Johns Hopkins Hospital, Baltimore, on October 4, 1951. Although her clinical
course may have been similar to that of other women dying of CxCa at that time, her
case proved extraordinary and scientifically significant.
Henrietta Lacks had noticed abnormal vaginal bleeding, and self-felt a nodule in
her uterine cervix. Appropriately, upon visual inspection, her local physician noted the
nodule but suspected it was syphilitic. When Henrietta’s tests returned negative for
syphilis, she was led to a gynecologist at the Johns Hopkins Hospital. A cervical biopsy
confirmed she had infiltrating squamous CxCa (Skloot, 2010). However, her cancer
proved highly malignant and was widely extensive at diagnosis. Henrietta Lacks, a
young mother of five children, succumbed to CxCa 31 years old.
Skloot (2010) described Henrietta Lacks’ suffering in vivid detail. In the context
of this dissertation, her book also manifested the attitudes and bleak realities of
advanced CxCa prevailing in the early-1950s. According to Skloot (2010):
“…Henrietta told her doctors several times that she thought the cancer was
spreading, that she could feel it moving through her, but they found nothing
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wrong with her. “The patient states that she feels fairly well,” one doctor wrote
in her chart, “however she continues to complain of some vague lower
abdominal discomfort…No evidence of recurrence. Return in one month.”
There’s no indication that Henrietta questioned him; like most patients in the
1950s, she deferred to anything her doctors said. This was a time when
“benevolent deception” was a common practice – doctors often withheld even
the most fundamental information from their patients, sometimes not giving
them any diagnosis at all. They believed it was best not to confuse or upset
patients with frightening terms they might not understand, like cancer. Doctors
knew best, and most patients didn’t question that…Especially black patients in
public wards.”
The case of Henrietta Lacks altered the history of medicine as malignant cells
from her cervix were removed just months before her death without her knowledge or
permission. This was done to salvage cells for cancer research based on cell cultures.
Unlike other cell cultures of malignant cells that follow finite cell division cycles,
Henrietta Lacks’ cells continue dividing in vitro through to this day. They are
biologically immortal. Her cells are otherwise scientifically known as: The HeLa cell line.
Her CxCa cells have facilitated revolutionary advancements in vaccine development,
virology, oncology, and chemotherapy due to their immortality allowing research to be
conducted and repeatedly validated. Nonetheless, along with the infamous Tuskegee
syphilis experiment in the US (Brown, 2017), Henrietta Lacks’ case led to the
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establishment of the Discipline of Medical Ethics, and its ramifications in the conduct of
modern medical research globally (Skloot, 2010).
The overall impact of CxCa in 1951 in the US, with a glimpse of the impediments
to Pap test uptakes, was also alluded to by Skloot (2010):
“At that point, more than 15,000 women were dying each year from cervical
cancer. The Pap smear had the potential to decrease that rate by 70 percent or
more, but there were two things standing in its way: first, many women – like
Henrietta – simply didn’t get the test; and, second, even when they did, few
doctors knew how to interpret the results accurately, because they didn’t know
what the various stages of cervical cancer looked like under the microscope.
Some mistook cervical infections for cancer and removed a woman’s entire
reproductive tract when all she needed was antibiotics. Others mistook
malignant changes for infection, sending women home with antibiotics only to
have them return later, dying from metastasized cancer. And even when doctors
correctly diagnosed precancerous changes, they often didn’t know how those
changes should be treated.”
Dr. Richard Wesley TeLinde was a gynecological surgeon amongst the medical
team attending to Henrietta Lacks at Johns Hopkins Hospital. He was then actively
involved in the US-wide debate of: “What qualified as cervical cancer, and how best to
treat it” (Skloot, 2010). Pertaining to DC, anatomical pathology, and surgical treatment
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of CxCa, the following narrative embodied the state of gynecological healthcare in the
US in the early-1950s (Skloot, 2010):
“In 1951, most doctors in the field believed that invasive carcinoma was deadly,
and carcinoma in situ wasn’t. So they treated the invasive type aggressively but
generally didn’t worry about carcinoma in situ because they thought it couldn’t
spread. TeLinde disagreed – he believed carcinoma in situ was simply an early
stage of invasive carcinoma that, if left untreated, eventually became deadly. So
he treated it aggressively, often removing the cervix, uterus, and most of the
vagina. He argued that this would drastically reduce cervical cancer deaths, but
his critics called it extreme and unnecessary…TeLinde presented his argument
about carcinoma in situ to a major meeting of pathologists in Washington, D.C.,
and the audience heckled him off the stage.”

The Memphis And Shelby County, Tennessee, Trial For Cervical Carcinoma In Situ
The Memphis and Shelby County, Tennessee, clinical trial was launched in 1951
to test the VFSM’s potential to identify carcinoma in situ (CIS) in asymptomatic women,
and to distinguish this lesion from invasive CxCa in symptomatic women (Dunn &
Sprunt, 1955). The study was among the first population-based trials in the history of
gynecological DC to assess a screening test, not a diagnostic test. The trial was authorized
and funded by the NCI and produced promising results in favor of VFSM-based
screening for early CxCa in asymptomatic women. Moreover, the Memphis and Shelby
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County trial produced important epidemiological data reflecting that local, clinical
population.
The Memphis and Shelby County trial was furthermore significant as it
considered societal attitudes, professional attitudes, and the deployment of a nonmedical workforce to analyze the arising volumes of smears, instead of pathologists who
only reviewed abnormal smears brought to their attention. As such, the Memphis and
Shelby County trial tested and introduced a model by which to analyze and report
VFSM cases for the detection of cervical precancer.
The Memphis trial had four objectives (Dunn & Sprunt, 1955): “(1) To determine
whether periodic vaginal exfoliative cytology as a screening procedure can be used to
diagnose cancer in the preinvasive stage; (2) To accumulate data for determining agespecific incidence and prevalence rates for both preinvasive and invasive cervical cancer;
(3) To estimate the frequency with which vaginal cytology needs to be applied to be
effective as a case-finding procedure; and (4) To determine whether, through this casefinding procedure, cervical cancer can become largely a curable disease.”
Dunn and Sprunt (1955) emphasized that, in this trial, “cytology is used for
screening; it is not competing with the tissue study for relative accuracy in final
diagnosis.” Controversy and suspected professional encroachment between DC and
cervical biopsy were pervasive in 1951. And these conflicts became increasingly more
acute alongside the growing volumes of cervical smears generated through screening,
and the monetary returns affected due to reduced billing for cervical biopsies.
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Nevertheless, the Memphis and Shelby County trial also revealed gaps in public
literacy despite the extensive awareness campaigns conducted by the ACS, by its
predecessor the ASCC since 1913, and by the robust WFA. According to Dunn and
Sprunt (1955):
“It soon became evident that the public was not overly conscious of cancer as a
personal problem, and that more aggressive educational measures were needed.
Yet it was necessary that publicity should not antagonize practicing physicians
since their cooperation is a necessary part of the project…
Any apprehension about the public’s over-consciousness of cancer has been
completely dispelled. Enlightenment and motivation have become the leitmotivs
of the publicity program in the effort to reach women individually through every
possible medium, until they accept the fact that they can have cervical cancer,
and that the cytology examination is a means of detecting this cancer in a curable
stage.”
The political push-back exerted upon the cytologic method and its alleged
potential to detect cervical precancer in the early-1950s, were also manifested through
the Memphis trial. According to Dunn and Sprunt (1955):
“In a few instances, skeptics have put the cytology program to the test by
submitting specimens from known or clinically obvious cases. There are no
known instances in which the cytology examination has failed under these
circumstances.”
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The American Cancer Society At 75: Despair To Hopefulness, And Cancer Prevention
By 1988, the ACS had undergone a notable metamorphosis since its simple
beginnings. Commenting upon the significant organizational changes since 1913, the
Senior Vice President for Medical Affairs at the ACS, Dr. Arthur I. Holleb (1988) stated:
“From this vantage point we can say we have had a good 75 years at the wheel of
change:…Change in the way that cancer is understood by the medical profession
and the public as a group of more than 100 diseases, a growing number of which
are now clearly curable. Change in the focus of the patient from despair to
hopefulness for increased length of life and improved quality of life. And change
to the idea that cancer prevention, at home and in the workplace, is an achievable
goal for a broad spectrum of the population.”

The American Cancer Society At 100: Increasing Life Expectancy In The US, And Burden
Of Cervical Cancer
In 2013, as the ACS celebrated its centennial, reflecting upon lingering
epidemiological realities, Stobbe (2013) commented in the Daily Herald (New York):
“Back in 1913 when it [the ACS] was formed, cancer was a lesser threat for most
Americans. The biggest killers then were flu, pneumonia, tuberculosis, and
stomach bugs. At the time when average life expectancy was 47, few lived long
enough to get cancer...Cancer became the nation’s no. 2 killer in 1938, a ranking it
has held ever since.”
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The above excerpt from the feature article by Stobbe (2013) was predated
through more explicit epidemiological detail by Dr. Charles S. Cameron, the serving
Medical and Scientific Director of the ACS in 1956. Cameron stated (1956):
“In certain countries – especially the United States – cancer seems to be getting
more prevalent, but the amount of its increase approximately parallels the
lengthening span of life in those countries. In 1900, the death-rate from cancer in
the United States was 64 per 100,000; a baby boy could expect to live to be 48
years old and a baby girl could anticipate 51 years of life. Today, the life
expectancy of males is 68 years, and of women 72 years. But these added years
have not been won without paying a price – for the cancer death rate in U.S.A. is
now 147 per 100,000.”
Dr. Cameron’s speculations sustained their legitimacy since 1956. Pertaining
specifically to CxCa deaths in the US for the period spanning 1999 through to 2015, the
Centers for Disease Control and Prevention (CDC) validated Cameron’s deductions by
declaring (Centers for Disease Control and Prevention, 2017):
“While rates of cancer diagnoses and cancer deaths continue to decline each year,
the number of new cases and deaths are going up. This happens because the size
of our population is growing and aging each year.”
To conclude this account of macro-dynamics and arising impediments, despite
efficacious screening systems deployed to identify cervical precancerous lesions and
facilitate their timely ablation, the burden of CxCa is anticipated to increase
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proportionately with global population growth. In addition, the global discipline of
CxCa control may be vulnerable to societal, economic, political, and epidemiological
changes.

Impediments To The Development Of The Clinical Pap Test Arising From
Historical Micro-Dynamics
In large part, the development of the clinical Pap test was a derivative of
inevitable, impactful public health and historical macro-dynamics that orbited around
the realm of DC in the first half of the 20th century in the US in the context of CxCa. The
reactive discipline-specific micro-dynamics that impacted from within the realm of DC
were substantially more complex, but equally important. They in turn led to various
impediments related to Papanicolaou’s aspirations, his work, his professional
qualifications, and the conflicts that ensued following the introduction of the VFSM and
its proposed deployment in clinical screening service. Micro-dynamics also emerged due
to specific individuals that nonetheless played significant roles; either by contributing
towards the developmental evolution of the clinical Pap test, or by obstructing it.

Dr. George N. Papanicolaou: PhD Research, Employment At Cornell Medical College,
New York
Relevant to DC and the assessment of cellular morphology through microscopy,
Papanicolaou’s graduate studies proved exceptionally important.
George N. Papanicolaou was born on May 13, 1883, in Kymi, Greece. His father,
Dr. Nicholas A. Papanicolaou, was a physician and a prominent politician (Carmichael,
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1973). Although George’s early study interests were philosophy and the violin, he
abided by his father’s wishes and enrolled into medical school at the University of
Athens in 1898. In 1904, he graduated with honors at the age of 21. His knowledge of
anatomy, clinical symptoms, and disease proved invaluable throughout his career at
CMC-NY. These foundations assured the contentious concepts he introduced and
crafted in DC were credible, and not clinically irrelevant (Carmichael, 1973; Boon &
Chantziantoniou, 2013; Chantziantoniou, 20141).
Nonetheless, Papanicolaou remained uninterested in practicing medicine and
eventually refused to work as such in the family clinic in Kymi (Papanicolaou-Kokkori,
2008). Instead, he painfully gained his father’s support to pursue PhD studies in
Germany to study philosophy and the biological sciences (Carmichael, 1973; Boon &
Chantziantoniou, 2013; Chantziantoniou, 20141). In the first decade of the 20th century,
the role of chromosomes in Mendelian genetics and the fundamentals of Darwinian
biology for trait inheritance were the prominent subject matters for research and study.
These sciences were irresistible for Papanicolaou. These sciences were also the pillars of
Eugenics ideology (Black, 2003).
In the spring of 1907, Papanicolaou attended studies at the University of Jena, in
Germany, under the renowned Ernst Haeckel. Within his first semester he doubted the
suitability of his program. He thereafter relocated to Freiburg, Germany, to study under
the mentorship of August Weisman. But after another six months he was convinced that
he belonged in the Zoological Institute of Munich, to study under the distinguished

44

Professor Richard Hertwig. The Zoological Institute of Munich was then regarded the
eminent academic center for biological and zoological research (Carmichael, 1973;
Papanicolaou-Kokkori, 2008).
One activity assigned to Papanicolaou’s initial studies at the Institute was
termed: “Fertility day”. During such studies, he and his classmates observed the process
of fertilization and cell division in sea urchin cells under the microscope. These
phenomena were enthralling and proved life-changing for Papanicolaou. It was then he
chose to devote his life to biological research and not to the service of medicine per se
(Papanicolaou-Kokkori, 2008). Papanicolaou was assigned the doctorate research topic
of differentiation and determination of sex in Daphnides.
Shortly after obtaining his PhD degree in 1910, Papanicolaou returned to Kymi.
There he struggled between his personal desire to pursue biological research and his
father’s pleas he practice medicine in Kymi to promote the family clinic. Papanicolaou
stood adamant against this proposition. On September 15, 1910, he married
Andromache Mavroyeni, the daughter of a prominent military official in Greece, and the
couple journeyed immediately to France in pursuit of suitable employment
opportunities (Chantziantoniou, 20143). Fortuitously between 1911 and 1912
Papanicolaou worked as a marine zoologist at the Oceanographic Museum in Monaco,
and accompanied Prince Albert I of Monaco on Mediterranean expeditions to classify
marine species. After the death of his mother, Papanicolaou and Andromache returned
to Greece, and he was soon thereafter enlisted in the Greek military to provide medical
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support in the Balkan War in 1912 (Papanicolaou-Kokkori, 2008; Boon &
Chantziantoniou, 2013).
During his Balkan War service Papanicolaou befriended Greek-American
volunteers that spoke to him of the promise of opportunity in the far off land of the US.
These acquaintances convinced Papanicolaou that what he longed for was to pursue
biological research in the United States of America; a new life, and the opportunity to
achieve what it was that he was destined for (Boon & Chantziantoniou, 2013;
Chantziantoniou, 20142). Despite opposition from their respective families, on October
19, 1913, Dr. George N. Papanicolaou and his wife, Andromache, landed in New York,
and registered as newly-arriving immigrants to the US. Papanicolaou was then 30 years
old (Carmichael, 1973; Papanicolaou-Kokkori, 2008).
Coincidentally, it was also in 1913 that the ASCC was established in response to
the growing problem of CxCa in the US.
Soon after their arrival to New York, Dr. Papanicolaou and Andromache faced
inevitable problems, and the need for employment became imperative. Shortly
thereafter Papanicolaou met with the distinguished zoologist and Nobel Laureate at
Columbia University, Dr. Thomas Hunt Morgan, seeking his advice. In 1913, Morgan
had published a book, entitled Heredity And Sex, in which he incorporated data from
Papanicolaou’s PhD thesis (Carmichael, 1973; Chantziantoniou, 20141). This coincidence
worked in Papanicolaou’s favor as Morgan genially referred him to Dr. William James
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Elser, of the Department of Pathology and Bacteriology, at the New York Hospital. Elser
promptly hired Papanicolaou as part-time laboratory technician (Koss, 2000).
Noting Papanicolaou’s skills and passion for biological research, Elser brought
Papanicolaou to the attention of Dr. Charles Rupert Stockard at CMC-NY for possible
employment in a formal research setting. Stockard hired Papanicolaou as Instructor of
Anatomy in September 1914. Andromache Papanicolaou was thereafter permitted to
volunteer as laboratory assistant alongside her husband to manage the technical work
arising from his research starting in November 1914 (Carmichael, 1973;
Chantziantoniou, 20141).
It was also in 1914 that “negative eugenics” practices prevailed across the US to
address undesirable human diseases such as CxCa; a disease perceived to be associated
with societal immorality; and, one likely genetically transmissible (Black, 2003).

Development Of The Experimental Vaginal Fluid Smear Method In Lower Mammals
(1915-1920)
When Papanicolaou joined CMC-NY in 1914, Stockard was researching the
genetic transmission of acquired chromosomal aberrations to Guinea pig progeny.
Chromosomal impairments were induced in Guinea pigs through exposure to alcohol
vapors. Laboratory animals were bred in controlled studies to assess the inheritance of
alcohol-induced chromosomal damage against the resulting congenital anomalies
(Carmichael, 1973). Given the large colony of experimental Guinea pigs at CMC-NY,
Papanicolaou launched a research study assessing the biology of sex differentiation
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through X and Y chromosome analysis. Both Stockard’s and Papanicolaou’s research
was mutually dependent on chromosomal analysis in mitotically-active cells in Guinea
pig ovaries at ovulation (Koss, 2000).
Papanicolaou had to surgically harvest ovaries precisely at ovulation. As the time
of ovulation was unapparent, an excessive number of laboratory animals were sacrificed
without scientific advantage. Papanicolaou considered that these mammals
menstruated, although feebly. He also considered if vaginal secretions, however
miniscule, may perhaps reveal clues to help him pinpoint time of ovulation. To acquire
vaginal fluids, he obtained a nasal speculum and, using a pipette, blindly collected
vaginal fluids from animals every day over a course of months. Fluids were smeared
onto glass slides, air-dried, stained with Hematoxylin and Eosin (H&E), and
microscopically examined for repeating cellular characteristics (Chantziantoniou,
Donnelly, Mukherjee, Boon, & Austin, 2017).
Using this simple method Papanicolaou observed epithelial cell alterations that
reflected cyclical ovarian and hormonal physiology. Based on their observations,
Stockard and Papanicolaou defined the Guinea pig oestrous cycle and revealed time of
ovulation precisely. These findings were published in an obscure 3-page report in
Science in 1917 (Stockard & Papanicolaou, 19171). Concerned that the scientific
significance of their research may not be represented by 3 pages, Papanicolaou
republished their data in greater detail also in 1917 in the American Journal Of Anatomy
(Stockard & Papanicolaou, 19172). The follow-up 58-page report triangulated epithelial
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cell cytomorphology with ovarian and uterine histology, and introduced terms and
concepts that transcended into modern DC practice (Boon & Chantziantoniou, 2013;
Chantziantoniou, Donnelly, Mukherjee, Boon, & Austin, 2017; Chantziantoniou, 2017).

Transformation Of The Experimental Vaginal Fluid Smear Method Into The Clinical
VFSM In Women (1920-1948)
In 1920, being also a trained physician, Papanicolaou questioned whether the
epithelial cell changes noted in the Guinea pig experimental model may possibly occur
in the human model. However, not being a licensed clinician in New York, he had no
access to women to test this curiosity. It was in 1920 that he started applying the very
same method on Andromache. He collected a sample daily and analyzed the epithelial
cells in her vaginal secretions. This practice lasted 21 years, till 1941, from which exercise
Papanicolaou perfected the Pap stain method (Chantziantoniou, Donnelly, Mukherjee,
Boon, & Austin, 2017). It was from Andromache’s cells that baseline ‘typical’
gynecological cytomorphology was established, forming the contrast against the
morphology of ‘atypical’, malignant cells arising from CxCa (Boon & Chantziantoniou,
2013).
In 1925, Papanicolaou started analyzing vaginal fluids collected from other
women in the New York Hospital under a special professional arrangement. Some of
those women were being followed for cervical pathology. As such, in 1925, he
encountered malignant cells arising from CxCa. These encounters sparked a new
chapter in Papanicolaou’s career that ultimately led to the development of the clinical
Pap test (Chantziantoniou, 20141).
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With gained confidence in the cytologic method and in his abilities to identify
malignant cells exfoliated from CxCa, Papanicolaou embarked on a journey in 1928 to
propose the clinical VFSM as being an effective diagnostic test to confirm cervical cancer
through a presentation, entitled New Cancer Diagnosis (Papanicolaou, 1928). His
discoveries were utterly disregarded by the medical community accompanied by overt
resistance even hostility (Papanicolaou-Kokkori, 2008; Naylor, 1988). The notion that the
VFSM could become an alternative to cervical biopsy was sharply contested by his
peers. According to Davis (2007):
“…in the 1930s, the medical world was not moved by Papanicolaou’s work, and
women, black and white, continued to die at alarming rates.”
After the dismissal of the clinical VFSM following Papanicolaou’s New Cancer
Diagnosis presentation, he scaled back his research work on CxCa succumbing to a sense
of failure, and to what he feared the most in life: Embarrassment and professional
ridicule (Koss, 1973; Papanicolaou-Kokkori, 2008). Papanicolaou attributed his failure to
the poor staining of malignant cells that simply did not impress pathologists (Casper &
Clarke, 1998). This belief sparked a campaign for Papanicolaou to perfect a stain for
CxCa cells that lasted until just before his death in 1962 (Chantziantoniou, Donnelly,
Mukherjee, Boon, & Austin, 2017).
However, his 1928 presentation was also perceived as being inspired by the then
raging negative Eugenics movement in the US (Casper & Clarke, 1998; Austin &
Chantziantoniou, 2014). The initial framing of Papanicolaou’s discoveries alongside
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nuances of Eugenics ideology in the lay press was incongruent with the importance of
the revolutionary work that ultimately established gynecological DC (Chantziantoniou,
20141).
The clinical VFSM was evidently perceived as being a method through which to
identify and weed-out cancer patients for the generation of a well-bred elite race; one
immune to cancer, presumably leading to societal betterment (Carmichael, 1973; Casper
& Clarke, 1998). Papanicolaou’s presentation was delivered in the 3rd Race Betterment
Conference in Battle Creek Michigan, on January 4, 1928 (Cameron, 1962). That
conference was a conclave of “negative” eugenicists envisioning population control
through human sterilization and other tactics. It was not a formal medical meeting to
address the mounting challenges posed by a worrisome malignancy in women
(Papanicolaou, 1928; Casper & Clarke, 1998; Black, 2003; Austin & Chantziantoniou,
2014).
Four days after Papanicolaou’s 1928 Battle Creek presentation, an article
appeared in the Buffalo Evening News on January 8, 1928, by Watson Davis, entitled
Cancer Diagnosing System Discovered (Chantziantoniou, 20142). Davis stated (Davis, 1928):
“The discovery was made as a byproduct of fundamental work on the nature of
sex in women, following successful investigations of the sexual cycle of guinea
pigs and other animals, the same method of research were applied to women in
health and disease with results that promise to confer real blessings upon the
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human race just as soon as they are developed and taboos are overcome to allow
their application.”
Davis’ article manifested Eugenics undertones and alluded to “taboos” or to
prohibitions pertaining to the acceptance and application of the VFSM.
In 1928, Papanicolaou’s chairman, Dr. Charles R. Stockard, was an active and
prominent participant in the Eugenics campaign through his teachings and research at
CMC-NY (Casper & Clarke, 1998). Likewise, the director of the ASCC in 1929, Dr.
Clarence C. Little pioneered research in targeted breeding and genetic experiments in
laboratory mice at Harvard University. Little proposed that the experience arising from
the experimental mouse model may also be applied to humans. He participated in the
Eugenics movement in the US, and although immigration laws then protected the
“American gene pool from defectives, he urged sterilization of the mentally and
criminally deficient” (Davis, 2007).
Another prominent eugenicist in the US was the zoologist, Dr. Charles Benedict
Davenport, a Harvard graduate (Black, 2003). The core mantra of the eugenicists was the
control of human defects thus the menace they posed upon society; and, therefore,
protection of the purity of American society. According to Black (2003):
“Several principle areas of scholarly investigation were identified from the
worthy realms of geophysics, astronomy and plant biology. Now another
scientific endeavor would be added: negative eugenics. The program would
quickly become known as “the practical means of cutting off defective germ-
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plasm” and would embrace a gamut of remedies from segregation to sterilization
to euthanasia. The radical human engineering program would sprint not from
the medical schools and health clinics of America, but from the pastures, barns
and chicken coops – because the advocates of eugenics were primarily plant and
animal breeders.”
Therefore, any relationship perceived between Davenport, a zoologist and
prominent eugenicist, and Papanicolaou, a former zoologist researching sex
differentiation in Guinea pig breeding experiments at CMC-NY, could easily cloud the
scientific significance of the VFSM, or its relevance in diagnostic medicine and CxCa
management.
During the ‘lost decade’ that followed his 1928 Battle Creek presentation,
Papanicolaou experimented with staining techniques and developed medical
procedures and hormonal cytopathology in collaboration with Dr. Ephraim Shorr, an
endocrinologist, and avid researcher at CMC-NY (Casper & Clarke, 1998;
Chantziantoniou, 20141). To achieve workable tools by which to indirectly assay
circulating hormones, Papanicolaou engineered dyes and colors to act as markers of
varied epithelial cell origin, maturity, and viability. Along with these objectives, he also
experimented with wet fixation and staining protocols to improve the visualization of
CxCa cells in smears believing that this problem led to his professional demise
(Chantziantoniou, Donnelly, Mukherjee, Boon, & Austin, 2017). Despite the 1928 Battle
Creek setback, Papanicolaou’s curiosity and interest in CxCa and its diagnosis never
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eased - neither did encouragement from his wife and laboratory assistant, Andromache
(Mary) Papanicolaou, for him to stay the course (Hinsey, 1962; Chantziantoniou, 20143).
As it were, in 1939, Papanicolaou’s professional prospects changed utterly when
Dr. Joseph Clarence Hinsey became Chairman of the Department of Anatomy at CMCNY following the passing of Stockard. After reviewing Papanicolaou’s professional
portfolio, Hinsey was particularly impressed by Papanicolaou’s New Cancer Diagnosis
presentation and saw potential in the VFSM. But he also saw weakness. Hinsey urged
Papanicolaou to reinstate his research work channeling his efforts towards the
prevention of CxCa, not solely its diagnosis (Papanicolaou-Kokkori, 2008). The
following excerpt reflected Hinsey’s recollections of their encounters in 1939 (Hinsey,
1962):
“His first paper on this subject was presented to the Third Race Betterment
Conference and was published in its proceedings in 1928…It was met with
indifference and skepticism. He said: “I failed to create much faith among my
colleagues in the practicability of this procedure.” The prevailing opinion,
expressed to him by one of the outstanding pathologists of the time, was that
“since the uterine cervix was accessible to diagnostic exploration by biopsy, a
relatively simple procedure, the use of a cytologic examination was
superfluous.” Others less persistent and dedicated might have given up but
“Pap”, encouraged by Mary, continued.”
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Hinsey was amply cognizant of the background macro-socio-political
developments in the US following the National Cancer Act enactment in 1937, and
assertively leveraged financial support for Papanicolaou’s work from The
Commonwealth Fund, and subsequently from the ACS. Until 1941, Papanicolaou’s work
had been supported through CMC-NY; thereafter, The Commonwealth Fund provided
an initial grant of $1,800, while their total support had amounted to $124,000 by 1952
(Hinsey, 1962). Also according to Hinsey (Hinsey, 1962):
“He [Papanicolaou] came to me one day to get approval for a grant of some $4,000
from one of the pharmaceutical firms to support a project in endocrinology. He
was somewhat taken back when I urged him not to take it, but instead to devote
all his time to developing his cytologic method for diagnosis of early cancer in
the reproductive tracts of women. I told him then how I had been impressed by
his work first reported in 1928. He told me of his previous disappointments and
his fears about securing adequate support and sufficient clinical material. The
American Cancer Society was not then as vigorous as it is today and the Federal
programs for research support had not been begun. I assured him of my whole
hearted support and we both agreed that he should proceed step-wise, (1) to
develop the method and establish its validity, (2) to train others to use it, (3) then
to educate the profession and the public as to what it had to offer.”
Hinsey was visionary, and administratively savvy. He foresaw potential but also
specific impediments to Papanicolaou’s progress. He realized Papanicolaou lacked
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medical credentials in the US thus had no access to patients; he also lacked formal
training in anatomical pathology thus had neither qualifications nor authority in the
field; also, that he needed ample clinical material for analysis with tissue correlation to
test and validate his work. In light of these vulnerabilities, against a backdrop of
pervasive skepticism, Hinsey brokered the collaboration of Dr. Herbert F. Traut, a
gynecological oncologist at CMC-NY with knowledge in anatomical pathology.
Papanicolaou and Traut’s synergy, and their epic publications in 1941 and in 1943,
manifested in the renaissance of gynecological DC (Papanicolaou & Traut, 1941; Boon &
Chantziantoniou, 2013). Their works created a sensation, thrusting the discipline of DC
into the formal arena of CxCa diagnostic medicine in the US (Papanicolaou-Kokkori,
2008). These dynamics also created resistance and opposition.
Hinsey’s decision-making was the spark that catalyzed the subsequent course of
events that led to the establishment of the clinical Pap test in 1948, and to its deployment
in screening practice in the US since 1957. In a short article published in the Journal
Oncologia, in memory of Papanicolaou’s life and career, entitled Necrologia – Obituary For
George N. Papanicolaou, M.D., Ph.D., Traut referred to additional impediments in the
backdrop of World War II (Traut, 1963):
“As the material from pathological specimens became available, and the vaginal
smears matched with the observations from this material, it became probable
that the vaginal smear might adequately represent the presence of early cancer.
However, it took a number of years, approximately six, before there was enough
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data accumulated so that the collaborators could make a definite statement with
regard to the reliability of vaginal smears as an indication of the growth of
cancerous changes. The paper, read before the New York ObstetricalGynecological Society in 1938, by Papanicolaou and Traut, was the first
contribution announcing these possibilities. The studies were not readily
acceptable to pathologists in general, and the idea was not grasped with great
vigor, partly because it appeared at the time when the United States were
involved in World War II, and had many other matters to consider.”
Nevertheless, Papanicolaou and Traut’s publications and the VFSM appealed to
weary gynecologists facing the problem of advanced CxCa in their patients in the mid1940s. Among them were two prominent gynecologists: Dr. J. Ernest Ayre (Montreal,
Canada), and Dr. Joe V. Meigs (Boston, US). Ayre and Meigs promptly adopted and
tested the method in their respective clinical practices. Their contributions eventually
redefined the clinical VFSM and formalized the concept of early detection of cervical
precancer and its surgical ablation. Collectively, Ayre and Meigs entrenched the
feasibility of prevention of advanced disease through systematic screening in
asymptomatic women (Hinsey, 1962; Traut, 1963; Stewart, 1971; Hutter, 1981; Koss,
1993).
After World War II, being a gynecological surgeon, Meigs modified the practice
of radical hysterectomy for advanced CxCa and his methods led to a significant decrease
in surgical mortality rates from near 20% to 1% (Olson, 1989). Furthermore,
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epidemiological evidence in the mid-1940s then associated higher rates of CxCa with
married or widowed women, rekindling the suspicion of disease causality through
sexual activity (Olson, 1989).
Yet, the VFSM, and the cytologic method it embodied, required procedural
overhauling to offer attractive, undeniable advantages to both gynecologists and
pathologists. In this regard, Ayre’s resourcefulness proved invaluable.
J. Ernest Ayre was a gynecologist turned cytopathologist, and a staunch
proponent of Papanicolaou’s work and of the VFSM. Ayre’s hybrid skillsets afforded
him unique advantages. As a cytopathologist, he naturally related with malignant cells
arising from CxCa, the target disease of the VFSM. Meanwhile, as a former gynecologist,
Ayre understood the reservations voiced by his clinical colleagues accustomed to
confirming the disease visually and through conventional biopsies. Attempting to
reconcile these polarities, and to render the VFSM more attractive to gynecologists, Ayre
proposed a modification in Papanicolaou’s simple test in a key publication, entitled A
Simple Office Test For Uterine Cancer Diagnosis, appearing in the Canadian Medical
Association Journal, in 1944 (Ayre, 1944).
In essence, Ayre identified major deficiencies in Papanicolaou’s method of blind
vaginal pool fluid collection through a pipette. He thus redefined the VFSM making it a
two-smear test performed under direct cervical visualization. He wanted the test to be
successful but also simple enough for any clinician to perform in the office setting,
anywhere, without prerequisite gynecological specialization. In so doing, cervical
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sampling could then become ubiquitous, performed by family physicians throughout
the US, not unlike a blood test. This innovation vastly expanded the scope of practice
and outreach for the screening VFSM. Ayre proposed that under direct cervical
visualization, a standard smear be prepared from vaginal pool secretions as proposed by
Papanicolaou to include exfoliated epithelial cells from the vaginal and external cervical
surfaces. Thereafter, another dedicated smear could be prepared from mucus sampled
directly from the cervical external os to include exfoliated cells from the transformation
zone and endocervical canal (Ayre, 1944).
In 1946, Ayre reported his success in detecting cervical precancer using the twosmear modification (Ayre, 1946). But as it was subsequently questioned if his approach
may miss lesions adjacent to the cervical os on the ecto-cervix, Ayre developed the
eponymous Ayre spatula to sample the outer epithelial circumference of the cervix and
internal os (Ayre, 1947). The spatula smear Ayre termed: “surface biopsy”, contending it
would make the procedure “more rapid and more efficient” (Ayre, 1951). Ayre’s
intuitive choice of terminology conjoined the disciplines of gynecology and DC for the
sampling and screening for cervical precancer through the modified clinical VFSM.
Ayre’s work also targeted particular impediments to the deployment of the
VFSM. According to Ayre (1944):
“The statement that uterine cancer may be accurately diagnosed by the vaginal
or cervical os smear probably arouses an initial skepticism in the minds of many.
The idea at first glance perhaps appears somewhat far-fetched. It may be the
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impression of some that the vaginal smears consist only of vaginal epithelial cells
scraped off from the vaginal mucosa, and that the diagnosis of cancer is
attempted from the morphological and staining characteristics of the vaginal
cells themselves. It is difficult to conceive how any diagnosis of uterine cancer
could be made from a study of these cells alone. When one considers, however,
that the vaginal secretions contain not only vaginal cells but also cells thrown off
from the cervix, the endometrium, and the tubal epithelium, the horizon of the
diagnostic possibilities might appear to be broadened.”
Ayre defended the two-smear VFSM as follows (Ayre, 1944):
“Uterine cancer annually takes a toll of 26,000 lives in the United States. There
has been little improvement in these statistics during the last 20 years. According
to the findings of Bigelow and Lombard, the average time lost in uterine cancer
cases from the first signs of bleeding to the time of operation is almost eight
months. Therefore, delay in diagnosis is a major factor in maintaining the high
mortality rate. So often when the patient in the menopausal age presents herself
with irregular bleeding the physician finds it impossible to differentiate between
the more frequent menopausal changes and a beginning malignant growth.
A simple office test which may be taken by any physician when the first signs of
spotting are reported should be of great value speeding up the diagnosis. It is
relatively easy to diagnose cancer clinically, once the growth is advanced, but it

60

is not so simple when there is nothing abnormal palpable or visible to be found.
This is the stage when diagnosis would allow more certain cure.”
In 1947, in Iowa, Dr. Arthur W. Erskine also adopted the VFSM but ensured it
stayed locally accessible as an office test as previously advocated by Ayre, rather than it
being administered solely through distant urban medical clinics. Erskine’s approach
proved transformational in the evolution of Pap test screening. According to Gardner
(2006):
“Such local commitment, experience, and activism, coupled with women’s
traditional philanthropy, made the Iowa ACS a breeding ground for new
programs. While the national ACS debated the best way to proceed with the
vaginal smear as a screening tool for the population at large, locally the Iowa
ACS embarked on a small and specific study that would determine the test’s
effect in this community…
It was Erskine who first convinced the Iowa ACS to subsidize a local study of the
Pap smear. The ACS donated $12,000 to the program, which started in 1947
when personnel at the Gynecology Department of the State University of Iowa
City performed vaginal smears on all women over thirty years of age who were
admitted to the hospital. In addition, physicians performed vaginal smears on all
female residents of the two state mental hospitals. Clinicians collected a total of
5,214 smears and from these diagnosed 200 cancer cases.
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By 1948, preliminary results of the Iowa study confirmed the effectiveness of the
Pap smear as an effective screening tool. Cancer activists in Cedar Rapids
proposed an expansion of the Pap study to include routine tests in both Cedar
Rapids hospitals and private offices in the area. Vaginal smears could be
collected in any location, cells could be fixed to slides there, and then slides could
be transported to a central cytology lab in Iowa City for final reading. The Iowa
ACS approved the proposal, and in 1948 Cedar Rapids became the first city in
Iowa, and one of the first cities in the United States, to begin mass screening of
women using Pap smears.
The Iowa study would ultimately serve as a model for a national program for
cervical cancer screening.”
The favorable reports produced by Ayre and Meigs demonstrating clinical
progress and the outcomes from Erskine’s initiatives gave the national ACS the traction
it needed. The ACS capitalized upon these post-World War II dynamics to reconsider its
approach. It encouraged deployment of the clinical VFSM in diagnostic medicine
disregarding skepticism amongst pathologists.
As World War II had ended, and as American society yearned for a sense of
victory and enlightenment, the ACS achieved a much needed signature triumph in
public health and in societal medicine: The alleged defeat of CxCa. Collectively, these
developments were effective in raising the levels of national optimism following the
setbacks of World War II and Pearl Harbor, alongside the political and financial weight
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of the National Cancer Act of 1937, that of Mrs. Mary W. Lasker, and that of the
repositioned ACS.

The Clinical Pap Test (1948 Henceforth)
It was under the directorship of the astute Dr. Charles S. Cameron that the
national ACS coined the term Pap test for the clinical VFSM in 1948.
The ACS then actively funded major educational meetings to disseminate
knowledge, and boldly promoted the Pap test into screening service to mitigate the
growing number of unnecessary deaths due to lacking or delayed sampling (Koss, 1993).
Cameron served the ACS as its Medical and Scientific Director from 1948 to 1958 (Davis,
2007). That was the most critical decade in the history of DC, and the last decade of
Papanicolaou’s career at CMC-NY (Boon & Chantziantoniou, 2013). Nonetheless, despite
the energy projected by the ACS during the 1950s, advanced CxCa reemerged as a
profound dilemma in the US. Accounts of deaths due to purportedly preventable CxCa,
such as that of Henrietta Lacks in 1951, stoked societal distress not unlike that
experienced in the 1930s during the Great Depression, and in the 1940s prior to the
understanding of cervical precancer. Referring specifically to CxCa in the early-1950s,
Hendrix stated (The Washington Post, 2017):
“…when Lacks, a mother of five, was being treated in East Baltimore during the
Truman era, it was an illness clouded in secrecy, shame and dread.”
In post-World War II US society characterized by advancing modernization and
life-style changes, premature deaths in young women due to supposedly preventable
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CxCa became a source of awkwardness for the ACS. This was particularly poignant for
Charles Cameron. He needed to foster a paradigm shift to eternalize the notion that
CxCa had indeed been successfully defeated through availability of the Pap test. To
achieve this, he altered the direction and organizational culture of the ACS.
Until the mid-1950s, the ACS had focused essentially all its efforts towards
identifying a cure for cancer, a “downstream approach”; Cameron then advocated that,
instead, energy ought to be invested towards cancer prevention, an “upstream
approach” (Casper & Clarke, 1998). The paradigm shift that Cameron envisaged started
to materialize riding on the positive outcomes from the Memphis and Shelby County
trial, and Erskine’s accomplishments in Iowa.
On October 24, 1952, the New York Times published a poignant article, entitled
Cancer Care Seen Saving More Lives – Up To 100,000 A Year Forecast By Dr. C. S. Cameron In
Full Use Of Detection Centers. The article not only revealed the political and professional
push-back Cameron faced, it also communicated his frustration. However, it also
introduced his concept of specialized medical centers that would be dedicated to detect
thus prevent cancer, and his justification for them. Cameron’s assertion was based upon
Ayre’s proposition of the “simple office test” (Ayre, 1944). In the context of this
dissertation, the New York Times article warrants complete reproduction as follows (New
York Times, 1952):
“Dr. Charles S. Cameron, medical and scientific director of the American Cancer
Society, predicted yesterday that 75,000 to 100,000 persons could be saved
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annually if physicians and clinics gave each of their patients a six-point cancer
check-up. The examination would include the following danger areas: skin, oral
cavity, female generative tract, breast, rectum and lung with the lung requiring
the further check of an x-ray.
Dr. Cameron told the thirty-ninth annual meeting of the society at the Park
Sheraton Hotel that its cancer detection programs were coolly received by
individual doctors and local medical groups. He said the cancer detection center
idea was criticized as threatening to dislocate the traditional doctor-patient
relationship. Another program to promote cancer detection in the doctor’s office
in cooperation with state or county medical societies, he added, also had “hardly
encouraging results”.
Dr. Cameron reported that in some localities where doctors were asked to
provide cancer detection examination service, five out of six doctors indicated
their unwillingness to cooperate.
In his annual report he defended the early detection principle, replied to criticism
of the cancer detection center by holding that it served to establish direct
relations between private physicians and patients and urged reappraisal of the
program to make the doctor’s office a detection center.
He proposed a new program for detecting cancer early by centering upon the
3,500,000 persons receiving social security, all of whom are over 65 years old. Dr.
Cameron said 500,000 of these people would die of cancer if present rates held.

65

Observing that 3,500,000 persons could be examined once yearly or oftener by
100,000 doctors, he maintained that such a program could save 75,000 to 100,000
lives.
He suggested that the society might embark on a five-year plan for this special
segment of the public. He contended that if the precision weapons designed to
detect early cancer could not produce measurable results in five years there
would be reason to reconsider the validity of all cancer control.”
Four years after Cameron’s ultimatum to the ACS, in an effort to quell lingering
skepticism and societal anxiety, without belittling the plight that cancer posed upon
humanity, Cameron stated (Cameron, 1956):
“Incurable cancer, then, need no longer be a sentence to unremitting agony.
Medical science is steadily making it possible for more patients with cancer, even
though it cannot be cured, to live longer, to live more fully, and to enjoy greater
comfort. But these are not always easy to come by. They require all the ingenuity
and resourcefulness the doctor has. They call for understanding, persistence, and
gentle firmness on the part of the family. And they call for determination in the
patient to fight a good fight.”
Being the Medical and Scientific Director of the ACS in 1956, Cameron’s
statements were calculated. The responsibility perceived to be shared between clinician
and patient in the war against cancer was undeniable. But Cameron’s rhetoric inferred
beyond that relationship: He alluded to the unique responsibility that the ACS and the
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medical establishment at large also shared in that war. Cameron likewise alluded to the
fervor and clinical significance of the developments then occurring in DC overall.
Along with Hinsey, Cameron was equally aware of the politics impeding the Pap
test’s development and deployment, and was fretful of ongoing delays particularly
when time was a proven determinant of the likely success or failure of CxCa
management. Time was a predictable variable to delays in diagnosis and treatment. In
turn, delays were a predictable variable to extent of disease at presentation and
diagnosis. These key, interrelated elements were detailed by Davis, from which the
following remarks about Cameron’s frustrations are reproduced (Davis, 2007):
“Cameron’s outrage over delays in using the Pap smear in medicine finally
boiled over in 1956…Women were dying while doctors debated who should be
in charge and proposed ever more elaborate studies on the issue. At the 1956
annual ACS meeting, Cameron demanded that the board of directors stop
stalling and put the Pap test into place nationwide. “I hold that we need not wait
for more evidence; that there is enough evidence”, he declared; “that there is
enough evidence on hand to justify taking the position – women over 40, vaginal
smear twice a year. Can we justify any longer delaying a vigorous campaign to
press the use of the smear? …My conscience and the opinion of those with the
widest experience in its use say no.”
The emergence of cervical precancer from Papanicolaou’s and Traut’s work had
decisively transformed the role of the VFSM. Likewise, its diagnostic potential in
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gynecology gained the trust and buy-in from most gynecologists. Conversely, in
anatomical pathology, skepticism and opposition prevailed. At issue was the underlying
proposition of non-infiltrating cervical precancer (i.e., carcinoma in situ).
Although the concept of cervical CIS was described by another prominent
gynecologist in New York, Dr. Isidor Clinton Rubin, in 1910 (Olson, 1989), this concept
sparked a controversy amongst leading pathologists as to if cervical precancer was
indeed cancer. That is, was treated cervical intraepithelial precancerous disease truly
cured CxCa? The prospect of cervical precancer challenged the core tenets and then
understanding of cancer - being, exclusively and conceptually, an invasive, progressive,
irreversible disease (Stewart, 1971; Hutter, 1981; Koss, 1993).
These controversies resurfaced intensely in 1951 when Henrietta Lacks presented
with advanced CxCa and soon thereafter died of it age 31; after never having a cervical
smear test although it was available since 1941, when she was 21 (Skloot, 2010). Lacks’
case projected worrisome inadequacies in societal and diagnostic medicine overall that
could have conceivably affected, and taken the life of, any woman. Collectively, these
issues posed contentious impediments that lingered beyond Papanicolaou’s death in
1962, well into the late-1970s. This debate lingered until the HPV-associated etiology of
CxCa was unraveled, and high-grade squamous intraepithelial lesion (HSIL) became a
formal diagnostic, clinical, and therapeutic entity (Hutter, 1981; Koss, 1993; Syrjanen,
2017).
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The indiscriminate menace of CxCa and its widespread societal ramifications in
humanity were underscored in an article in The Washington Post, entitled When Henrietta
Lacks Had Cervical Cancer, It Was A ‘Death Sentence’. Her Cells Would Help Change That, by
Steve Hendrix, published on April 22, 2017. According to Hendrix (The Washington
Post, 2017):
“One month after Lacks was buried, another woman whose name would live
forever was wheeled into an operating room to be treated for cervical cancer, and
she didn’t even know it. Eva Peron, the glamorous and powerful wife of
Argentinian President Juan Peron, was never told she had the disease.
Evita thought she was having a procedure by a leading Buenos Aries surgeon to
stop some cervical bleeding. Instead, after she was anesthetized, George Pack, a
cancer specialist from New York who had been flown secretly to South America,
entered the O.R. and performed a radical hysterectomy.
There was such a taboo around cancer that many doctors didn’t want to use the
C-word at all, lest the patient lose hope – or commit suicide – at a time when
cancer seemed always to lead to a coffin.
With Peron, of course, politics and power also played a role in the secrecy. But
even when the surgery failed to stop the cancer, and she went into a painful
decline, she was kept in the dark.
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Peron and Lacks fell to cervical cancer right at the beginning of a new age in
fighting the disease. The biggest breakthrough was the introduction of a
remarkably effective test for pre-cancerous cells developed by a Greek-born
violin player and doctor named George Papanicolaou. His simple “pap smear”,
which allowed doctors to treat and cure the cancer before it became established,
was just coming into general use as a screening tool when Lacks fell ill.
Cervical cancers are now considered one of the more treatable malignancies, but
not everywhere. In poor areas, where screening and treatment remain out-ofreach for many women, it’s still 1951.”
In 1956, due to his growing frustration, Cameron produced a book aimed for the
general public but to also implicitly press the medical establishment for unacceptable
behavior in its efforts to control cancer in the US. His book was written to increase
layman’s awareness of cancer and to arouse action in seeking medical attention early.
Cameron’s book framed time as being the key determinant between possible cure or
death from cancer, entitled The Truth About Cancer (1956), Cameron stated (1956):
“The woman who is wise enough to play it safe, then, will insist on a careful
examination of her pelvis twice a year – no matter how strong and healthy she
seems to be. Do you doubt the wisdom of this procedure? Then just compare the
curability of cancer of the uterus in very early, moderately advanced stages with
its curability in late stages: Treatment of very early cancer of the uterus will cure
70% per cent or more. About 35 per cent of the moderately advanced cases,
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which is the condition in which most women with the disease are first seen by
the doctor, can be cured. And of the late and extensive cases, fewer than 10 per
cent can be saved.”
As the clinical Pap test was being increasingly deployed into service, Cameron’s
book in 1956 alluded to unfavorable odds for 5-year survivals from advanced cervical
cancer despite the availability of the clinical VFSM since 1941 and improved surgical
procedures developed by Meigs (Olson, 1989). Cameron aimed to persuade the general
public to exercise self-empowerment and advocacy through increased knowledge of
cancer and of its symptoms. Cameron transferred ownership and political leverage to
the public and, particularly, to the patient. His commentaries also aimed to subtly off-set
the lagging medical establishment as screening practices for CxCa were being
frustratingly deliberated in the US in the latter-1950s primarily due to widespread
skepticism and inaction. Nonetheless, in the absence of promising therapies, and due to
poor long-term survival outcomes for all cancer patients, the disease remained dreaded
as an indiscriminate hindrance to societal betterment throughout the US (Cameron,
1956).
As screening services were being implemented throughout the US, other
impediments promptly emerged. A prominent issue became the lack of laboratories and
therefore the lack of expertise to manage the growing volumes of smears that were being
prepared as a result of increased health literacy. Secondly, pathologists remained
resistant as not accustomed to grading abnormal cells appearing singly or in groups on
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glass slides using unfamiliar stains (Boon & Chantziantoniou, 2013). Thirdly, neither
reporting nomenclature nor therapeutic approach was consistent throughout the US.
And, fourthly, the deployment of low-paid, non-medical cytologists to read the
cumbersome smears became yet another matter of contention (Casper & Clarke, 1998).
As the majority of screening cytologists were women, the overall system became
imbalanced with engendered polarities: Most pathologists were men, and most
screening cytologists were women. These situations led to serious problems for the
burgeoning clinical Pap test and for the ACS struggling to establish it through
Cameron’s insistence (Casper & Clarke, 1998).
Furthermore, the expanding screening system for early detection of a dreaded
woman’s cancer, supported by women cytologists, for the benefit of all women,
rekindled the gender sensitivities surrounding the woman-physician relationship in the
context of CxCa. Sensitivities implied: Could male doctors truly understand and
prioritize the defeat of cervical cancer in all women? (Casper & Clarke, 1998).
In a commemorative article published in the Journal Of The American Medical
Association in 1962, entitled Dedication Of The Papanicolaou Cancer Research Institute,
Cameron summed-up the salient accomplishments arising from Papanicolaou’s 50-year
journey in research and in CxCa diagnosis and prevention (Cameron, 1962):
“He devised a means of identifying cancer of the uterus in the presymptomatic
stage and thereby placed beyond 80% the curability of the second most fatal
cancer in women…He defined with superb precision carcinoma in situ of the
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uterine cervix and demonstrated that the smear will discover the precursor to
invasive cancer before it can be seen with the naked eye and when it can be
eradicated in 100% of cases. By these 2 achievements he has provided the means
of delivering women from the threat of death by uterine cancer…
He has provided science with a precision system of investigation which makes
possible the detailed analysis of cellular morphologic changes – in transition
from wholly normal to the frankly neoplastic – and thereby he has opened to
scientists a new avenue of the study of mechanisms of carcinogenesis.”
Nevertheless, CIS altered the epidemiology and understanding of CxCa. It also
impacted on screening practice, the concepts of cervical pathobiology, and how these
parameters may ultimately yield the control of CxCa.

Screening Principles And World Health Organization Targets
Preclinical CxCa prompted reassessment of the linear model of cervical
carcinogenesis considered in the 1920s. By the late 1960s, sufficient knowledge of CxCa
had been garnered through Pap test screening whereby the fundamentals of medical
‘screening’ required reformulation. It became evident that screening for cervical
precancer in asymptomatic women was synonymous with CxCa prevention. That is, by
detecting the intraepithelial entity, the invasive entity may be negated through
intervention. The Pap test was therefore aligned for the preclinical entity; although, it
could detect either entity. The complexities of CxCa gradually challenged the theory of
linear carcinogenesis. This was due to the regressive nature of some cervical lesions
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relative to progressive lesions that quickly led to invasive disease although variably, and
not inevitably between patients. The inability for the profession to explain these
phenomena was problematic. But they did nonetheless manifest yet another mysterious
dimension of CxCa.
These developments compelled the WHO to formulate its Principles and Practice
of Screening for Disease in 1968 (Croswell, Ransohoff, & Kramer, 2010). The WHO’s
principles aimed to guide the development of screening methods. The WHO’s criteria
follow (Croswell, Ransohoff, & Kramer, 2010):


The condition sought should be an important health problem.



There should be an accepted treatment for patients with recognized disease,
and treatment should be better at an earlier stage.



Facilities for diagnosis and treatment should be available.



There should be a recognizable latent or early symptomatic stage.



There should be a suitable test or examination.



The test should be acceptable to the population.



The natural history of the condition, including development from latent to
declared disease, should be adequately understood.



There should be an agreed-upon policy on whom to treat as patients.



The cost of case-finding (including diagnosis and treatment of patients
diagnosed) should be economically balanced in relation to possible
expenditure on medical care as a whole.
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Case-finding should be a continuing process and not a “once and for all”
project.

From a contemporary lens, both the nature of CxCa and the experience generated
by Pap test screening collectively aligned with the criteria set out by the WHO in 1968.
But outcomes arising from the intensifying screening practices throughout the US since
the mid-1950s revealed an even greater complexity for CxCa prevention stemming from
the subjective, interpretive nature of the Pap test itself, and its inherent diagnostic error
rates. These problems of course played into the hands of myopic skeptics, but they also
influenced future design and application of screening practices, and screening interval
guidelines.
Eventually, the Pap test resolved the very issue that obstructed its establishment
in 1928: That cervical CIS was a lesion typically unapparent for biopsy; therefore, biopsy
alone may be insufficient to negate CxCa. This reality was repeatedly cautioned by Ayre
since 1944 (Ayre, 1944). This outcome governed the foundations for prospective
cytologic screening. Effective precancer surveillance, and ensuing disease prevention,
commanded that the Pap test and cervical biopsy become one in purpose: Mutuallydependent.

Sequential (Two-Stage) Testing Model For Cervical Cancer Prevention Through
Screening
Due to its preclinical phase and invasive phase, CxCa was branded a two-phase
disease (Croswell, Ransohoff, & Kramer, 2010; Skloot, 2010; Gordis, 2014). This
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characterization and the complement formed between the Pap test and biopsy led to the
Sequential Two-Step Testing model for CxCa screening. According to Gordis (2014):
“In sequential or two-stage screening, a less expensive, less invasive, or less
uncomfortable test is generally performed first, and those who screen positive
are recalled for further testing with a more expensive, more invasive, or more
uncomfortable test, which may have greater sensitivity and specificity. It is
hoped that bringing back for further testing only those who screen positive will
reduce the problem of false positives.”
The Sequential Two-Stage Testing model manifested the basis for Pap test
screening. From the effort to identify a subgroup of women in a given population, two
additional factors emerged: (a) Classification of individuals at risk for developing this
disease; and (b) Qualification of disease prevention through screening (Gordis, 2014).
Therefore, with definition of the at risk subgroup, the benefits of screening may be
maximized; and as the Pap test could detect preclinical disease in asymptomatic women,
it was destined to serve as a tool for secondary disease prevention.
Reports by Foltz and Kelsey (1978), Greenwald, Cullen and McKenna (1987), and
Foulks (1998), methodically described the incremental expansion of the theoretical and
practical essentials pertaining to Pap test screening for CxCa. But with expanding
screening practices throughout the US, previously unforeseen epidemiological
limitations soon emerged. These problems were due to biases produced from screening,
as they impacted upon the calculation of actual incidence or prevalence rates of disease.
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The dominant biases were: Healthy volunteer bias; Lead-time bias; and, Over-diagnosis
bias (Croswell, Ransohoff, & Kramer, 2010).
It is nonetheless important to impress that the eventual acceptance of the clinical
Pap test by 1957 was a direct result of its transformation from the 1928 VFSM prototype
driven by key modifications incorporated into the method, and into the organizational
infrastructure supporting and promoting Pap test screening. Major improvements
included the dedicated Papanicolaou staining method (Chantziantoniou, Donnelly,
Mukherjee, Boon, & Austin, 2017); the Ayre two-smear VFSM and office test, and the
subsequent Ayre collection spatula (Ayre, 1944; Ayre, 1947); conceptualization of
precancerous (i.e., carcinoma in situ) cervical lesions (Meigs, 1947; Ayre & Ayre, 1949;
Ayre, 1949; Papanicolaou & Koprowska, 1951; Koss & Durfee, 1956; Ayre, 1961); method
verification through large population trials such as the Iowa Cedar Rapids project, and
the Memphis and Shelby County study with corroboration from prominent institutions
(Dunn & Sprunt, 1955; Gardner, 2006); women’s advocacy and empowerment (Reagan,
1997); and, the establishment of a low-paid, non-medical workforce trained to analyze
the growing numbers of smears arising from expanding screening practices (Casper &
Clarke, 1998).

Promotion And Endorsement Of Pap Test Screening In The US
In 1957, despite the ongoing achievements, the control of CxCa remained dismal.
The ACS was left with little alternative but to once again bolster the significance of time,
to push ahead with Pap test screening endorsement.
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Television had then supplanted radio as being the prominent technology by
which to reach the public throughout the vastness of the US. To reemphasize the
significant impact of time in the diagnosis and management of CxCa, and to highlight
accrued knowledge for the lay public, the ACS commissioned a television documentary
in 1957 narrated by the prominent gynecologist, Dr. Joe V. Meigs. The program was
titled: Time And Two Women. The transcript of that documentary, along with specific
photos and images of gynecological anatomy, was also published in the Journal Of The
American Medical Association by Meigs in 1957 (Meigs, 1957). The Abstract from that
publication follows (Meigs, 1957):
“Seeking to motivate women to adopt the lifesaving habit of health checkups,
this film was released as a part of a broad education program which will be
undertaken in communities where technical facilities are available for
interpreting vaginal smears, and where the county medical societies approve use
of this film. The uterine cancer cell examination, the “Pap” smear, is explained in
an effort to alert women to the urgency of early detection of uterine cancer. The
film deals with diagnosis of cancer of the uterus with special emphasis on
cytology and dramatizes the fate of two women: one who ignored warning
signals and saw her doctor too late and the other whose early cervical cancer was
detected in the course of a periodic checkup.”
Although the transcript alluded to possibly inadequate infrastructure throughout
the US, and to reluctance by some county medical establishments to air the
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documentary, it may be stated that subsequent to 1957, the clinical Pap test was
arguably understood, established, and decisively set upon a US-wide course of
deployment supported by remarkable health literacy and promotion, and the vested
interests of the ACS. According to Gardner (2006):
“The history of the vaginal smear offers one illustration of the technological
innovations that redefined female cancers in the second half of the twentieth
century. As scientists, practitioners, female patients, and cancer activists sought
ways to detect cancer as early as possible, screening technology gained
impressive financial and academic support that shaped cancer awareness
advocacy. Undoubtedly, Mary Lasker’s influence and emphasis on funding
cancer research contributed to the promotion of the Pap smear in U.S. culture.
Although cancer educators waited until the late 1950s to launch a cervical cancer
screening awareness campaign, the evolution of the technology and the scientific
responses to cancer screening dated back to the early twentieth century.”

Dr. George N. Papanicolaou: Personal Letters, Character, Aspirations, And Professional
Conflicts
Papanicolaou’s sensitivities may be appreciated through his major (i.e., larger)
publications listing laborious narratives describing preceding work by his peers
(Chantziantoniou, 20141). This may be evident in the publications through which he
introduced novel methods or concepts; such as: The introduction and role of the
experimental VFSM in Guinea pigs (Stockard & Papanicolaou, 19172), and the
application of the VFSM in women along with inception of the Papanicolaou staining
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method (Papanicolaou, 1933). To him, the more novel and potentially controversial the
concept, the more support it demanded. Papanicolaou structured commensurate
scientific evidence upon which to frame his observations, hypotheses, and conclusions.
Papanicolaou’s intuitive style of writing may also be appreciated in his personal
correspondences that were reviewed for this dissertation. During the difficult period
when he was trying to convince his father of what he wanted in life and why,
Papanicolaou composed letters mirroring a ‘scientific’ defense. Laborious
correspondences were exchanged between 1907 and 1910 designed to debate yet frame
his preferences and counter-arguments against the prospect of him practicing medicine.
The similarities between his personal and scientific writings are striking; revealing
Papanicolaou’s ability to precisely organize and set, and communicate convincing
propositions (Papanicolaou-Kokkori, 2008).
After reviewing the pertinent English and Greek literature, and Papanicolaou’s
personal correspondences in the context of this dissertation, it may be argued that his
character remained unchanged throughout life. Since boyhood, Papanicolaou yearned to
understand and to champion the forces of nature (Carmichael, 1973; Boon &
Chantziantoniou, 2013; Chantziantoniou, 20141). He frequently and purposely put
himself in perilous situations to test his determination and resilience (PapanicolaouKokkori, 2008). Throughout life, he also remained awestruck by the rhythmic vitality
and demise of cells and living organisms in nature’s Kingdoms. These grand aspirations
and dilemmas drove his decision-making throughout life, transcending into the passion,
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energy, and determination encoded within the fabric of his scientific work in DC. These
aspirations allowed him to dare curiosity and failure, to surpass defeats, but also to
intuitively organize observations into articulate scientific deductions.
It is important to reiterate that although Dr. George N. Papanicolaou held a
Medical Doctor degree from the University of Athens, he was not a practicing clinician
in the US. Neither had he pursued formal training in anatomical pathology. Throughout
his 43-year career at CMC-NY, he was employed in the Department of Anatomy
working in the research and academic arenas. His career’s work at CMC-NY was upheld
by his post-graduate PhD degree from the University of Munich. Papanicolaou was not
a formal anatomical pathologist.
Understandably, Papanicolaou’s work on the diagnosis of CxCa inevitably led to
various professional conflicts. These conflicts manifested into impediments due to him
lacking qualifications thus authority in the field of anatomical pathology (Koss, 1973).
He was never oblivious of the realities however, nor viewed the risks as being trivial
(Carmichael, 1973). Papanicolaou’s sensing of controversial concepts in DC as being
potential obstacles to his progress was highly intuitive.
Papanicolaou’s character and aspirations were important throughout his career,
affording him the necessary tools by which to overcome and navigate past contentious
issues, and what seemed oftentimes as impassable obstacles. Nevertheless, his career’s
journey was neither painless nor straightforward and support, through various forms,
was necessary to sustain momentum in the development of the clinical Pap test and DC.
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Papanicolaou sustained a life-long fear of embarrassment and of insecurity in general
(Carmichael, 1973; Papanicolaou-Kokkori, 2008). In the professional setting, he was
particularly sensitive to producing work that may attract ridicule from pathologists; and
particularly when his conceptualizations over-extended onto their realms of authority
(Koss, 1973). These problems became most profound in 1943 and in 1951 when
Papanicolaou introduced his concepts of CIS in gynecological and pulmonary
cytopathology respectively, and the existence of dyskaryotic cells.

Dr. George N. Papanicolaou: Dyskaryotic Cells Pathognomonic Of Cervical Precancer
The cytomorphology of the dyskaryotic cells Papanicolaou asserted as being
pathognomonic of non-infiltrating cancer became another major impediment. The topic
of dyskaryotic cells was a highly contentious issue in cervical DC in the mid-1950s. Dr.
Leopold G. Koss was an enduring skeptic of Papanicolaou’s propositions. In 1956, Koss
and Grace R. Durfee stated (Koss & Durfee, 1956):
“The cellular abnormalities characterizing koilocytotic atypias, of course, have
been noticed before. They fall into Papanicolaou’s category of superficial,
intermediate, and parabasal cell dyskaryosis. This classification of abnormal cells
is of didactic value only, since pathologic findings clearly indicate that large
atypical cells may be found at all levels of the epithelium.”
The matter of dyskaryotic cells became an extraordinary flashpoint. These cells
posed a challenge squarely on pathologists accustomed to reading histologic sections, as
they struggled to assimilate with the cytomorphology of exfoliated, oftentimes single
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epithelial cells in smears arising from CIS (Foote & Li, 1948; Carson & Gall, 1953; Ayre &
Scott, 1961; Johnson, Easterday, Gore, & Hertig, 1964; Hutter, 1981). Despite the
opposition, and lack of authority, Papanicolaou stood adamant to the proposed
diagnostic value of dyskaryotic cells. His posturing was not always welcome, and this
led to conflicts with prominent pathologists. But unlike pathologists, Papanicolaou had
the advantage of not being bound by cells in histologic sections, nor by H&E staining.
This matter led to various confrontations and was exceptional enough that it captured
entirely the texts and discussions of Symposium A published in the maiden issue and
volume of Acta Cytologica in 1957 (Koprowska, 1997; Bibbo, 2011; Chantziantoniou,
2017).

Divides Of Authority Between Papanicolaou’s Experimental Work And Clinical
Practice
Throughout the saga of the clinical Pap test, Papanicolaou’s wife and closest
associates helped him persevere and stay the course. Andromache, Hinsey, Traut,
Cameron, Hashime Muryama, Dr. Andrew A. Marchetti, and Dr. Irena Koprowska were
equally as conscious of his character and risks, and from their own personal efforts
allayed Papanicolaou’s weaknesses facilitating incremental progress (Hinsey, 1962;
Marchetti, 1969; Carmichael, 1973; Koprowska, 1997).
From all the historical dynamics, perhaps, Hinsey’s thoughtfulness and
administrative stances resolved the majority of impediments. Hinsey’s decision to
broker the collaboration between Papanicolaou and Traut (and later to include the
gynecologist, Dr. Andrew A. Marchetti) proved critical in bridging the divides of
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authority between Papanicolaou’s experimental work and clinical practice (Carmichael,
1973). This was imperative for progress. Their synergy, and their publications describing
the cytomorphology of cervical CIS, cemented a bond between the VFSM and
beleaguered gynecologists facing the dire challenges of advanced CxCa, and family
physicians eager for guidance. Hinsey successfully managed the tethering between
experimental laboratory methods with the clinical management of a dreaded
malignancy in women. Traut’s involvement in that historical juncture was crucial. Like
Ayre, Traut understood the language of anatomical pathology; he also understood the
histological patters of CxCa, and he readily assimilated with the respective dyskaryotic
cells scattered in smears arising from those cancers. Being a gynecologist, Traut also
understood the problems posed by occult cervical precancer in asymptomatic women,
and the urgencies and surgical challenges posed by advanced cancer in symptomatic
women. Traut successfully entrenched the clinical relevance of Papanicolaou’s work in
preventive medicine; something Papanicolaou almost certainly may not have been able
to achieve solely. However, the triangulation between subjective DC, anatomical
pathology, and clinical gynecological oncology, did not materialize with ease. Koss
stated the following in 2010 (Koss, 2010):
“Dr. Pap himself was a rather insecure diagnostician. Instead of using clear
terminology to describe his findings, he used classes; he subdivided his smears
into classes from I to V because he felt safer if he used the term “Class III” rather
than saying the smear was suspicious of cancer.
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It became quite evident to me that there were some serious problems with that
technique, that the people who were interpreting smears, such as Dr. Pap, had
really no idea of the underlying pathology. The pathologists on the other hand,
had a very vague idea of what cytology could offer. It became clear to me from
the beginning that there ought to be someone who would know both areas of
diagnosis and could combine them. Ultimately, I wrote a number of books,
which were attempting to explain or to clarify the relationship of the techniques
for the benefit of mankind.”
It must also be emphasized that development of gynecological cytopathology
through its arduous evolutionary course was a testament of Papanicolaou’s personality.
Our understanding of his nature, and of its pertinence during this saga, may be formed
as gleaned from his personal letters, and from various remarks and accounts
communicated by his closest associates and relatives, but also from his critics (Hinsey,
1962; Koss, 1963; Koss, 1973; Koss, 1983; Koprowska, 1997; Papanicolaou-Kokkori, 2008).
Overall, he was a patient, sentimental, soft-spoken man; although, one reserved,
and painfully steadfast in his convictions and decisions. No matter the hardship, he was
determined to pursue what he regarded logical, scientifically sound, and beneficial to
humanity. Papanicolaou was also naturally intelligent and briskly aware of imminent
risk or opportunity. He was introverted and overly cautious, oftentimes difficult to be
understood (Koss, 1973; Koprowska, 1997). Nonetheless, although his attributes and
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dynamism occasionally reared interpersonal conflicts with various colleagues, they also
ultimately governed his overall sense of vision, and sense of purpose.
In the late-1940s, supported by the ACS, Papanicolaou, Traut, and Marchetti,
were actively speaking in various academic and professional forums to disseminate
knowledge of cervical DC and the value of the clinical Pap test in preventing disease.
After all, dissemination of knowledge was one of the mutually-agreed upon
recommendations posed to Papanicolaou by Hinsey in 1939 (Hinsey, 1962). Following
one such meeting, Marchetti recollected as follows (Marchetti, 1969):
“At the greater number of these meetings it was the pathologists who were the
most vehement in stating that Dr. “Pap’s” smear was a superfluous procedure
when the more reliable biopsy of the cervix was already available for cancer
diagnosis. I could sense that during a discussion the then current point of view of
the pathologists would hurt Dr. “Pap” very much. The few times that I presented
the subject I would conclude by stating that the cytologic smear of the cervix and
vagina in screening for cancer would eventually become as important as the
peripheral blood smear in diagnosing hematologic disease. This conclusion, I
suspect, gave heart to Dr. “Pap” when he made his concluding remarks, since he
knew I believed it. That conviction, in my humble judgement, remains
unchanged. Indeed, if facilities for cytologic screening were made available to
every woman on the universe and if all women were willing to take advantage of
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these facilities, currently I am ready to state that death from carcinoma of the
cervix, in two or three decades, would become unacceptable.”
Marchetti’s narrative embodied the essence of the overall micro-dynamics in DC
prior to 1957 when Papanicolaou retired from CMC-NY. More importantly, however,
Marchetti’s convictions were prophetic as CxCa has indeed become a preventable
disease through effective Pap test screening. And, as a result, deaths due to advanced
CxCa may appropriately be regarded as being proxies of suboptimal Pap test uptakes, or
of underperforming screening systems (Foltz & Kelsey, 1978; Koss, 1989; Dickey, 2001).

Salient Impediments To The Development Of The Clinical Pap Test In The
US, Categorized And Stratified For Two Salient Timeframes: 1928-1941 And
1941-1957
This sub-section organizes the salient historical impediments to the development
of the clinical Pap test in the US.

Evolutionary Timeframes Of Pap Test Development
Papanicolaou and Traut reintroduced the VFSM to the medical community in
1941 as being an effective method by which to detect precancerous lesions of the uterine
cervix through an epic paper, entitled The Diagnostic Value Of Vaginal Smears In
Carcinoma Of The Uterus (Papanicolaou & Traut, 1941; Austin & Chantziantoniou, 2014).
Their descriptions of CIS became a formative turning point in the evolution of
gynecological DC and defined a pivotal historical reference focus. As the clinical Pap test
evolved over a period of 29 years (i.e., 1928-1957), it appeared prudent to organize the
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associated impediments to its development as stratified before and after 1941. For the
intents and purposes of this dissertation, the two timeframes are defined as follows:


Timeframe 1 (1928-1941): Introduction of the clinical Vaginal Fluid Smear
Method as a diagnostic test for advanced cervical cancer



Timeframe 2 (1941-1957): Reintroduction of the clinical Vaginal Fluid Smear
Method as a screening test for cervical precancer

The salient historical impediments to the overall development of the clinical Pap
test from 1928 through to 1957, before and after 1941, were summarized specifically
through nine categories and dedicated Tables:
1. Socio-economic factors
2. Socio-political factors
3. Socio-behavioral factors
4. Cervical cancer: burden, diagnosis, treatment, and prognosis
5. Method imperfections, and interruptions
6. Method framing, public awareness, and advocacy
7. Clinical application, and validation
8. Infrastructure, and human resources
9. Dr. Papanicolaou: vulnerabilities, professional qualifications, and conflicts

Tables Summarizing The Salient Historical Impediments
Tables 1 through 9 summarizing the salient historical impediments to the overall
development and application of the clinical Pap test follow:
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TABLE 1: Salient impediments to the development of the clinical Pap test in the United
States due to socio-economic factors, stratified before and after 1941.
Impediments: Socio-economic factors
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)



Great Depression: widespread



World War II

economic and societal declines,



Papanicolaou’s work in CxCa detection





curtailed medical services

was underfunded at CMC-NY until

Underfunding: ASCC unable to invest

1944 when the ASCC was rebranded

towards the control of CxCa

and espoused allocation of research

Papanicolaou’s work in CxCa detection

funds

not supported at CMC-NY thus
underfunded


Higher rates of CxCa linked with
poorer women



Lack of funding to support research in
overall cancer control
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TABLE 2: Salient impediments to the development of the clinical Pap test in the United
States due to socio-political factors, stratified before and after 1941.
Impediments: Socio-political factors
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)



Disruptions due to Great Depression,



Disruptions due to World War II

societal decline



Unmet societal expectations for





Perceived association between VFSM

effective cancer control; inaction by the

and negative Eugenics movement

ASCC to control CxCa till its

3rd Race Betterment Conference; not a

rebranding in 1944

medical conference


VFSM deemed unnecessary by
pathologists, gynecologists





The Womens Field Army deemed
inappropriate, disbanded



Papanicolaou lacking professional

Lacking support for Papanicolaou’s

credentials and authority in anatomical

work in CxCa diagnosis by Stockard at

pathology

CMC-NY


Skepticism and resistance to the VFSM
by pathologists

Perceived encroachment by VFSM on
conventional cervical biopsy





Societal expectations for cancer control
unmet by the ASCC



Questioned role of the clinical Pap test
in diagnostic medicine
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TABLE 3: Salient impediments to the development of the clinical Pap test in the United
States due to socio-behavioral factors, stratified before and after 1941.
Impediments: Socio-behavioral factors
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)





Etiology and pathobiology of CxCa
unknown; dreaded disease leading to

Etiology and pathobiology of CxCa
unknown; mysterious, dreaded disease

certain death



Societal distress, anxiety



Societal distress, anxiety, hopelessness



Stigmatization from CxCa



Stigmatization from CxCa



Societal sensitivities, taboos



Societal sensitivities, taboos



Lacking health literacy; diagnostic



Lacking health literacy; diagnostic
information withheld from women



information withheld from women


Lacking women’s sense of

Lacking women’s sense of
susceptibility to CxCa

susceptibility to CxCa



Lacking women’s self-empowerment



Lacking women’s self-empowerment



Delayed diagnosis and treatment of



Delayed diagnosis and treatment of
CxCa



Inadequate doctors’ engagement,
commitment, and buy-in

CxCa


Inadequate doctors’ engagement,
commitment, and buy-in
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TABLE 4: Salient impediments to the development of the clinical Pap test in the United
States due to cervical cancer burden: diagnosis, treatment, and prognosis, stratified before and
after 1941.
Impediments: Cervical cancer burden: diagnosis, treatment, and prognosis
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)



Death rates due to cancer increasing





CxCa burden out-paced population

availability of VFSM due to inaction

growth

towards prophylactic screening







Diagnosis of CxCa through visual

Unfavorable 5-year survival rates due

inspection of cervix with biopsy

to advanced cancer at delayed

confirmation

presentation and time of surgical

Treatment solely through radical

intervention

hysterectomy with surgical mortality



Inconsistent treatment for CxCa

rates at 20%



Disagreement about cervical CIS, its

Poor prognosis due to delayed
detection of advanced disease at
presentation, 60% inoperability





CxCa death rates increasing despite

Pathologists, gynecologists unaware of
cervical precancer

qualification, and how to treat it

92

TABLE 5: Salient impediments to the development of the clinical Pap test in the United
States due to VFSM imperfections, and interruptions, stratified before and after 1941.
Impediments: VFSM imperfections, and interruptions
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)





Disruptions due to Great Depression,
lost decade of cytopathology



VFSM smears cumbersome to read due

Great Depression


to excessive blood, necrosis


Poor staining due to air drying, H&E



Pathologists lacking skill sets to grade





Questioned role of the VFSM in
preventive medicine



VFSM perceived as being unnecessary
relative to conventional cervical biopsy

single, dyskaryotic cells in smears



Opposition by pathologists

Opposition to VFSM by pathologists;



Pathologists resistant to concept of

method deemed unnecessary relative

cervical CIS, and diagnostic value of

to conventional biopsy

dyskaryotic cells

Lacking correlative diagnostic



nomenclature with anatomical
pathology


Disruptions due to WWII following the

Gynecologists and pathologists not
engaged

Resistance to VFSM screening for CxCa
by medical establishment



Lacking health literacy throughout the
US
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TABLE 6: Salient impediments to the development of the clinical Pap test in the United
States due to VFSM method framing, public awareness, and advocacy, stratified before and
after 1941.
Impediments: VFSM framing, public awareness, and advocacy
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)





3rd Race Betterment Conference; not a
formal medical meeting



Perceived association between VFSM

pathobiology, and precancer


and negative Eugenics movement


Unfavorable initial framing of the

Lacking public awareness of VFSM



Women lacking sense of susceptibility



ASCC underfunded, leading to

Concern of alienating women,
physicians, and pathologists



to CxCa


Women lacking sense of susceptibility
to CxCa

benefits


Lacking public awareness of VFSM
benefits

VFSM in lay press


Lacking awareness of CxCa etiology,

Reluctance to adopt the ‘simple office
test’ proposed by Ayre



Reluctance by some States to

diminished political influence

participate in improving health literacy



VFSM not endorsed by ASCC

of CxCa



Geographic vastness of the US,
compromised health literacy
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TABLE 7: Salient impediments to the development of the clinical Pap test in the United
States due to VFSM clinical application, and validation, stratified before and after 1941.
Impediments: VFSM clinical application, and validation
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)





VFSM dismissed by pathologists,
gynecologists







Population-based trials lacking due to

application by pathologists


Population-based trials lacking till 1947

Depression, lost decade of

(Erskine) and 1951 (Memphis and

cytopathology, and skepticism

Shelby County trial)

VFSM imperfections; lacking technical



Political push-back against CxCa

optimization, suboptimal staining

screening as a ‘simple office test’, or

VFSM unattractive to gynecologists

through cancer detection centers

due to lacking knowledge of cervical



Widespread resistance to VFSM



Disagreement amongst clinicians of

precancer

CxCa screening practice; inaction,

VFSM unattractive to pathologists due

deliberations of Pap test application

to lacking skill sets in grading single



Lacking infrastructure; laboratories,

abnormal cells in smears using

expertise, workforce to sustain

unfamiliar stains

screening system expansion and smear
analysis
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TABLE 8: Salient impediments to the development of the clinical Pap test in the United
States due to infrastructure, and human resources, stratified before and after 1941.
Impediments: Infrastructure, and human resources
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)





Lacking knowledge and infrastructure
to support the newly-introduced VFSM



Lacking support by Stockard at CMC-

organized CxCa screening


NY for VFSM clinical testing


Lacking scientific foundations by
which to support the VFSM at CMCNY



Lacking professional multi-disciplinary
collaborations at CMC-NY till 1939

Lacking infrastructure to support

Lacking skilled personnel (i.e.,
pathologists and screening cytologists)



Lacking US-wide adoption of Pap test
screening
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TABLE 9: Salient impediments to the development of the clinical Pap test in the United
States due to Dr. Papanicolaou’s vulnerabilities, professional qualifications, and conflicts
stratified before and after 1941.
Impediments: Dr. Papanicolaou: vulnerabilities, professional qualifications, and conflicts
Timeframe 1 (1928-1941)

Timeframe 2 (1941-1957)



Perceived relationship between



Papanicolaou not a licensed clinician

Papanicolaou and negative Eugenics



Papanicolaou lacking qualifications

movement


Papanicolaou not a licensed clinician;

and authority in anatomical pathology


lacked qualifications and authority in
anatomical pathology; concepts

Papanicolaou’s concepts questioned,
dismissed by pathologists



Papanicolaou’s diagnostic terminology

questioned, dismissed by pathologists

(i.e., Dyskaryotic cells, Pap Class



The lost decade of cytopathology

Reporting system) incongruent with



Papanicolaou’s perceptions of failure,

diagnostic language of anatomical

inability to solely perfect the VFSM

pathology leading to push-back



Lacking professional multi-disciplinary
collaborations at CMC-NY



Lacking support from CMC-NY for
Papanicolaou’s work
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CHAPTER 3: CERVICAL CANCER BURDEN,
EPIDEMIOLOGICAL EXPERIENCE, CLINICAL PAP TEST
UPTAKES, AND HEALTH PROMOTION IN THE STATE OF
QATAR

Pap Test Uptakes In The Extended Middle East And North Africa Region
Practically all the nations that comprise the Extended Middle East and North
Africa (EMENA) geographic region have not adopted organized, national populationbased Pap test screening programs for the secondary prevention of CxCa in the
asymptomatic female population; nor strategically in women deemed at risk for
developing this disease. In the EMENA region, Pap test uptakes are overwhelmingly
opportunistic (Seoud, 2013; Sancho-Garnier et al., 2013).
Opportunistic Pap test sampling may be defined as: The uptake of Pap test
cervical sampling services as the clinical opportunity warrants (Gustafsson, Ponten,
Zack, & Adami, 1997). Opportunistic screening systems typically do not involve an
initial patient call to screening or recall.
Essentially all nations and territories in the EMENA region deploy opportunistic
screening practices in their public and private healthcare sectors (Sancho-Garnier et al.,
2013). However, most of the wealthier nations in this region, notably the Gulf Arab
States, and Saudi Arabia, operate standard-of-practice tertiary medical institutions, most
of which serve patients through premier diagnostic laboratory services modeled after
American practices and accredited by the College of American Pathologists (CAP).

98

As the Pap test is not widely deployed for population-based screening in the
EMENA region, it is instead utilized as a diagnostic test to rule out or rule in CxCa in
response to presenting, suspicious symptomatology. Consequently, nearly all cervical
cancers in this region are initially detected through opportunistic Pap test sampling.
And, as was the situation in the early 20th century in the US, the majority of cervical
cancers diagnosed in the EMENA region are characteristically in advanced stages at
diagnosis (Sancho-Garnier et al., 2013; Alemrayat et al., 2018). In such clinical settings,
opportunistic Pap test sampling may also be defined as being optional; not strategically
or formally advocated for disease detection or prevention in the at risk, asymptomatic
clinical population.
In the context of public health and women’s welfare in the EMENA region
however, the impact of advanced CxCa poses potentially devastating, highly impactful
societal detriments. This holds particularly true in the predominantly conservative,
traditional societies that are characteristic of this region largely based on matriarchicallystructured cultural norms, and the considerable societal importance placed upon female
fertility (Seoud, 2013; Jumaan, Ghanem, Taher, Braikat, AlAwaidy, & Dbaido, 2013).
It is important to nonetheless emphasize the remarkable health promotion
initiatives and campaigns undertaken in the State of Qatar to increase health literacy for
CxCa, and particularly since 2014. Major initiatives conducted mainly through the
QMoPH, the PHCC, and the QCS are listed in chronological sequence in subsequent
sub-sections in this Chapter.
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Global Cervical Cancer Burden
Cervical Cancer Burden In Resource-Poor, Developing Global Regions
According to World Health Organization (WHO) estimates, over one million
women globally have CxCa although unaware of their disease. Most of these women in
developing nations face no prospect of access to Pap testing or to gynecological services
(Cibas & Ducatman, 2014; World Health Organization, 2014). These women comprise a
population sub-set harboring preclinical disease and, therefore, the most likely
beneficiaries of secondary disease prevention through Pap test screening.
According to the Institut Catala d’Oncologica (ICO), 527,624 new cases of CxCa
were diagnosed worldwide in 2012; whereas, 265,672 proved fatal (Institut Catala
d’Oncologica, 20171). These data equate into a global death rate of 50.3% for new cases
alone. However, 230,158 of those fatal cases (86.6%) occurred in low- to middle-income
developing nations due to financial or screening disparities (Institut Catala
d’Oncologica, 20171).
Alarmingly, in the absence of secondary preventative screening, the death rate
due to CxCa in resource-poor nations is projected to increase by 25% within the next
decade (Consul, Agrawal, Sharma, Bansal, Gutch, & Jain, 2012).
In 2017, according to the ICO World Report (ICO, 20171), CxCa ranked as the 4th
leading type of cancer in women globally, and the 2nd most common cancer in women in
the 15-44 years age group globally.
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Cervical Cancer Burden In The US
Of the half million new cases of CxCa anticipated globally and annually
according to the WHO (World Health Organization, 2014), the ACS estimated that
13,170 of those cases will be registered in the US for the year 2019; whereas, 4,250 of
those women would die of their disease (World Health Organization, 2014; Limmer,
LoBiondo, & Dains, 2014; American Cancer Society, 2018). These ACS estimates suggest
a 32.2% US-specific death rate due to CxCa in modern clinical practice.
Importantly, the 13,170 new cases expected in the US for 2019 equate to nearly
2.5% of the total global burden of new cases estimated by the WHO and the ACS (World
Health Organization, 2014; American Cancer Society, 2018).

Cervical Cancer Burden And Management In The State Of Qatar
The State of Qatar is a sovereign nation amongst the Gulf Arab States, and a
member country of the EMENA region (Seoud, 2013). Qatar is also assigned to the
greater geographic region of Western Asia by the ICO (Institut Catala d’Oncologica,
20172).
Qatar is an affluent sea-fairing Arab State forming a small Peninsula jutting
acutely into the Persian Gulf from the eastern flank of the greater Saudi Arabian
heartland. The State of Qatar boasts a modern, hospitable, educated society, although
one embedded in the fabric of a traditional, conservative, Bedouin culture as is
characteristic of most Gulf Arab States (Qatar Ministry of Foreign Affairs, 2019). The
State of Qatar has experienced an unprecedented economic boom in the past 40 years
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resulting in remarkable multi-sector modernization (Qatar Ministry of Economy and
Commerce, Oxford Business Group, 2019). Qatar is currently in the midst of massive
infrastructure development in the run-up to the FIFA World Cup event in 2022. The
healthcare sector has similarly expanded medical services in tandem with these national
developments.
According to information published by the World Population Review, pertaining
to Qatar and to the US, the population of Qatar was estimated to be 2.7 million in July
2018, relative to 327 million for the US in February 2018 (World Population Review,
20181; World Population Review, 20182). In Qatar, women comprised 25.09% of the
entire population, estimated to be 676,137 (World Population Review, 20181). In 2018, the
minority of these women were Qatari nationals, and the majority expatriate women
residing in Qatar originating from various countries, predominantly from Asia.
Accordingly, the population pyramid of Qatar is significantly skewed towards
males. The vast majority of the male population comprises an expatriate, blue-collar
migrant workforce employed in the infrastructural megaprojects. The female population
is characterized by a primary age group component of 30-34 years, followed by a
secondary component of 35-39 years (Institut Catala d’Oncologica, 20172).
Of the entire female population in Qatar in 2017, 481,127 women (71.1%) were
over the age of 15 and deemed at risk for developing CxCa according to the ICO (Institut
Catala d’Oncologica, 20172).
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Accessing Pap Test Sampling In The State Of Qatar
Access to Pap test sampling is currently available through private and public
healthcare providers in the State of Qatar (QMoPH Guide To Healthcare Services In
Qatar General Adult Population, 2018).
The public healthcare system is robust and multi-tiered. The Qatar Primary Health
Care Corporation (PHCC) (www.phcc.qa) operates 26 community-based healthcare
centers strategically located throughout the nation based on population density. The
community-based centers provide a wide range of primary care services acting as the
first contact of consultation for non-emergent patients. Depending on the medical
concern, patients may either undergo treatment locally or be referred to larger centers in
the capital city, Doha, for additional investigations and treatment.
The largest public tertiary hospital in Qatar is the Hamad Medical Corporation
(HMC) in Doha (www.hamad.qa). The HMC was established in 1979 through Emiri
decree as a not-for-profit healthcare organization. The HMC currently integrates 12
specialist hospitals and provides comprehensive standard-of-practice medical services to
accommodate patients that could not be treated in the community-based setting. The
HMC houses the largest, comprehensive DC service in Qatar managing the vast majority
of Pap test cases (approximately 10,000 cases annually) arising from the public system,
predominantly cases received from PHCC centers. The HMC DC service is modeled
after American (i.e., Bethesda) guidelines for the reading and reporting of gynecological
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Pap test cases, as also dictated through the College of American Pathologists (CAP)
inclusive of HPV reflex genotyping for high-risk HPV.
Expatriate residents in Qatar that have a Qatar Identification number (QID) may
access medical services at PHCC centers or HMC and settle a nominal deductible fee.
Medical consultations, treatment, and pharmacological prescriptions are heavily
subsidized by the State. Emergency medical services are provided without fee
throughout Qatar.
Another major establishment in Doha is Sidra Medicine (www.sidra.org). Sidra
Medicine is a private, fee-for-service, ultramodern academic Women’s and Children’s
hospital. Sidra Medicine is affiliated with CMC-NY, through the Cornell Medical
College-Qatar campus located in the Education City complex adjacent to Sidra Medicine.
The DC service at Sidra was launched in February 2018. The Sidra DC service is likewise
modeled after American and CAP accreditation guidelines, inclusive of HPV reflex
genotyping.

Current Pap Test Uptake Practice In The State Of Qatar
At the time of this writing, the State of Qatar has not implemented a formal,
organized, national population-based Pap test screening program for cervical cancer
prevention for all asymptomatic resident women inclusive of initial patient call to
screening or recall. Through guidance from the QMoPH, PHCC, and the QCS, the State
is currently providing opportunistic Pap testing services due to the low prevalence of
this disease (discussed in greater detail in Chapter 6).
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Cervical Cancer Epidemiology In The State Of Qatar
Cervical Cancer Rates In The State Of Qatar
According to the Human Papillomavirus And Related Disease Report For Qatar in
2017 (Institut Catala d’Oncologica, 20172), CxCa ranks as the 5th most common cancer in
women in the State of Qatar, and the 6th most common cancer in women in the 15-44
years age group.
Also according to the ICO (Institut Catala d’Oncologica, 20172), the State of Qatar
had a crude incidence rate of 3.2 cases per 100,000 for CxCa (relative to 3.8 cases for
Western Asia); and a crude mortality rate of 0.9 cases per 100,000 (relative to 1.6 cases for
Western Asia). Recent studies by Sathian, van Teijlingen, & Rajesh (2018) report an agestandardized incidence and death rate for CxCa in Qatar as being: 5.1 and 2.4 per
100,000 respectively. In comparison, the age-standardized incidence and death rates for
CxCa in the US for the period spanning 2011-2015 were: 7.6 and 2.3 per 100,000
respectively according the American Cancer Society (2018).
Cervical Cancer Registry, Presentation, And Diagnosis In The State Of Qatar
Under the auspices of the Qatar National Cancer Program, the National Cancer
Registry initiative was launched at HMC in 2012 to record prevalence statistics from
cancer cases (A.A. Hmaidan; personal communication, March 21, 2016). Prevalence
statistics prior to 2012 were computed from case studies based on treatment course and
outcomes, hence regarded potentially inaccurate. As such, epidemiologically-accurate
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cancer statistics became available in Qatar from 2012 henceforth through the National
Cancer Program.
From 1970-2015, in Qatari women, 61 invasive CxCa cases and 18 CIS cases were
experienced totaling 79 cases; whereby, 77.2% were invasive cases, and 22.8% were
precancerous cases. In the same timeframe, in expatriate women, 178 invasive CxCa
cases and 32 CIS cases were experienced totaling 210 cases; whereby, 84.8% were
invasive cases, and 15.2% were precancerous cases.
The National Cancer Registry, Cancer Incidence 2014 report (Appendix A) (QMoPH
National Cancer Program, 2014) revealed that 18 cases of CxCa were registered in 2014
along with 17 cases of CIS of the cervix. The report also declared that of the 18 cases of
invasive cervical cancer registered, 28% of these cases were in Qatari women while the
remainder 72% of cases were in non-Qatari, expatriate women. Also, importantly, that
greater than 60% of all the CxCa cases registered in 2014 were subsequently shown to
harbor Stage II/III disease at histologic diagnosis; and, that these cases produced a
bimodal pattern of prevalence distribution based on two peak age groups: 40-44, and 6064 years. The clinical and demographic data of CxCa cases arising from the
contemporary Qatar setting closely align with ICO World Report estimates. The ICO
(Institut Catala d’Oncologica, 20172) published an anticipated annual CxCa burden of 15
cases for Qatar; four of which may be fatal, reflecting an estimated death rate of 26.7%
annually.
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Cervical Cancer Health Literacy And Healthcare Promotion In The State Of
Qatar
Sidra Medicine Symposium: The 1st Century Of Gynecological Cytopathology, The Pap
Test – Then, Now And The Future
The author took employment at Sidra Medicine starting in November 2013. In
line with the National Cancer Registry, Cancer Incidence 2014 report (QMoPH National
Cancer Program, 2014), the Sidra DC Section and the Department of Pathology
organized a dedicated symposium to raise awareness of CxCa, Pap test screening
practices, and vaccination for HPV. The symposium, entitled The 1st Century Of
Gynecological Cytopathology, The Pap test – Then, Now And The Future, was conducted on
December 07, 2014 (Appendix C, D, and E). The symposium was open to all
stakeholders affiliated with the detection and management of CxCa in the State of Qatar.
Attendees included clinicians, diagnostic cytologists, and representatives from the
QMoPH. The symposium and its outcomes were widely acknowledged in the local
English and Arabic language press and web-based media.
Following the Sidra Medicine symposium in 2014, the author was invited to
participate in an ad-hoc committee at the QMoPH to explore the prospect of organized
CxCa screening in the State of Qatar. The author’s participation ended in March 2016.

Guidelines For Cervical Cancer Screening In The State Of Qatar
In 2016, the QMoPH, through its National Cancer Program, published draft
guidelines for the management of CxCa inclusive of screening practice in a report,
entitled Guidelines For Cervical Cancer Screening In The State of Qatar (QMoPH National
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Cancer Program, 20161) (Appendix F). The guidelines produced General Principles
suggesting:
“All eligible and asymptomatic women aged 25 to 64 years and sexually active
should be invited for routine cervical screening at given age ranges and
screening intervals:


Women aged 25 to 49 years should be screened every 3 years;



Women aged 50 to 64 years should be screened every 5 years.”

Moreover:
“Depending on the cervical screening result, human papillomavirus test (HPV
test) will be conducted.”
The General Principles also recommended that women ought to give consent to
Pap test sampling after being adequately educated of the risks and benefits of screening.
Nevertheless, in due course, the QMoPH decided that CxCa management
through Pap test population-based screening with patient call and recall shall remain
under consideration as a work-in-progress. Shortly thereafter, the author was advised
that given the relatively low incidence rates recorded for this disease in this
geographically-small clinical setting, Pap test uptakes were to remain opportunistic in
the State of Qatar (V.V. Recreo; personal communication, March 17, 2016).

Guideline For Suspected Cancer Referral In The State Of Qatar
Also in 2016, the QMoPH, through its National Cancer Program, published its draft
guidelines for clinicians to follow a referral process for suspected cancer patients,
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entitled Guideline For Suspected Cancer Referral In The State Of Qatar (QMoPH National
Cancer Program, 20162) (Appendix G). The guidelines were based on a flow-chart
guiding the management of patients depending on presenting symptoms, and suspected
cancer type; whereas:
“The suspected cancer referral guidelines have been produced with the
assistance of a multidisciplinary group of clinicians to provide a comprehensive
overview of the suspected cancer patient’s journey from referral to timely
diagnosis and treatment.”
The purpose of the guidelines was to assure least possible delays in cancer
diagnosis and treatment. The proposed Patient Referral Pathway included a flow chart,
entitled Urgent Suspicion Of Cancer. The referral pathway proposed clinical examinations
and diagnostic investigations be conducted within 48 hours of patient presentation; and,
that definitive treatment be initiated within 14 days of diagnosis. Such initiatives are
highly extraordinary.
Specifically for suspected gynecological cancers (i.e., cervical, endometrial and
ovarian cancers), the clinical criteria for clinicians to apply the 48-hour Urgent Suspicion
Of Cancer pathway follow:


Post-menopausal bleeding



Abnormal high grade cervical smear (HSIL, ASC-H, AGC)



Suspicious mass



Suspicious imaging
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Radiological findings strongly suspicious of invasive malignancy

Similarly, the clinical criteria for a patient’s referral within 14 days for additional
investigations follow:


LSIL



Irregular bleeding in a woman on hormone replacement therapy



Purulent vaginal discharge



Bloodstained vaginal discharge



Inter-menstrual bleeding



Post-coital bleeding



Persistent abdominal distention/bloating



Abdominal/pelvic pain



Feeling full quickly and/or having difficulty eating (loss of appetite)

Qatar Cancer Society Awareness Campaign For Cervical Cancer: “Be Well”
In January 2017, the QCS launched an extensive health awareness campaign,
entitled Be Well (Qatar Cancer Society, 2017) (Appendix H). The campaign ran
throughout the month of January 2017 to raise awareness of CxCa, of its symptoms, of
its potential prevention through Pap test screening, and to ultimately encourage women
to “check out the Pap smear.” The campaign also included lectures and workshops
conducted by authorized officials. The article posted on January 11, 2017, in the
QatarIsBooming website (www.qatarisbooming.com), stated:
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“…cervical cancer often does not cause symptoms until it is advanced, so it is
important to start the early detection tests regularly even when you feel healthy,
and in Qatar: you can do the Pap test in Primary Health Care Center (Women’s
Health Clinic).”

National Health Strategy 2018-2022
In 2018, the QMoPH published the National Health Strategy 2018-2022, under the
subtitle, Our Health Our Future (QMoPH National Health Strategy 2018-2022, 2018)
(Appendix I). The national strategy stipulated an increased but comprehensive effort for
the early detection of disease and its possible prevention through improved health
education and best-practice services for cancer treatment. The ultimate target of the
strategy, through to 2022, was a 15% reduction in premature mortality due to chronic
diseases such as cancer (QMoPH National Health Strategy 2018-2022, 2018).

National Clinical Guidelines For The State Of Qatar (2nd Edition)
In April 2017, in the run-up to the National Health Strategy 2018-2022, the QMoPH
had published its 2nd edition clinical guidelines, entitled National Clinical Guidelines For
The State Of Qatar – 2nd Edition (Appendix J). The QMoPH capitalized upon the extensive
internet connectivity and mobile phone networks installed throughout the State to
provide practice guidelines for all registered clinicians through dedicated websites,
apps, and e-medicine platforms. The rationale of the guidelines follows (QMoPH
National Clinical Guidelines For The State Of Qatar – 2nd Edition, 2017):
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“The majority of healthcare practitioners working in Qatar have been trained
overseas. As we draw upon the advantages brought forward by the diverse set of
specialized skills, languages and perspectives in patient and peer interactions, it
is also of utmost importance to acknowledge that this may innately contribute to
a significant variation in the standard of care provided.
The National Clinical Guidelines project started in April 2015. Initially, through
consultations with stakeholders, the MoPH NCG team mapped the processes for
guideline development and localization by different organizations across Qatar’s
health economy. The gaps between current practice in Qatar and the
international best practice approach were identified and accordingly a model for
guideline development was agreed and established.”

Qatar Ministry Of Public Health Infographic: “What Is Cervical Cancer?”
Also in 2017, the QMoPH produced a public health infographic, entitled What Is
Cervical Cancer (Appendix K(a) and K(b)). The 2-page fold-out brochure illustrated
salient information about CxCa: Its global incidence; its etiology; what is HPV; the
symptoms of CxCa and of HPV infection; how women may protect themselves from
HPV and CxCa; the purpose of HPV vaccination; and, encouragement for women to
seek medical care (QMoPH What Is Cervical Cancer, 2017).

HPV Vaccination Protection In The State Of Qatar
In February 2018, the QMoPH announced its endorsement and immediate rollout of the national vaccination program for HPV (Sathian, van Teijlingen, & Rajesh,

112

2018; QMoPH Health Protection & Communicable Disease, 2018). The program
advocated prompt availability of the HPV vaccine throughout the State to facilitate
protection and primary prevention of CxCa. The program proposed that HPV
vaccination be made available to females and males age 12 to 26.

Opportunities For Healthcare Promotion Research
Along with the myriad of initiatives and health literacy campaigns conducted in
the State of Qatar since 2014, the introduction of HPV vaccination in 2018 manifested an
unprecedented potential for effective CxCa control. As such, these developments posed
a unique opportunity for research to assess current public awareness of CxCa, of the Pap
test, and, of perceptions and attitudes towards HPV vaccination. Similarly, to assess
likely public support for a formal population-based CxCa screening program for all
resident women through a needs-assessment survey offered to both women and men.
In addition to the knowledge gained from the historical development of the Pap
test in the US, such survey-based data may reveal gaps to guide the consideration of
tailored cytopathology and gynecology services at Sidra Medicine in keeping with the
governmental initiatives and long-term healthcare ambitions for the State. Such research
data may also aid in the optimization of existing CxCa management philosophies and
practices in the State of Qatar to mitigate the number of women presenting with
advanced disease at diagnosis.
Through a collaborative research team effort at Sidra Medicine, a needsassessment survey was strategically designed to test for these opportunities. Relevant
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survey-based research designs were reviewed for the development of the needsassessment survey: (Kahn, Chiou, Allen, Goodman, Perlman, & Emans, 1999; Badrinath,
Ghazal-Aswad, Osman, Deemas, & McIlvenny, 2004; Lyva, Byrd, & Tarwater, 2006;
Denny & Wright, 2009; Fernandez, Diamond, Rakowski, Gonzales, Tortolero-Luna,
Williams, & Morales-Campos, 2009; Guvenc, Akyuz, & Acikel, 2010; Tanner-Smith &
Brown, 2010; Ma, Gao, Fang, Tan, Feng, Ge, & Nguyen, 2013; Jaglarz, Tomaszewski,
Kamzol, Puskulluoglu, & Krzemieniecki, 2014; Lee & Carvallo, 2014; Ebu, Mupepi,
Siakwa, & Sampselle, 2015; Glanz, Rimer, & Viswanath, 2015; Interis, Anakwenze, Aung,
& Jolly, 2016).
The structure of the survey, along with its questions and responses, and their
rationale, are listed in Chapters 4 and 5 respectively.
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CHAPTER 4: NEEDS-ASSESSMENT SURVEY MATERIALS AND
METHODS

Preceding Survey-Based Research In The State Of Qatar
To uncover relevant, preceding survey-based research from the State of Qatar, a
PubMed search was conducted using the following four key terms inclusively: Cervical +
Cancer + Survey + Qatar. The search revealed one indexed survey-based study by AlMeer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) reporting findings arising from a
needs-assessment project conducted in 2008 reflecting women participants visiting
PHCC centers in Qatar. Two other studies were also revealed from the PubMed search
reporting epidemiological data arising from Qatar, but not from needs-assessment
surveys. A Google search using the same key terms inclusively revealed a second
survey-based study by Alali, Salem, Elmahdi, Alkubaisi, Alwahedi, Taher, Yousuf,
Aljaber, & Mostafa (2016) not indexed in PubMed. These two survey-based exercises
analyzed responses exclusively from women participants.
It is the author’s belief that this dissertation comprises the third survey-based
exercise conducted in the State of Qatar; although, it was the first to assess perceptions
and magnitude of support for a formal, national Pap test screening program for all
resident women; from both women and men participants.
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Needs-Assessment Survey Design
The needs-assessment survey research protocol was composed following
guidelines from the National Institutes of Health (NIH) (National Institutes of Health,
2018). The research protocol, survey questions, and responses were produced
collaboratively in both English and Arabic, and submitted to the Sidra Institutional
Review Board (IRB) Ethics Committee for consideration on November 02, 2017.
Following two revisions, the research study was formally approved by the Sidra IRB on
December 11, 2018, under protocol number: MoPH-Sidra-IRB-099. The distribution of
300 surveys commenced on December 28, 2018, and ended on April 03, 2019. The Sidra
IRB approval stipulated that survey distribution be conducted within the Sidra Medicine
caption area.
The survey was voluntary, self-reported, and anonymous as no personal
identification information was requested or recorded. Invited participants were women
or men, either visitors or patients accessing gynecological services at Sidra Medicine, or
interested employees. The survey was exclusively in hard-copy format. After
participants’ completion of the survey, all surveys were enclosed in dedicated envelopes
and subsequently organized to support data capture.
The Sidra IRB committee dictated the final wording of the survey questions and
responses in both the English and Arabic survey versions to sustain cultural sensitivity
and the societal norms of the State of Qatar. Specific wording nonetheless aimed to
uphold the intent and rationale of the questions as direct translations from English to
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Arabic were not always appropriate or comprehensible. The Sidra IRB committee also
approved a Leaflet to accompany the surveys to welcome the respondents and provide
an introduction to the aims of the research effort. The Leaflet, produced in both English
and Arabic, also functioned to document participants’ consent to survey participation,
with an attestation of their age not being under 18 years. Given the laws and stipulations
applicable to medical practice and research in the State of Qatar, an exclusion criterion
was imposed such that the survey would not be made available to participants younger
than 18 years of age.

Needs-Assessment Survey Questions, Responses, And Rationale
The needs-assessment survey was considered through a collaborative research
team effort (see Acknowledgments) and consisted of 31 questions. The English version
of the survey, in its entirety, appears in Appendix B. The survey questions were worded
with relevance to the current practices for CxCa management in the State of Qatar, and
took into account preceding survey-based research. The overall intent was to produce
robust data reflecting the views and opinions of women and men, to support services
development at Sidra Medicine, and ongoing, follow-up research and academic work.

Needs-Assessment Survey Questions And Data Categories
The needs-assessment questions and responses were designed to capture
information based on four broad data categories: (1) Socio-demographic; (2) Healthcare
Services; (3) Health Literacy; and, (4) Self-efficacy and Perceptions.
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The breakdown of questions (i.e., variables) incorporated into the four data
categories follows:


Category 1: Socio-demographic (Questions 1-8, and 31)



Category 2: Healthcare Services (Questions 9-11)



Category 3: Health Literacy (Questions 12-20)



Category 4: Self-efficacy and Perceptions (Questions 21-30)

Needs-Assessment Survey Questions
The needs-assessment survey questions, responses, and their specific rationale
follow:
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Question 1
Nationality.
o

Qatari

o

Middle Eastern

o

Asian

o

European

o

North American

o

South American

o

African

o

Other

Rationale: Question 1 aimed to capture socio-demographic data based on:
Nationality. The intent was to produce a breakdown of the nationalities arising from all
respondents to facilitate correlation with the proportionality of nationalities amongst all
residents currently in the State of Qatar. Such data may elucidate population
representation.

Question 2
Gender.
o

Female

o

Male

Rationale: Question 2 aimed to capture socio-demographic data based on:
Gender. The intent was to facilitate stratification of the entire data set based on gender.
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Question 3
Age group (Years).
o

Under 20

o

20-29

o

30-39

o

40-49

o

50-59

o

Over 60

Rationale: Question 3 aimed to capture socio-demographic data based on: Age
group (years). This question aimed to capture age-related data from all
respondents based on six age-group categories. The intent was to reveal
distributions particularly from women to allow correlations with preceding
epidemiological data arising from Qatar as published by the QMoPH (QMoPH
National Cancer Program, 2014) in the context of CxCa. This question would also
facilitate the exclusion of participants younger than age 20.

Question 4
Highest education level.
o

Middle School

o

High School

o

University

o

Other

Rationale: Question 4 aimed to capture socio-demographic data based on: Highest
education level. This question aimed to capture the extent of education from all
respondents to facilitate correlations with population-based statistics arising from the
State of Qatar.
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Question 5
Marital status.
o

Never married

o

Married

o

Divorced

o

Widowed

Rationale: Question 5 aimed to capture socio-demographic data from all
respondents based on: Marital status. This question would also facilitate correlation with
previously-reported studies, and statistics arising from the State of Qatar.

Question 6
Marriage duration.
o

Under 5

o

5-10

o

10-20

o

Over 20

o

Not applicable

Rationale: Question 6 aimed to capture socio-demographic data from all
respondents based on: Marriage duration (in periods of years).

Question 7
Employment status.
o

Employed

o

Unemployed

o

Other

Rationale: Question 7 aimed to capture demographic data from all respondents
based on: Employment status. The intent was to reveal extent of likely financial
independence amongst respondents.
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Question 8
You have health insurance coverage?
o

Yes

o

No

Rationale: Question 8 aimed to capture socio-demographic data from all
respondents based on: Health insurance coverage.

Question 9
You had a Pap test before?
o

Yes

o

No

o

Not applicable

Rationale: Question 9 aimed to capture healthcare services data based on: Pap test
uptake. This question aimed to assess the likelihood of Pap test uptakes from all women
respondents; allowing subsequent exclusion of male respondents.

Question 10
If you had a Pap test before, when was it performed?
o

1-3 years ago

o

4-6 years ago

o

Over 6 years ago

Rationale: Question 10 aimed to capture healthcare services data based on: Years
duration since previous Pap test. This question aimed to assess time-frames of preceding
Pap test uptakes from all women respondents; allowing subsequent exclusion of male
respondents. These data may correlate with the screening intervals currently
recommended by the QMoPH based on age-group.
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Question 11
Did you, or any member of your family have cervical cancer before?
o

Yes

o

No

o

Don’t know

Rationale: Question 11 aimed to capture healthcare services data based on:
History of cervical cancer in family member. This question aimed to assess awareness of
CxCa from all respondents.

Question 12
Cervical cancer may be preventable.
o

Yes

o

No

o

Don’t know

Rationale: Question 12 aimed to capture health literacy data based on: Knowledge
of cervical cancer preventability. This question aimed to assess awareness pertaining to the
possible prevention of CxCa from all respondents.

Question 13
You are aware of the Pap test smear cytologic method.
o

Yes

o

No

Rationale: Question 13 aimed to capture health literacy data based on: Awareness
of the Pap test smear cytologic method. This question aimed to assess public awareness
pertaining to the Pap test smear cytologic method from all respondents.
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Question 14
Where did you hear of the Pap test smear cytologic method for the first time?
o

Relatives, friends

o

Gynecologist

o

Mass media (newspaper, internet, television)

o

Family physician

o

Nurse

o

Other

o

Not applicable

Rationale: Question 14 aimed to capture health literacy data based on: Source of
knowledge of the Pap test smear cytologic method. This question aimed to assess the
predominant sources of information regarding the Pap test cytologic method from all
respondents.

Question 15
You have knowledge of cervical cancer.
o

Yes

o

No

Rationale: Question 15 aimed to capture health literacy data based on: Knowledge
of cervical cancer. This question aimed to assess knowledge pertaining to CxCa from all
respondents.
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Question 16
Early detection of cervical cancer is important for effective treatment.
o

Yes

o

No

o

Don’t know

Rationale: Question 16 aimed to capture health literacy data based on: Importance
of early detection of cervical cancer for effective treatment. This question aimed to assess
awareness pertaining to the importance of early detection of CxCa to facilitate effective
treatment for all respondents.

Question 17
Regular Pap tests may protect you from cervical cancer.
o

Yes

o

No

o

Don’t know

Rationale: Question 17 aimed to capture health literacy data based on: Knowledge
of protection afforded through regular Pap test uptakes. This question aimed to assess
awareness pertaining to likely disease prevention through protection availed by regular
Pap test uptakes from all respondents; allowing subsequent exclusion of male
respondents.
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Question 18
Cervical cancer may be curable.
o

Yes

o

No

o

Don’t know

Rationale: Question 18 aimed to capture health literacy data based on: Curability
of cervical cancer. This question aimed to assess awareness pertaining to the likely
curability of CxCa from all respondents.

Question 19
Vaccination for the Human Papilloma Virus protects against cervical cancer
and other HPV-associated cancers.
o

Yes

o

No

o

Don’t know

Rationale: Question 19 aimed to capture health literacy data based on: Knowledge
of protection for HPV-associated cancers, and cervical cancer, through HPV vaccination. This
question aimed to assess awareness pertaining to the likely protections offered through
HPV vaccination for the development of CxCa and other HPV-associated cancers from
all respondents.
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Question 20
Menopausal women need a Pap test.
o

Yes

o

No

o

Don’t know

Rationale: Question 20 aimed to capture health literacy data based on: Knowledge
of need of Pap testing for menopausal women. This question aimed to assess knowledge
pertaining to the need for Pap testing by menopausal women from all respondents. This
question may reveal significant findings as the peak incidence of CxCa in the State of
Qatar occurs in the 60-64 years age group as published by the QMoPH (National Cancer
Program, 2014).

Question 21
More information is needed to improve your knowledge of cervical cancer.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 21 aimed to capture self-efficacy and perceptions data based
on: Need for additional information to improve participant’s knowledge of cervical cancer. This
question aimed to assess self-efficacy and agreement/support reflecting the need for
additional health literacy pertaining to CxCa from all respondents.
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Question 22
Regular Pap tests are a good health practice.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 22 aimed to capture self-efficacy and perceptions data based
on: Degree of good health practice through regular Pap testing. This question aimed to assess
self-efficacy and agreement/support of the perceived value embedded in regular Pap
test uptakes as being a good health practice from all respondents.

Question 23
Getting a Pap test performed is too difficult.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 23 aimed to capture self-efficacy and perceptions data based
on: Difficulty of getting a Pap test performed. This question aimed to assess degree of selfefficacy and agreement/support of the likely difficulty in getting a Pap test performed
from all respondents; allowing subsequent exclusion of male responders. This question
may reveal perceptions of barriers to Pap testing specifically in women.
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Question 24
You would recommend a Pap test to your family, friends, and colleagues.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 24 aimed to capture self-efficacy and perceptions data based
on: Recommendation of the Pap test for family, friends, and colleagues. This question aimed to
assess degree of self-efficacy and agreement/support of the respondent to recommend
the Pap test to family, friends, and colleagues from all respondents. This question may
also reveal a reflection of overall knowledge of CxCa and of Pap testing, and of
perceived barriers to Pap test uptakes.

Question 25
Getting a Pap test is a valued investment for good healthcare.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 25 aimed to capture self-efficacy and perceptions data based
on: Value of investment in a Pap test for good healthcare. This question aimed to assess
degree of self-efficacy and agreement/support of the perceived value of investment
embedded in the Pap test for good health from all respondents.
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Question 26
You would support a Pap test screening program for cervical cancer.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 26 aimed to capture self-efficacy and perceptions data based
on: Support for a screening program for cervical cancer. This question aimed to assess degree
of self-efficacy and agreement/support for a Pap test screening program from all
respondents.

Question 27
A formal Pap test screening program for cervical cancer should be established
for all women in the State of Qatar.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 27 aimed to capture self-efficacy and perceptions data based
on: Support for the establishment of a formal screening program for cervical cancer for all
resident women in the State of Qatar. This question aimed to assess degree of self-efficacy
and agreement/support for the establishment of a formal, national Pap test screening
program for all resident women in the State of Qatar from all respondents.
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Question 28
You know where to go to get a Pap test performed.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 28 aimed to capture self-efficacy and perceptions data based
on: Knowledge as to where to get a Pap test performed. This question aimed to assess degree
of self-efficacy and agreement/support for knowledge as to where to get a Pap test
performed in the State of Qatar from all respondents; allowing subsequent exclusion of
male responders.

Question 29
A Pap test has no value for you.
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 29 aimed to capture self-efficacy and perceptions data based
on: Value of a Pap test for the respondent. This question aimed to assess degree of selfefficacy and agreement/support as to if the Pap test has or has not value for the
respondent, from all respondents; allowing subsequent exclusion of male responders.
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Question 30
If a self-test for cervical cancer was available you would prefer it?
o

Strongly agree

o

Agree

o

Undecided

o

Disagree

o

Strongly disagree

Rationale: Question 30 aimed to capture self-efficacy and perceptions data based
on: Support (i.e., preference) for a self-test for cervical cancer if available. This question aimed
to assess degree of self-efficacy and agreement/support as to the preference for a self-test
for CxCa if available from all respondents; allowing subsequent exclusion of male
responders. This question may also reveal a reflection of perceived barriers to Pap test
uptakes.

Question 31
If employed, are you employed in the healthcare sector?
o

Yes

o

No

Rationale: Question 31 aimed to capture socio-demographic data based on:
Employment in the healthcare sector. This question aimed to assess likely employment in
the healthcare sector from all respondents allowing correlation with data from preceding
survey-based research conducted in the State of Qatar.
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CHAPTER 5: NEEDS-ASSESSMENT SURVEY RESULTS

Needs-Assessment Survey Data Set
Three-hundred surveys were distributed, completed, and retrieved for this study
using either the English or Arabic hard-copy versions depending on participants’
preference. Completed surveys were organized and registered as per date of data
capture, and sequentially numbered 001 to 300.

Needs-Assessment Survey Data Set Analysis
Responses from all surveys were transcribed into a dedicated Excel spreadsheet
designed with columns and drop-down menus to coincide with all survey questions and
responses. The complete data set from the spreadsheet was imported electronically into
a dedicated file using the R version 3.5.1 software (The R Foundation©) for the
generation of contingency tables, figures representing data through bar plots, and for
bivariate and multi-factorial statistical computations (Diez, Barr, & Cetinkaya-Rundel,
2015).
The entire data set was analyzed through three levels of statistical analysis. As
the survey produced exclusively categorical data, every question was considered a
variable for statistical associations. Calculations for standard deviations, confidence
intervals, and mean were not applicable.
Firstly, all data counts (i.e., responses) from all answered questions were
represented as being a proportion of the total data set of 300 surveys to produce a
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Percent Response Rate, as: [(n= /300) Response Rate: %] for each question (i.e., variable).
This was done to reflect questions possibly left unanswered by respondents. Thereafter,
responses were analyzed through univariate categorical data analyses calculating the
counts and frequencies against the total number of responses captured for every specific
question.
Secondly, every question (i.e., variable) was subjected to bivariate correlations to
reveal dependencies against all other variables based on category. This was achieved
using a G-test analysis, a robust version of the Chi-Square test. Bivariate analyses
produced a matrix revealing the p-values reflecting associations between variables for
the entire data set. The p-value threshold for statistical significance in this study was set
at p0.05.
Thirdly, multi-factorial analyses were attempted using Multiple Correspondence
analysis and clustering techniques in an effort to reveal the contributing influence
towards the dependencies throughout the data set for any one variable. However, these
multivariate analyses did not produce computations or graphics with sufficient
definition to contribute additional, meaningful statistical information, and were
therefore not incorporated in this dissertation.
All data analyses were performed using R version 3.5.1 software (The R
Foundation©).
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Needs-Assessment Survey Data Set Organization
Responses arising from each question were tabulated as counts (n) and
frequencies (%) in dedicated Tables stratified by Gender. The Tables demonstrated the
complete array of responses for all 31 questions for the entire 300 survey data set.
Percent values were rounded to 3 significant figures.
The entire survey data set was tabulated through nine Tables (Table 10-18). The
Tables demonstrated survey questions sequentially and descriptively (in italics), with all
response options as counts (n) and frequencies (%), and this data was thereafter
segregated through stratification by Gender.
The p-values generated from the bivariate statistical analyses were organized in
five Tables (Table 19-23). These Tables demonstrated matrices of p-values to reveal
statistically significant associations between variables as organized in the four
categories: Socio-demographic, Healthcare Services, Health Literacy, and Self-efficacy &
Perceptions. Significant p-values were highlighted using bold font.

Needs-Assessment Survey Limitations
Listed below are conceivable limitations arising from this survey-based research
work given its design and clinical context. As a result of these limitations and their likely
impact, potentially unreliable data or conclusions may have been proposed. Where
applicable, these limitations were rationalized and addressed in the remarks and
interpretations as appearing per survey question (i.e., variable) in the dissertation
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Discussion (Chapter 6). The intent was to alert the readership of the likely impact posed
by the following possible limitations.


Survey Comprehension: As the needs-assessment survey was voluntary, selfreported, and anonymous, it remains impractical to presume that all
respondents comprehended equally the survey questions and/or answer
options. As such, any possible incomprehension or confusion on the part of
the respondent may have led to problematic statistical computations;



Language Barriers: Nearly 81.5% of the 2.7 million people currently residing in
the State of Qatar are multi-national expatriates employed through passportbased work permits and originated from essentially all nationalities and
regions of the world. It is therefore plausible that a substantial proportion of
these expatriates may not have had English or Arabic as their mother
languages, or may not have had proficient command of these languages.
Language barriers may have impacted on respondents’ comprehension of
survey questions and answers as alluded to above;



Percent Response Rates: Percent Response Rate calculations intended to
demonstrate the percentage of respondents that answered every question in
the 300 distributed surveys. It is plausible that questions left unanswered
may have reflected Survey Comprehension or Language Barriers limitations as
argued above. However, the Percent Response Rates may also effectively
represent the potential extent and thus impact of these limitations. Also,
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Percent Response Rates may reflect conservative cultural norms obstructing
respondents’ willingness to answer questions that may have been perceived
as being sensitive;


Employment In The Healthcare Sector: As this survey-based research was
conducted in Sidra Medicine given Sidra IRB stipulations, 54.1% of survey
respondents indicated being employed in the healthcare sector (Table 18;
Question 31). It is plausible that healthcare employees may demonstrate
increased levels of CxCa health literacy compared to the general public by
virtue of their employment status in a specialized Women’s and Children’s
hospital; therefore, healthcare employees may not be representative of the
general public at large in the State of Qatar. Nevertheless, data was
interpreted cautiously herein under the presumption that responses from
healthcare workers posed a reasonable representation of the general public;



Population Representation: As an extension of the aforementioned limitation, as
this survey research was conducted within Sidra Medicine, inclusive of
patients and visitors in a specialized hospital, it is equally plausible that
survey respondents may not be representative of the general public at large
in the State of Qatar;



Incidence Of Cervical Cancer In The State Of Qatar: The incidence of CxCa in the
State of Qatar is reported as being 3.2 cases per 100,000 (Chapters 3 & 6).
However, without a dedicated registry system to track and measure actual
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incidence rates of CxCa it is plausible that the reported incidence rate is
under-estimated. Although this potential limitation is neither avoidable nor
challenged in the context of this dissertation, remarks and interpretations put
forward in Chapter 6 may need to be considered cautiously;


Question 6 (Marriage Duration): Given the overlap of years in the answer
options for Question 6, data arising from this variable may be erroneous as it
poses a delimitation on the part of the researchers. The answer options were
nonetheless intended to represent time periods, and this limitation may not
be adversely impactful pertaining to the remarks, interpretations or
conclusions raised relative to the dissertation hypotheses. Nevertheless, this
potential limitation is emphasized accordingly in the dissertation Discussion
(Chapter 6). Any additional research work conducted to assess the impact of
Marriage Duration in the clinical setting of Qatar ought to reconstruct the
answer options for Question 6 to avoid time period overlap.

Needs-Assessment Survey Tables For Categorical Data And Statistical Dependencies
Analyses
Tables (10 through 23) follow:
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TABLE 10: Categorical data from the survey data set for Questions 1-4 including Response Rates. Data presented as counts (n) with
corresponding frequencies (%) stratified by Gender.

Question
Q1
(n=300/300)
Response Rate: 100%

Description

Q2
(n=293/300)
Response Rate: 97.7%
Q3
(n=292*/300)
Response Rate: 97.7%

Gender.

*after exclusion of (1)
male under 20 years
old
Q4
(n=293/300)
Response Rate: 97.7%

Count

Frequency

53
46
80
38
13
2
51
17
N/A

17.6
15.3
26.7
12.7
4.34
0.67
17.0
5.69
N/A

Nationality.
Qatari
Middle Eastern
Asian
European
North American
South American
African
Other

Age group (years).
Under 20
20-29
30-39
40-49
50-59
Over 60
Highest education level.
Middle School
High School
University
Other

(1)
89
117
52
27
7

30.5
40.0
17.8
9.20
2.50

4
30
243
16

1.36
10.2
82.9
5.54

Women
Count
Frequency

Men
Count

Frequency

n=180
19
22
64
26
10
1
28
10
n=173

60.0%
10.6
12.2
35.6
14.4
5.56
0.56
15.6
5.56
59.0%

n=120
34
24
16
12
3
1
23
7
n=120

40.0%
28.3
20.0
13.3
10.0
2.50
0.83
19.2
5.83
41.0%

n=173
51
68
35
14
5
n=173
2
17
144
10

59.2%
28.5
39.3
20.2
8.09
2.89
59.0%
1.15
9.82
83.2
5.78

n=120
(1)
38
49
17
13
2
n=120
2
13
99
6

40.8%
31.7
40.8
14.2
10.8
1.67
41.0%
1.67
10.8
82.5
5.00
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TABLE 11: Categorical data from the survey data set for Questions 5-9 including Response Rates. Data presented as counts (n) with
corresponding percentages (%) stratified by Gender.

Question
Q5
(n=293/300)
Response Rate: 97.7%

Q6
(n=265/300)
Response Rate: 88.3%

Q7
(n=287/300)
Response Rate: 95.7%
Q8
(n=288/300)
Response Rate: 96.0%
Q9
(n=286/300)
Response Rate: 95.3%

Description
Marital status.
Never married
Married
Divorced
Widowed
Marriage duration. (Years)
Under 5
5-10
10-20
Over 20
Not applicable
Employment status.
Employed
Unemployed
Other
You have health insurance
coverage?
Yes
No
You had a Pap test before?
Yes
No
Not applicable

Count

Frequency

92
186
11
4

31.4
63.5
3.75
1.35

41
66
54
33
71

15.5
25.0
20.3
12.5
26.7

212
63
12

73.9
21.9
4.20

229
59

79.5
20.5

105
149
32

36.7
52.0
11.3

Women
Count
Frequency

Men
Count

Frequency

n=173
57
106
8
2
n=165
28
30
30
22
55
n=169
132
30
7
n=170

59.0%
32.9
61.3
4.62
1.16
62.2%
17.0
18.2
18.2
13.3
33.3
58.9%
78.1
17.7
4.14
59.0%

n=120
35
80
3
2
n=100
13
36
24
11
16
n=118
80
33
5
n=118

41.0%
29.2
66.7
2.50
1.67
37.8%
13.0
36.0
24.0
11.0
16.0
41.1%
67.8
27.9
4.24
41.0%

142
28
n=168
82
79
7

83.5
16.5
58.7%
48.8
47.0
4.17

87
31
n=118
23
70
25

73.7
26.3
41.3%
19.5
59.3
21.2
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TABLE 12: Categorical data from the survey data set for Questions 10-13 including Response Rates. Data presented as counts (n)
with corresponding percentages (%) stratified by Gender.

Question
Q10
(n=104/300)
Response Rate: 34.7%

Q11
(n=286/300)
Response Rate: 95.3%

Q12
(n=288/300)
Response Rate: 96.0%

Q13
(n=288/300)
Response Rate: 96.0%

Description
If you had a Pap test
before, when was it
performed?
1-3 years ago
4-6 years ago
Over 6 years ago
Did you, or any member of
your family have cervical
cancer before?
Yes
No
Don’t know
Cervical cancer may be
preventable.
Yes
No
Don’t know
You are aware of the Pap
test smear cytologic
method.
Yes
No

Count

Frequency

Women
Count
Frequency

Men
Count

Frequency

n=82

78.8%

n=22

21.2%

74
21
9

71.1
20.2
8.70

59
17
6
n=168

71.9
20.7
7.32
58.7%

15
4
3
n=118

68.2
18.2
13.6
41.3%

10
266
10

3.49
93.0
3.51

8
153
7
n=170

4.76
91.1
4.17
59.0%

2
113
3
n=118

1.69
95.7
2.54
41.0%

242
3
43

84.0
1.00
15.0

142
3
25
n=170

83.5
1.76
14.7
59.0%

100
0
18
n=118

84.7
0.00
15.3
41.0%

191
97

66.3
33.7

123
47

72.4
27.6

68
50

57.6
42.4
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TABLE 13: Categorical data from the survey data set for Questions 14-16 including Response Rates. Data presented as counts (n)
with corresponding percentages (%) stratified by Gender.

Question
Q14
(n=280/300)
Response Rate: 93.3%

Q15
(n=290/300)
Response Rate: 96.7%
Q16
(n=290/300)
Response Rate: 96.7%

Description
Where did you hear of the
Pap test smear cytologic
method for the first time?
Relatives, friends
Gynecologist
Mass media (newspaper,
internet, television)
Family physician
Nurse
Other
Not applicable
You have knowledge of
cervical cancer.
Yes
No
Early detection of cervical
cancer is important for
effective treatment.
Yes
No
Don’t know

Count

Frequency

Women
Count
Frequency

Men
Count

Frequency

n=171

61.0%

n=109

39.0%

46
72

16.4
25.7

25
46

14.6
26.9

21
26

19.2
23.9

41
16
5
52
48

14.6
5.71
1.89
18.6
17.1

27
14
4
26
29
n=173

15.8
8.18
2.34
15.2
17.0
59.7%

14
2
1
26
19
n=117

12.8
1.83
0.92
23.9
17.4
40.3%

203
87

70.0
30.0

135
38
n=173

78.0
22.0
59.7%

68
49
n=117

58.1
41.9
40.3%

271
1
18

93.4
0.40
6.20

159
1
13

91.9
0.57
7.51

112
0
5

95.7
0.00
4.27
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TABLE 14: Categorical data from the survey data set for Questions 17-19 including Response Rates. Data presented as counts (n)
with corresponding percentages (%) stratified by Gender.

Question
Q17
(n=286/300)
Response Rate: 95.3%

Q18
(n=290/300)
Response Rate: 96.7%

Q19
(n=287/300)
Response Rate: 95.7%

Description
Regular Pap tests may
protect you from cervical
cancer.
Yes
No
Don’t know
Cervical cancer may be
curable.
Yes
No
Don’t know
Vaccination for the
Human Papilloma Virus
protects against cervical
cancer and other HPVassociated cancers.
Yes
No
Don’t know

Count

Frequency

Women
Count
Frequency

Men
Count

Frequency

n=169

59.0%

n=117

41.0%

243
8
35

84.9
2.79
12.3

146
6
17
n=172

86.4
3.55
10.1
59.3%

97
2
18
n=118

82.9
1.71
15.4
40.7%

190
8
92

65.5
2.70
31.8

116
6
50
n=170

67.4
3.48
29.1
59.2%

74
2
42
n=117

62.7
1.69
35.6
40.8%

180
6
101

62.7
2.10
35.2

123
2
45

72.3
1.17
26.5

57
4
56

48.7
3.41
47.9
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TABLE 15: Categorical data from the survey data set for Questions 20-22 including Response Rates. Data presented as counts (n)
with corresponding percentages (%) stratified by Gender.

Question
Q20
(n=281/300)
Response Rate: 93.7%

Q21
(n=286/300)
Response Rate: 95.3%

Q22
(n=286/300)
Response Rate: 95.3%

Description
Menopausal women need
a Pap test.
Yes
No
Don’t know
More information is
needed to improve your
knowledge of cervical
cancer.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree
Regular Pap tests are a
good health practice.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree

Count

Frequency

Women
Count
Frequency

Men
Count

Frequency

n=169

60.1%

n=112

39.9%

194
8
79

69.0
2.80
28.2

124
6
39
n=169

73.3
3.55
23.1
59.1%

70
2
40
n=117

62.5
1.78
35.7
40.9%

147
117
12
10
0

51.4
40.9
4.21
3.49
0.00

89
65
10
5
0
n=169

52.7
38.5
5.92
2.95
0.00
59.1%

58
52
2
5
0
n=117

49.6
44.4
1.71
4.27
0.00
40.9%

196
72
15
2
1

68.5
25.1
5.24
0.70
0.46

118
41
7
2
1

69.8
24.2
4.14
1.18
0.59

78
31
8
0
0

66.7
26.5
6.83
0.00
0.00
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TABLE 16: Categorical data from the survey data set for Questions 23-25 including Response Rates. Data presented as counts (n)
with corresponding percentages (%) stratified by Gender.

Question
Q23
(n=284/300)
Response Rate: 94.7%

Q24
(n=285/300)
Response Rate: 95.0%

Q25
(n=288/300)
Response Rate: 96.0%

Description
Getting a Pap test
performed is too difficult.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree
You would recommend a
Pap test to your family,
friends, and colleagues.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree
Getting a Pap test is a
valued investment for
good healthcare.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree

Count

Frequency

Women
Count
Frequency

Men
Count

Frequency

n=168

59.2%

n=116

40.8%

19
36
85
116
28

6.70
12.7
29.9
40.8
9.90

11
27
50
64
16
n=169

6.55
16.1
29.7
38.1
9.52
59.3%

8
9
35
52
12
n=116

6.89
7.75
30.2
44.8
10.3
40.7%

177
89
17
1
1

62.1
31.6
5.96
0.35
0.35

109
50
9
0
1
n=169

64.5
29.6
5.32
0.00
0.59
58.7%

68
39
8
1
0
n=119

58.6
33.6
6.89
0.86
0.00
41.3%

177
95
13
2
1

61.5
33.0
4.51
0.69
0.30

104
57
7
1
0

61.5
33.7
4.14
0.59
0.00

73
38
6
1
1

61.3
31.9
5.04
0.84
0.84
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TABLE 17: Categorical data from the survey data set for Questions 26-28 including Response Rates. Data presented as counts (n)
with corresponding percentages (%) stratified by Gender.

Question
Q26
(n=287/300)
Response Rate: 95.7%

Q27
(n=286/300)
Response Rate: 95.3%

Q28
(n=282/300)
Response Rate: 94.0%

Description
You would support a Pap
test screening program for
cervical cancer.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree
A formal Pap test
screening program for
cervical cancer should be
established for all women
in the State of Qatar.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree
You know where to go to
get a Pap test performed.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree

Count

Frequency

Women
Count
Frequency

Men
Count

Frequency

n=168

58.5%

n=119

41.5%

196
81
10
0
0

68.3
28.2
3.50
0.00
0.00

116
45
7
0
0
n=168

69.0
26.8
4.17
0.00
0.00
58.7%

80
36
3
0
0
n=118

67.2
30.3
2.52
0.00
0.00
41.3%

193
78
14
1
0

67.4
27.2
5.40
0.35
0.00

116
46
6
0
0
n=165

69.0
27.4
3.60
0.00
0.00
58.5%

77
32
8
1
0
n=117

65.3
27.1
6.77
0.85
0.00
41.5%

88
84
53
34
23

31.2
29.8
18.8
12.0
8.20

59
47
27
21
11

35.8
28.5
16.4
12.7
6.67

29
37
26
13
12

24.8
31.6
22.2
11.1
10.3
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TABLE 18: Categorical data from the survey data set for Questions 29-31 including Response Rates. Data presented as counts (n)
with corresponding frequencies (%) stratified by Gender.

Question
Q29
(n=284/300)
Response Rate: 94.7%

Q30
(n=283/300)
Response Rate: 94.3%

Q31
(n=279/300)
Response Rate: 93.0%

Description
A Pap test has no value
for you.
Strongly agree
Agree
Undecided
Disagree
Strongly disagree
If a self-test for cervical
cancer was available you
would prefer it?
Strongly agree
Agree
Undecided
Disagree
Strongly disagree
If employed, are you
employed in the
healthcare sector?
Yes
No

Count

Frequency

Women
Count
Frequency

Men
Count

Frequency

n=167

58.8%

n=117

41.2%

6
12
25
103
138

2.10
4.22
8.80
36.3
48.5

2
5
11
58
91
n=168

1.19
2.99
6.58
34.7
54.5
59.4%

4
7
14
45
47
n=115

3.42
5.98
11.9
38.5
40.2
40.6%

123
88
46
23
3

43.4
31.0
16.2
8.10
1.30

73
49
29
15
2
n=161

43.5
29.2
17.3
8.92
1.19
57.7%

50
39
17
8
1
n=118

43.5
33.9
14.8
6.96
0.87
42.3%

151
128

54.1
45.9

93
68

57.7
42.3

58
60

49.2
50.8
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TABLE 19: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q18, 31) in Category 1, and Health Services variables (Q9-11) in Category 2 (significant p-values appear in bold font).
Category 2:
Healthcare
Services
Variables
Q9 Had a Pap
test before
Q10 If had a Pap
test before, when
was it performed
Q11 Family
history of CxCa

Q1

Q2

Q3

Nationality

Gender

Age group

0.00000012

0.000000006

0.5665

0.5512

Category 1: Socio-demographic Variables
Q4
Q5
Q6

Q7

Q8

Q31

Marital
status

Marriage
duration

Employment
status

Health
insurance
coverage

0.000000008

Highest
education
level
0.03798

0.00000004

0.0000032

0.000018

0.9377

Employed in
healthcare
sector
0.0003357

0.6679

0.8776

0.08175

0.3181

0.03648

0.3497

0.1781

0.4238

0.2526

0.8759

0.4913

0.593

0.4116

0.1158

0.08225

0.5599

148

TABLE 20: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q18, 31) in Category 1, and Health Literacy variables (Q12-16) in Category 3 (significant p-values appear in bold font).
Category 1: Socio-demographic Variables
Q4
Q5
Q6

Q1

Q2

Q3

Health Literacy
Variables

Nationality

Gender

Age group

Highest
education
level

Marital
status

Q12 CxCa may
be preventable
Q13 You are
aware of the Pap
test cytologic
method
Q14 Where did
you hear of the
Pap test method
before
Q15 You have
knowledge of
CxCa
Q16 Early
detection of
CxCa is
important for
effective
treatment

0.6504

0.203

0.5918

0.8562

0.03766

0.009553

0.1407

0.1212

0.1059

0.000022

0.7644

Category 3:

Q7

Q8

Q31

Marriage
duration

Employment
status

Health
insurance
coverage

0.1113

0.3495

0.09697

0.4663

Employed in
healthcare
sector
0.0001159

0.06513

0.9244

0.1719

0.1989

0.004242

0.0000065

0.04087

0.1308

0.002733

0.02039

0.1255

0.4708

0.0005167

0.000304

0.1206

0.3161

0.8381

0.7295

0.1249

0.03714

0.0003576

0.3042

0.517

0.3228

0.4728

0.5452

0.8334

0.1369

0.0004853
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TABLE 21: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q18, 31) in Category 1, and Health Literacy variables (Q17-20) in Category 3 (significant p-values appear in bold font).
Category 1: Socio-demographic Variables
Q4
Q5
Q6

Q1

Q2

Q3

Health Literacy
Variables

Nationality

Gender

Age group

Highest
education
level

Marital
status

Q17 Regular
Pap tests may
protect you from
CxCa
Q18 CxCa may
be curable
Q19 Vaccination
for HPV protects
against CxCa
and other HPVassociated
cancers
Q20
Menopausal
women need a
Pap test

0.5621

0.2776

0.3541

0.6093

0.004244

0.3612

0.8374

0.0000026

0.0002238

0.01045

0.05802

Category 3:

Q7

Q8

Q31

Marriage
duration

Employment
status

Health
insurance
coverage

0.4012

0.3052

0.07667

0.08415

Employed in
healthcare
sector
0.02428

0.9297

0.3412

0.3456

0.01827

0.1408

0.0000623

0.3403

0.6515

0.2085

0.0273

0.1814

0.4581

0.003599

0.8842

0.2837

0.8848

0.09809

0.07443

0.4436

0.02444
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TABLE 22: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q18, 31) in Category 1, and Self-efficacy & Perceptions variables (Q21-25) in Category 4 (significant p-values appear in bold font).

Category 4:
Self-efficacy &
Perceptions
Variables
Q21 Information
is needed to
improve your
knowledge of
CxCa
Q22 Regular
Pap tests are
good for health
practice
Q23 Getting a
Pap test
performed is too
difficult
Q24 You would
recommend a
Pap test to
family, friends
Q25 Getting a
Pap test done is a
valued
investment

Category 1: Socio-demographic Variables
Q4
Q5
Q6

Q1

Q2

Q3

Q7

Q8

Q31

Nationality

Gender

Age group

Highest
education
level

Marital
status

Marriage
duration

Employment
status

Health
insurance
coverage

Employed in
healthcare
sector

0.09256

0.2262

0.04504

0.5698

0.01028

0.02365

0.2134

0.8437

0.2293

0.4393

0.3629

0.1502

0.4466

0.5316

0.8438

0.1016

0.342

0.238

0.5385

0.3088

0.1085

0.2865

0.1268

0.04028

0.7795

0.7002

0.8119

0.4181

0.4246

0.07992

0.7831

0.6696

0.514

0.04067

0.1035

0.1419

0.6466

0.7317

0.4497

0.6395

0.6208

0.7334

0.1147

0.3275

0.7594
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TABLE 23: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q18, 31) in Category 1, and Self-efficacy & Perceptions variables (Q26-30) in Category 4 (significant p-values appear in bold font).

Category 4:
Self-efficacy &
Perceptions
Variables
Q26 You would
support a Pap
test screening
program for
CxCa
Q27 A formal
screening
program should
be established, all
women in Qatar
Q28 You know
where to go to
get a Pap test
performed
Q29 A Pap test
has no value for
you
Q30 If a self-test
for CxCa was
available you
would prefer it

Category 1: Socio-demographic Variables
Q4
Q5
Q6

Q1

Q2

Q3

Q7

Q8

Q31

Nationality

Gender

Age group

Highest
education
level

Marital
status

Marriage
duration

Employment
status

Health
insurance
coverage

Employed in
healthcare
sector

0.09911

0.6406

0.1715

0.05745

0.331

0.5249

0.09047

0.6946

0.6357

0.795

0.3409

0.6989

0.8102

0.6961

0.8417

0.2855

0.8942

0.4663

0.003118

0.2504

0.2983

0.1304

0.1847

0.2102

0.6531

0.6023

0.2191

0.06362

0.07646

0.1012

0.2248

0.3868

0.01878

0.4397

0.9227

0.343

0.3133

0.886

0.3237

0.699

0.1174

0.2863

0.09273

0.4196

0.2823
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Needs-Assessment Survey Data Set Representation
The entire survey data set was represented through 16 Figures. Each Figure
included 2 bar plots separated by a line for definition where possible.
Figure 1 represented responses from survey questions 1 and 2 as illustrated in
dedicated univariate bar plots. Gender was utilized as the stratification determinant
thereafter for all questions (i.e., Questions 3-31).
Responses from survey questions 3 through 31 were represented in dedicated
composite bar plots with data stratification between women and men based on counts,
and contrasted by grey-scale colors (Figures 2-16).

Needs-Assessment Survey Data Set Figures
Figures (1 through 16) follow:
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FIGURE 1: Two bar plots representing Socio-demographic survey data captured for
Questions 1 and 2 reflecting the breakdown of response counts; all respondents, for
Nationality and Gender.
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FIGURE 2: Composite figure of 2 bar plots representing Socio-demographic survey data captured for Questions 1 and 3 reflecting
the breakdown of response counts; all respondents, for Nationality and Age Group respectively stratified by Gender.
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FIGURE 3: Composite figure of 2 bar plots representing Socio-demographic survey data captured for Questions 4 and 5 reflecting
the breakdown of response counts; all respondents, for Highest Education Level and Marital Status respectively stratified by Gender.
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FIGURE 4: Composite figure of 2 bar plots representing Socio-demographic survey data captured for Questions 6 and 7 reflecting
the breakdown of response counts; all respondents, for Marriage Duration and Employment Status respectively stratified by Gender.
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FIGURE 5: Composite figure of 2 bar plots representing Socio-demographic and Healthcare Services survey data captured for
Questions 8 and 9 reflecting the breakdown of response counts; all respondents, for Health Insurance Coverage and Pap test Uptake
respectively stratified by Gender.
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FIGURE 6: Composite figure of 2 bar plots representing Healthcare Services survey data captured for Questions 10 and 11 reflecting
the breakdown of response counts; all respondents, for Preceding Pap test and Family history of Cervical Cancer respectively stratified
by Gender.
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FIGURE 7: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 12 and 13 reflecting the
breakdown of response counts; all respondents, for Cervical cancer preventability and Pap test smear awareness respectively stratified by
Gender.
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FIGURE 8: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 14 and 15 reflecting the
breakdown of response counts; all respondents, for Initial Pap test knowledge and Knowledge of cervical cancer respectively stratified by
Gender.
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FIGURE 9: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 16 and 17 reflecting the
breakdown of response counts; all respondents, for perceived Importance of early cervical cancer detection and Protection through regular
Pap tests respectively stratified by Gender.
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FIGURE 10: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 18 and 19 reflecting the
breakdown of response counts; all respondents, for perceived Cervical cancer curability and HPV vaccination protection respectively
stratified by Gender.
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FIGURE 11: Composite figure of 2 bar plots representing Health Literacy and Self-efficacy & Perceptions survey data captured for
Questions 20 and 21 reflecting the breakdown of response counts; all respondents, for perceived Need of Pap testing for menopausal
women and Need for additional information regarding cervical cancer respectively stratified by Gender.
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FIGURE 12: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 22 and 23
reflecting the breakdown of response counts; all respondents, for perceived Value of Pap testing and Difficulty in getting a Pap test
performed respectively stratified by Gender.
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FIGURE 13: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 24 and 25
reflecting the breakdown of response counts; all respondents, for Willingness to recommend the Pap test to others and Perceived healthcare
value of a Pap test respectively stratified by Gender.
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FIGURE 14: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 26 and 27
reflecting the breakdown of response counts; all respondents, for Support for a Pap test screening program and Support for a formal Pap
test screening program for all resident women in the State of Qatar respectively stratified by Gender.
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FIGURE 15: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 28 and 29
reflecting the breakdown of response counts; all respondents, for Knowledge of where to go to get a Pap test performed and Perceived
personal value of a Pap test respectively stratified by Gender.
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FIGURE 16: Composite figure of 2 bar plots representing Self-efficacy & Perceptions and Socio-demographic survey data captured
for Questions 30 and 31 reflecting the breakdown of response counts; all respondents, for Support and preference for possible self-testing
for cervical cancer and for Employment in the healthcare sector respectively stratified by Gender.
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CHAPTER 6: DISCUSSION AND CONCLUSIONS

No other diagnostic test for cancer has impacted upon the intimacies of women’s
healthcare and social welfare to a greater extent than that of the Pap test in the history of
medicine (Foltz & Kelsey, 1978; Greenwald, Cullen, & McKenna, 1987; Casper & Clarke,
1998). While the clinical Pap test remains perfect and paradoxically imperfect given
various limitations, it has a proven legacy for saving lives since its deployment in the US
in 1957 (Koss, 1989; Gordis, 2014). According to Cibas and Ducatman (2014), nearly 90%
of women in the US claim to have had a Pap test within a preceding 3 year period.
Notably, the WHO has cautioned that less than 5% of women in developing, resourcepoor nations had, or may ever have, a Pap test (Sherris, Herdman, & Elias, 2001). This
striking incongruity is at the heart of this research effort.
The experience arising from 62 years of systematic Pap test screening in various
developed nations since 1957 is incontestable (Habbema, De Kok, & Brown, 2012). As
CxCa is now widely considered a preventable disease, Garner (2003) alleged that any
woman presenting with advanced CxCa ought to be viewed as a surrogate indicator of
failed screening practice. A complementary report by Suba and Raab (2004) pertaining
to Pap test sampling in developing nations, stated that failures in CxCa screening may
be attributable to programmatic shortfalls rather than to technical limitations inherent in
the Pap test. Consequently, a paradigmatic reconsideration of priorities may be
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universally warranted to yield improved access to screening hence to improved clinical
benefits.
It is hoped that insights brought forward from the historical experience in the
US, coupled with emerging technologies both in medicine and through global
modernization, may alleviate Pap test uptake disparities to facilitate equitable CxCa
control. Similarly, that data and conclusions drawn from this research may facilitate
optimization of existing Pap test sampling practices in the State of Qatar. The ultimate
objective would be a reduction in the number of women presenting with advanced
CxCa at diagnosis in this small clinical setting.

Insights Brought Forward From The Historical Development Of The Clinical
Pap Test In The United States
In the first 57 years of the 20th century, both anticipated and unforeseen situations
influenced the evolutionary course of the VFSM from its experimental prototype
through to its clinical deployment as the refined Pap test. Despite the various dynamics,
it was political will prompted by the burden of CxCa, its detection, and its ramifications
in women’s welfare that drove the evolutionary saga of the Pap test from 1928 through
to 1957, and henceforth.

Significance Of Cervical Cancer Definition Through Carcinoma In Situ
The most significant milestone was conceptualization and detection of cervical
precancer proposed by Papanicolaou and Traut in 1941. However, it ought to be
reiterated that CxCa was a mysterious disease in 1928 when Papanicolaou introduced
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the diagnostic VFSM in the Battle Creek conference. CxCa assumed definition with the
emergence of CIS, but this also led to unforeseen challenges. Preclinical, cervical CIS
posed a hermaphroditic phenomenon in the mid-1940s: On the one hand, it enticed
gynecologists with a screening tool by which to detect and ablate asymptomatic disease
and effectively prevent invasive cancer; from the other hand, it antagonized surgeons
and pathologists perceiving professional threats and challenges to medical tenets and
practices. History has witnessed the commendable efforts by various individuals and
organizations to resolve these dilemmas. The recognition of dyskaryotic cells
purportedly pathognomonic of cervical precancer using unfamiliar cytologic smears and
stains was a major, understandable challenge to conventional anatomical pathology. Yet,
in the overall timeline of events, it was cervical precancer that reformed the prospects
for Papanicolaou, for the Pap test, and for the management and control of CxCa in the
US, and in other developed nations.
Papanicolaou and Traut’s foundational monograph in 1943 produced a tangible
target for the medical establishment. That target had been elusive until 1943 even
though cervical CIS was a recognized entity in anatomical pathology. But what wasn’t
recognized was how to identify CIS, when still preclinical, using a non-invasive method.
The new target facilitated the revelation of early CxCa in asymptomatic women through
use of the VFSM. This target transcended into the basis for CxCa prevention through
Pap test screening. Papanicolaou and Traut’s work also facilitated novel concepts in the
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epidemiology of CxCa. Through CIS, the preclinical and latent phases of the disease
became measurable targets diagnostically and therapeutically from 1941 henceforth.
It may be reasonable to speculate that neither the success of the Pap test in
preventive medicine, nor the modern institution of gynecological cytopathology, may
have materialized had it not been for the cytologic detection and clinical impact of
cervical precancer. Cervical precancer demarcated a critical threshold for public health
surveillance and disease control.

Significance Of Organizational Policy, Promotion, And Advocacy
Macro-dynamics revealed the importance of formal organizational advocacy and
policy prompted by political will, along with allocation of commensurate human and
financial resources to address societal threats such as CxCa. Ironically, Papanicolaou’s
introduction of the diagnostic VFSM through his New Cancer Diagnosis presentation in
1928 coincided with profound, distractive priorities in the US: The Great Depression; an
increasing burden and death rate due to cancer; and the Eugenics campaign calculating
the eradication of unwanted human ailments through avant-garde tactics. The overall
backdrop to Papanicolaou’s 1928 presentation was complex and unaccommodating.
During the 1920s, the dreaded disease that oftentimes led to indiscriminate silent deaths
in women was a scientific oddity. Understandably, CxCa elicited adverse attitudes of
hopelessness, fatalism, and stigmatization in both society and medicine. And the overall
nature and intimacies of CxCa along with its anatomy and possible detection aroused
prohibitions trying both women and their clinicians. The ASCC had anticipated these
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challenges at its onset in 1913 but struggled to resolve them. The evolution of
policymaking and advocacy in parallel with the momentum generated from the Pap
test’s development was critical.
The contributions by Ayre, Meigs, and Erskine were most timely by the late1940s. They offered the reenergized ACS a convenient opportunity to demonstrate
servant leadership and assuredly claim the defeat of CxCa. This triumph in preventive
medicine spawned optimism towards the effective control of other cancers based on
emerging theories of carcinogenesis. These outcomes revealed the importance of
sponsorship, promotion, and professional collaboration to bring about efficacious
methods.

Significance Of Method Framing
The seemingly failed presentation by Papanicolaou in 1928 revealed the
importance of proper framing for a novel concept in medicine, to project its relevance
and facilitate its acceptance. In the author’s opinion, Papanicolaou’s setback reflected a
lack of judgement and leadership on the part of Stockard in sanctioning Papanicolaou’s
presentation in the sidelines of a formal negative Eugenics conference; arguably an
inappropriate venue to posit a potentially significant advancement in diagnostic
medicine.
The ‘lost decade of cytopathology’ that followed Papanicolaou’s failure led to an
incalculable compounding effect on public health and lives lost due to a likely 10-year

174

postponement of screening practices for CxCa in the US. The sheer cost to humanity
may never be amply grasped.

Significance Of Political Commitment And Financial Resources
Cancer in general and its alarming trends during the 1930s threatened political
stability in the US in the lead-up to World War II. This reality prompted enactment of
the National Cancer Act in 1937. The Act created unprecedented energy backed by
funding to support cancer research through the NCI, to mitigate threats to society posed
by cancer. But it was not until Dr. Joseph C. Hinsey capitalized upon these collective
dynamics in 1939 to bring the Act’s intents and purposes to bear for the eventual
prevention of CxCa. The National Cancer Act and the organizations it spawned revealed
the importance of policy, advocacy, mission, commitment, and financial reinforcement;
all driven by societal priorities and mainstream public demands. It was the culmination
of these dynamics through Hinsey’s administrative directives that revived
Papanicolaou’s potential, mitigated his vulnerabilities, and decisively ushered the
renaissance of gynecological cytopathology through the detection of cervical CIS by the
cytologic method.

Significance Of Field Testing And Method Modeling
The NCI-sponsored Memphis and Shelby County trial field tested the VFSM’s
potential to discriminate between cervical precancer and invasive disease cytologically.
Cervical precancer became the essence for the control of CxCa as proposed through a
prominent government-funded clinical study. The Memphis trial demonstrated how
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prevalence of CxCa may only be appreciated when non-infiltrating and progressive
epithelial lesions are taken into account as being integral elements of the same disease;
as was also proposed by TeLinde attending to Henrietta Lacks in 1951 (Skloot, 2010).
This archetype in epidemiological reasoning further challenged the classical tenets of
cancer and its purported obligatory invasiveness. Nevertheless, the Memphis study
produced an actionable model for population-based Pap test screening through cervical
precancer. Under Dr. Charles Cameron’s directorship, the ACS could not but boldly
exploit the scientific momentum and endorse the Pap test for prompt deployment in
population-based screening starting in 1957.
It is also speculated by the author that the timing of the ACS’s decision to launch
Pap test screening in 1957 coincided intentionally with Papanicolaou’s retirement from
CMC-NY. The ACS presumably assessed that sufficient experience was at hand to
proceed with screening expansion. And, not doing so would have placed the ACS
within an unwarrantable predicament. Societal and women’s empowerment in the late1950s reinforced the ACS’s decision making.

Significance Of Professional Collaboration And Perception
Micro-dynamics arose predominantly from 1939 onwards following Hinsey’s
initiatives. They reflected the actions and reactions emerging from within a medical
system coming to terms with the novelty of cervical precancer, its qualification, its
detection, and its ablation, and its likely relevance in the control of other cancers with
presumptive preclinical phases. Constructive forces reflected promoters such as
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Papanicolaou, Mary Lasker, Hinsey, Ayre, Meigs, Erskine, Marchetti, and Cameron;
organizations such as US Congress, The Commonwealth Fund, and the ACS; also, the
driving expectations posed by society at large prompting political and organizational
advocacy and commitment. Disruptive forces reflected push back from pathologists,
surgeons, and other facets of the medical establishment that perceived impending
professional insecurities, encroachment, challenges to medical basics, and threats to
authority. Micro-dynamics also manifested the complex nuances arising from multidisciplinary professional collaborations toiling to establish a novel method in diagnostic
medicine, and to bridge the gaps between varying perceptions, authorities, and skillsets.

Significance Of Adequate Health Literacy And Sense Of Disease Susceptibility
Notably, the Memphis and Shelby County trial also revealed concerning gaps in
health literacy, and therefore restressed the importance of improved public awareness of
CxCa and of its symptoms if the disease was to be rendered controllable. The Memphis
trial also demonstrated the importance of clinicians’ participation and commitment, to
actively promote Pap test utilization. Ultimately, the Memphis trial recommended that
every woman be made aware that she may develop CxCa in her lifetime, regardless of
age or societal eminence. An unwavering sense of susceptibility amongst women
appeared critical for adequate acceptance of the Pap test.
Finally, despite extensive health literacy campaigns conducted by the ASCC, the
WFA, and the ACS by 1951, the Memphis trial concluded that knowledge of CxCa, and

177

of the benefits possible through Pap testing remained insufficient in that clinical setting.
Cameron’s initiatives through the ACS and through his personal publications aimed to
increase the public’s sense of self-empowerment in seeking medical attention early, and
to encourage its active participation to facilitate improved cure rates. His aim was to offset a lagging medical establishment by transferring empowerment to the public. This
empowerment continues to govern the scope of the Pap test in the US, and elsewhere
through to modern practice.

Low Incidence Of Cervical Cancer And Screening Policy In The State Of Qatar
Based on the National Cancer Framework, currently in effect in the State of Qatar
for the period 2017 through to 2022, published by the QMoPH (QMoPH National Cancer
Framework, 2017) (Appendix L), the official position of the Ministry pertaining to
cervical cancer screening is the following:
“Cervical cancer screening currently operates within Qatar on an opportunistic
basis due to the relatively low prevalence of the disease. A situational analysis to
understand the evidence base for the adoption of a national population-based
cervical cancer screening service in Qatar is currently under evaluation between
screening service providers and the MOPH.”
The QMoPH’s position is based upon the low prevalence of CxCa in the State of
Qatar. This position may be argued given the State’s modest society and conservative
cultural norms pertaining to sexual behavior. However, with opportunistic screening,
the risk for incidence under-estimation is potentially substantial. Under-estimation of

178

the actual incidence of disease may undermine the currently-enforced strategy. As stated
in Chapter 2, due to widespread, mature screening practices in the US since 1957, the
incidence of CxCa was reduced to 7.6 per 100,000 as calculated for the period 2011
through 2015 by the ACS (American Cancer Society, 2018). In contrast, with
opportunistic screening practices in the State of Qatar the incidence was 3.2 per 100,000
in 2017 (Institut Catala d’Oncologica, 20172).
Given the importance of accurate assessment of actual CxCa incidence for the
State of Qatar, the disease’s preclinical and clinical phases ought to be assessed
collectively. That is, cases of cervical CIS ought to be included in the incidence
calculations, and therefore in the formal deliberations towards screening practice design,
as was also proposed by TeLinde and the Memphis trial in 1951 (Dunn & Sprunt, 1955;
Skloot, 2010). Sherris, Herdman, & Elias (2001) support the concept that CIS cases and
invasive CxCa cases ought to be viewed as elements of the same disease, and therefore
taken equally into account epidemiologically, and particularly in clinical settings
utilizing opportunistic screening practices.
Recent efforts by the WHO calling to action the elimination of CxCa globally
through increased screening and HPV vaccination have inspired development of
mathematical models predicting the eventual elimination of the disease over a course of
50 years, from 2020 to 2069 (Simms, Steinberg, Caruana, Smith, Lew, Soerjomataram,
Castle, Bray, & Canfell, 2019). Although the incidence threshold by which CxCa may be
regarded eliminated remains undetermined, Simms et al. (2019) have proposed two
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thresholds to guide public health initiatives: (1) Under 6 new cases per 100,000, to reflect
a rare disease; and, (2) Under 4 new cases per 100,000, to reflect an eliminated disease.
Should these mathematical models prove valid, then CxCa in the State of Qatar is
arguably both rare and eliminated; however, such arguments rest upon the accuracy of
actual incidence determination. It is surmised by the author, that in the background of
opportunistic screening with lacking surveillance of actual intraepithelial and invasive
disease in the entire female population at large, the incidence rate for CxCa may be
potentially inaccurate hence misguiding. The potentially under-estimated incidence of
CxCa in Qatar is an inevitable limitation in this study.
Moreover, should organized Pap test screening practices be eventually
introduced in the State of Qatar, the actual incidence of CxCa may likely increase simply
due to expanded sampling and the revelation of preclinical, intraepithelial lesions as
HSIL. A similar phenomenon was reported following increased sampling of papillary
thyroid cancer nodules due to improved imaging and diagnostic fine needle aspiration
biopsy methods (Gordis, 2014).

Data Analyses, Remarks, And Interpretations
Tables 10-18 tabulate the categorical data for all variables arising from this
research. Tables 19-23 tabulate the p-values computed from the bivariate statistical
analyses between the variables comprising Category 1 (Socio-demographic variables)
and all other survey variables (questions) throughout Categories 2, 3 and 4, to test for
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dependency. Socio-demographic variables are utilized as the reference for likely
dependency consistently with all other survey variables throughout Tables 19-23.
The following sub-sections discuss the salient categorical results from this study
per variable and category. Also, the statistically significant associations with all other
variables were discussed with p-value insertions. Proposed remarks and interpretations
were supported by relevant published literature where available. It is emphasized that
p-values reflected statistically significant differences between correlated variables.
However, as the questions in this survey listed several answer options, follow-up, and
targeted research may be required to delve into the data set to explore likelihood of
significance between specific questions and answers. Such detailed analyses would be
beyond the scope of this dissertation relative to the hypotheses raised herein.

Interpretation Of Socio-Demographic Research Data (Questions: 1-8, 31)
Category 1 incorporated survey Questions 1-8, and 31, in an effort to generate
Socio-demographic data. Tables 10, 11 and 18 reflect categorical data captured for all
variables from all participants; and likewise, thereafter stratified by Gender. These data
were represented through Figures 1-5, and 16.

Q1 Nationality.
Percent Response Rate: 100%, from 300 surveys. Table 10 and Figures 1 and 2 represent the
breakdown of Nationality from all participants in this study. Figure 1 represents the
distribution of nationalities for all respondents inclusive; Figure 2 represents the
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nationalities of all respondents stratified by Gender. Tables 19-23 represent the bivariate
analyses and matrices of p-values.
These data produced statistically significant associations between Nationality
and: Pap test uptakes (p=0.00000012); Awareness of the Pap test cytologic method (p=0.03766);
Knowledge of CxCa (p=0.000022); CxCa curability (p=0.004244); Perceived protection through
HPV vaccination (p=0.0000026); if Menopausal women require a Pap test (p=0.01045); and
Knowledge of where to get a Pap test performed in Qatar (p=0.003118).
These overall findings suggest that statistically significant differences exist
between respondents based on Nationality, in Healthcare Services (Q9-11), Health
Literacy (Q12-20), and Self-efficacy & Perceptions (Q21-30).
Remarks:
The largest proportion of all respondents by nationality, were Asian.
Respondents with Asian nationality produced the primary proportion of 26.7% of all
nationalities; followed by a secondary proportion from Qatari nationals of 17.6%;
followed by a tertiary proportion with African nationality of 17.0%. Of all Asian
respondents, 80% were women.
The distribution of nationalities in this study suggested a representative
sampling of the various nationalities of residents currently in the population of the State
of Qatar. According to the World Population Review report for Qatar for 2018 (World
Population Review, 20181), the dominant population component was reflected by Asian
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expatriates (i.e., Indian (24%), Nepali (16%), Filipino (11%), Bangladeshi/Sri Lankan
(16%)) collectively comprising 67% of the entire 2.7 million population of Qatar. The
17.6% of Qatari respondents in this study correlated satisfactorily with the national
Qatari population in 2018, then 15% of the entire population of Qatar.
The most significant association was noted between Nationality and Pap test
uptakes (p=0.00000012). Given the dominance of Asian women respondents in this study
relative to all other nationalities (26.7%), it is likely that these women reflected the
greater variability for Pap test uptakes. Moreover, of the women respondents in this
study that indicated never been Pap tested, 48.1% had also indicated being of Asian
nationality. These findings may facilitate targeted health promotion initiatives in Qatar
based on residents’ nationalities.
Relevant Research:
Survey-based research conducted by Ma et al., (2013) to study the perceptions of
Vietnamese American women to undergo a Pap test, concluded that 53% of the
respondents reported ever having a Pap test. The study reported that the most impactful
health promotion behavioral changes, through the Health Belief Model, occurred after
an increased sense of susceptibility to developing CxCa. However, the dominant
barriers to having a Pap test were embarrassment, believing a Pap test was not required
if feeling well, and, not understanding what is being done during a Pap test.
Another survey-based study by Lee & Carvallo (2014) studied the perceived
barriers of Asian American women to undergoing a Pap test. Their study concluded that
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the most impactful parameters to influence self-efficacy and a sense of susceptibility to
CxCa were: marital status and misbeliefs. Women revealed misperceptions of what is
‘healthy’ in the absence of symptoms, and lacking knowledge of CxCa and of Pap test
screening regardless of education; educated women lacked knowledge of CxCa
screening.
Similar survey-based studies conducted in South Ghana by Ebu, Mupepi,
Siakwa, & Sampselle (2015), reported that 68.4% of respondent women had never heard
of CxCa; 93.6% had no knowledge of risk factors; and 97.7% had no knowledge of the
Pap test.
The significant associations between nationality and Pap test uptakes will be
discussed below in greater detail in the section for Q9.

Q2 Gender.
Percent Response Rate: 97.7%, from 293 of 300 surveys. Table 10 and Figure 1 represent the
Gender distribution from all respondents in this survey. Tables 19-23 represent the
bivariate analyses conducted and matrices of p-values.
From 293 respondents, 173 (59.0%) were women, and 120 (41.0%) were men.
These data produced statistically significant associations between Gender and:
Pap test uptakes (p=0.000000006); Awareness of the Pap test cytologic method (p=0.009553);
Knowledge of CxCa (p=0.000304); and Perceived protection through HPV vaccination
(p=0.0002238). However, no significant associations between Gender and Category 4
variables reflecting Self-efficacy & Perceptions were revealed.
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These overall findings suggest that statistically significant differences exist
between respondents based on Gender, in Healthcare Services (Q9-11) and in Health
Literacy (Q12-20).
Remarks:
These data suggested a relatively balanced representation of public views
through the female and male participants in this research. The lack of significant
statistical associations with Category 4 variables reflecting Self-efficacy & Perceptions
may also be realized through Figures 11-16 illustrating the relatively equivalent
response counts between women and men recorded in this study without prominent
differences.

Q3 Age group (Years).
Percent Response Rate: 97.7%, from 292 of 300 surveys. Table 10 and Figure 2 represent the
Age group distributions from all respondents, also stratified by Gender. Tables 19-23
represent the bivariate analyses conducted and matrices of p-values.
The 97.7% Response Rate was calculated after exclusion of 1 survey from a male
respondent claiming an age of less than 20. This adjustment complied with the exclusion
criterion stipulated by the Sidra IRB.
These data produced statistically significant associations between respondents’
Age group and: Pap test uptakes (p=0.000000008); Where information was received of the Pap
test (p=0.04087); and Perceived need for additional information to improve knowledge of CxCa
(p=0.04504).
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These overall findings suggest that statistically significant differences exist
between respondents based on Age group, in Healthcare Services (Q9-11), in Health
Literacy (Q12-20), and in Self-efficacy & Perceptions (Q21-30).
Remarks:
The largest proportion of age group for all respondents was the 30-39 year age
group comprising 40.0% of all respondents. Of these, women accounted for 58.0%. The
second largest age group proportion was the 20-29 year age group comprising 30.5% of
all respondents; whereas 57.3% were women. The distribution of age groups (Figure 2)
suggested a satisfactory representation of the population currently in the State of Qatar;
as in 2018, according to the ICO (Institut Catala d’Oncologica, 20172), the primary age
group of all women was 30-34 years, followed by a secondary age group of 35-39 years.
The primary age group of all men in Qatar in 2018 was 25-29 years, followed by a
secondary age group of 35-39 years. The data arising from this research correlated with
the population pyramid for Qatar being skewed towards males; representing the
relatively large population proportion comprising young expatriate men employed in
the State’s megaprojects as discussed in Chapter 3.
The highly statistically significant association noted between Age group (Q3) and
the variable Had a Pap test before? (Q9) warranted particular consideration. From the total
of 173 women that participated in this study (Table 10), 79 (45.6%) claimed never having
a Pap test. This group of women showed a primary age group of 20-29 years, followed
by a secondary age group of 30-39 years. Practically, when combined, these women
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comprised a near 40-year age bracket. As the bimodal peak ages of CxCa cases with
Stage II/III disease at presentation in Qatar were 40-44 and 60-64 years in 2014 (QMoPH
National Cancer Program, 2014), the 30-39 year respondent women, that never had a
Pap test, may represent a cohort at increased risk for developing CxCa. The significance
of these observations will be discussed in greater detail in a subsequent sub-section in
this Chapter.
Relevant Research:
Research by Kahn, Chiou, Allen, Goodman, Perlman, & Emans (1999) studied the
relationship between beliefs about Pap smears and compliance for follow-up
instructions in adolescents. Their study concluded that strategies to provide adequate
health literacy, and the implementation of an appointment reminder system, improved
Pap test uptakes in adolescents. These collaborators also suggested that healthcare
promotion initiatives ought to be age-group specific.

Q4 Highest education level.
Percent Response Rate: 97.7%, from 293 of 300 surveys. Table 10 and Figure 3 represent the
Highest education level distributions from all respondents, also stratified by Gender. Tables
19-23 represent the bivariate analyses conducted and matrices of p-values.
These data produced statistically significant associations between respondents’
Highest education level and: Pap test uptakes (p=0.03798); however, no associations with
any of the Category 3 variables, or Category 4 variables were revealed. Yet, a relatively
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weak statistical dependency was noted between Highest education level and: Support for a
Pap test screening program for CxCa (Q26) (p=0.05745).
These overall findings suggest that statistically significant differences exist
between respondents based on Highest education level, in Healthcare Services (Q9-11).
Remarks:
The largest proportion of education level revealed from all respondents and
between genders was that of University level. From 293 participants, 243 (82.9%)
indicated a university level education; when stratified by gender, women (83.2%) and
men (82.5%) indicated a university level education essentially equally. These findings
correlated with demographic vital statistics arising from the State of Qatar as published
by the ICO. According to the ICO (Institut Catala d’Oncologica, 20172), the overall adult
literacy rate from the entire Qatar population age 15 and older in 2017 was 97.8%.
Moreover, the secondary school enrollment rate from the entire Qatar population was
94.5%. Overall, the population in Qatar boasts high levels of education and literacy.
Nevertheless, these overall findings were surprising given the relatively high
literacy rates amongst residents in Qatar according to the ICO (Institut Catala
d’Oncologica, 20172), relative to the alarming proportion of respondent women in this
study claiming never having a Pap test (47.0%). These findings may facilitate targeted
health promotion initiatives in Qatar based on education levels.
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Relevant Research:
The relationship between Pap test uptakes and women’s education levels in
Qatar have been researched by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011).
Their study also reported the statistically significant dependency noted between
education level and Pap test uptake. They concluded that knowledge of CxCa and of the
Pap test was inadequate in women less than 30 years of age, and in those women with
lower education levels. Their research also revealed that knowledge of CxCa was
significantly greater in women with a University degree education.

Q5 Marital status.
Percent Response Rate: 97.7%, from 293 of 300 surveys. Table 11 and Figure 3 represent the
Marital status distributions from all respondents, also stratified by Gender. Tables 19-23
represent the bivariate analyses conducted and matrices of p-values.
The data produced statistically significant associations between respondents’
Marital status and: Pap test uptakes (p=0.00000004); Where information was received of the Pap
test (p=0.002733); and Perceived need for additional information to improve knowledge of CxCa
(p=0.01028).
These overall findings suggest that statistically significant differences exist
between respondents based on Marital status, in Healthcare Services (Q9-11), Health
Literacy (Q12-20), and Self-efficacy & Perceptions (Q21-30).
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Remarks:
The largest proportion of marital status revealed from all respondents and
between genders was that of Married. From 293 participants, 186 (63.5%) indicated being
married; when stratified by gender: women (61.3%) and men (66.7%) indicated as being
married. The data also revealed respondents never before married. From all
respondents, 92 (31.4%) indicated never been married; when stratified by gender:
women (32.9%) and men (29.2%) indicated never been married.
The most significant association was noted between Marital status and Pap test
uptakes (p=0.00000004). This association is discussed in detail in this Chapter, in the subsection describing the subset of married women never before having a Pap test.
Relevant Research:
Consistent with this dissertation, Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail
(2011) also reported a relationship between marital status and awareness of CxCa and of
Pap test screening.

Q6 Marriage duration.
Percent Response Rate: 88.3%, from 265 of 300 surveys. Table 11 and Figure 4 represent the
Marriage duration distributions from all respondents, also stratified by Gender. Tables 1923 represent the bivariate analyses conducted and matrices of p-values.
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These data produced statistically significant associations between respondents’
Marriage duration and: Pap test uptakes (p=0.0000032); When was the previous Pap test
performed (p=0.03648); Where did you hear of the Pap test method before (p=0.02039); Perceived
protection from HPV vaccination (p=0.0273); Perceived need for additional information to
improve knowledge of CxCa (p=0.02365); Perception that getting a Pap test done is too difficult
(p=0.04028); and Perceived no value of the Pap test (p=0.01878).
These overall findings suggest that statistically significant differences exist
between respondents based on Marriage duration, in Healthcare Services (Q9-11), Health
Literacy (Q12-20), and Self-efficacy & Perceptions (Q21-30). However, as marriage
duration is a potential limitation in this study, conclusions ought to be considered
cautiously.
Remarks:
Although Q6 posed a limitation in this study, the largest proportion of marriage
duration revealed from all respondents and between genders was that of Not applicable:
71 (26.7%). The second largest proportion was for 5-10 years, followed by 10-20 years.
From 265 participants, 66 (25.0%) indicated being married 5-10 years; when stratified by
gender: women (18.2%) and men (36.0%) indicated being married 5-10 years. Likewise,
18.2% of respondent women indicated being married 10-20 years.
That 26.7% of the respondents in this study (and 33.3% of women) selected Not
applicable for Q6 was surprising. The relatively large component of Not applicable may
possibly reflect reluctance by some respondents to disclose marriage durations. These
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findings may also reflect the cultural norms characteristic of a conservative society as the
one in the State of Qatar.
Relevant Research:
Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) researched women’s
attitudes in Qatar and likewise reported an association between marriage duration and
Pap test uptakes. Their research revealed a greater awareness of CxCa particularly
amongst women married for greater than 15 years, and in women with greater parity.
However, survey-based research by Alali et al., (2016) reported that increasing parity
was regarded amongst the risk factors for CxCa development in Qatar.

Q7 Employment status.
Percent Response Rate: 95.7%, from 287 of 300 surveys. Table 11 and Figure 4 represent the
Employment status distributions from all respondents, also stratified by Gender. Tables 1923 represent the bivariate analyses conducted and matrices of p-values.
These data produced statistically significant associations between respondents’
Employment status and: Pap test uptakes (p=0.000018); CxCa may be curable (p=0.01827); and
Recommendation of the Pap test to family and friends (p=0.04067).
These overall findings suggest that statistically significant differences exist
between respondents based on Employment status, in Healthcare Services (Q9-11), Health
Literacy (Q12-30), and Self-efficacy & Perceptions (Q21-30).
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Remarks:
The largest proportion of employment status revealed from all respondents and
between genders was that of Employed. From 287 participants, 212 (73.9%) indicated
being employed; when stratified by gender: women (78.1%) and men (67.8%) indicated
being employed.
The highly significant association noted between Employment status and Pap test
uptakes (p=0.000018) was remarkable as amongst the women that indicated never been
Pap tested in this study, 83.5% had health insurance coverage through employment.
These findings are discussed in greater detail in a subsequent sub-section in this
Chapter.
Relevant Research:
Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) reported greater
knowledge of CxCa in employed women in Qatar, and particularly in women with a
University degree education. Their findings are consistent with the associations revealed
through this research.

Q8 You have health insurance coverage?
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 11 and Figure 5 represent the
Health insurance coverage distribution from all respondents, also stratified by Gender.
Tables 19-23 represent the bivariate analyses conducted and matrices of p-values.

193

These data produced no dependencies with variables in Category 2 reflecting
Healthcare Services; however, significant associations were noted with Awareness of the
cytologic method (p=0.004242); and Knowledge of CxCa (p=0.03714). No dependency with
variables in Category 4 reflecting Self-efficacy & Perceptions was revealed.
These overall findings suggest that statistically significant differences exist
between respondents based on Health insurance coverage, in Health Literacy (Q12-20).
Remarks:
From 288 respondents, 229 (79.5%) indicated having health insurance coverage;
whereas, 20.5% of respondents did not. Of the genders: 83.5% of women and 73.7% of
men indicated having insurance coverage.
The significant associations noted between Health insurance coverage and
awareness of the cytologic method (p=0.004242) and of CxCa (p=0.03714) was
remarkable as 83.5% of women participants may have access to Pap testing and
therefore awareness, although, this study revealed that 45.7% of women participants
claimed never been Pap tested. These findings suggest that lacking Health insurance
coverage may be a barrier to Pap test uptakes. These findings may further support
development of population-based screening practices in Qatar

Q31 If employed, are you employed in the healthcare sector?
Percent Response Rate: 93.0%, from 279 of 300 surveys. Table 18 and Figure 16 represent
the Employment in the healthcare sector distribution from all respondents, also stratified by
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Gender. Tables 19-23 represent the bivariate analyses conducted and matrices of pvalues.
These data produced significant associations between Employment in the healthcare
sector and: Previous Pap test uptake (p=0.0003357); CxCa may be preventable (p=0.0001159);
Awareness of the Pap test cytologic method (p=0.0000065); Where information of the Pap test
was heard (p=0.0005167); Knowledge of CxCa (p=0.0003576); Knowledge of importance of early
detection of CxCa for treatment (p=0.0004853); Regular Pap tests may protect from CxCa
(p=0.02428); CxCa may be curable (p=0.0000623); Perception of protection from HPV
vaccination (p=0.003599); and Perceptions if Menopausal women need a Pap test (p=0.02444).
No dependencies with variables in Category 4 reflecting Self-efficacy & Perceptions
were revealed.
These overall findings suggest that statistically significant differences exist
between respondents based on Employment in the healthcare sector, in Healthcare Services
(Q9-11), and Health Literacy (Q12-20).
Remarks:
From 279 respondents, 151 (54.1%) indicated being employed in the healthcare
sector; whereas, 128 (45.9%) of respondents were not. Of the genders: 57.7% of women
and 49.2% of men indicated being employed in the healthcare sector. These findings
reveal relatively balanced survey participation by women and men employed in the
healthcare sector, or elsewhere.
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Although participants’ likely employment in the healthcare sector may be a
potential limitation in this study, the aforementioned statistical associations may suggest
that healthcare sector employees continue to lack sufficient awareness of CxCa and of
the Pap test not unlike the greater population of women in the State of Qatar. These
findings may reflect conservative cultural norms universal amongst women in this
nation.
Relevant Research:
Survey-based research by Alali et al., (2016) in Qatar studying the attitudes of
women employed in PHCC centers as clinical staff reported that 42.2% of these women
had a Pap test before, and that the most impactful determinant was a sense of
embarrassment and of being noticed by their colleagues.

Interpretation Of Healthcare Services Research Data (Questions: 9-11)
Q9 You had a Pap test before?
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 11 and Figure 5 represent the
distribution of responses from all respondents for Q9, also stratified by Gender. Table 19
represents the bivariate analyses conducted and matrices of p-values.
These data produced statistically significant associations with 8 of the 9 variables
in Category 1 reflecting Socio-demographic variables (Q1-9, 31).
This variable demonstrated remarkable statistically significant associations with
all Socio-demographic variables except for Health insurance coverage. These data suggest
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that statistically significant differences exist between respondents based on Pap test
uptakes throughout the variables reflecting socio-demographic attributes of all
respondents.
Remarks:
From 286 respondents, 105 (36.7%) indicated having a Pap test before; whereas,
149 (52.0%) of respondents had not, and 32 (11.3%) indicated Not Applicable. Of the
genders: 48.8% of the women had a Pap test, and 47.0% had not. These outcomes are
considered to be epidemiologically important and warranted detailed analysis. The
significance of women not having a Pap test before is discussed in a subsequent subsection in this Chapter.
The sub-set of 19.5% of men that claimed to have had a Pap test before embody a
study limitation and may be regarded a surrogate of Health Literacy inadequacies.
Arguably, any lacking awareness of CxCa or of the Pap test may have led to confusion
in either women or men respondents. It is speculated that these men had confused the
Pap test as being some other test they may have had, that may also have sounded alike
phonetically, either through the English or Arabic language.
This potential limitation may have been intensified given the variable
nationalities of the survey respondents and their likely mother languages that may have
been other than English or Arabic.
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Relevant Research:
The findings arising from this study are consistent with survey-based research by
Alali et al., (2016). In their research, they assessed knowledge of CxCa and of the Pap
test amongst women employed in PHCC centers in Qatar. Their findings revealed that
42.2% of respondent women indicated having a Pap test. The most impactful barrier was
embarrassment (17.3%), followed by inadequate knowledge of CxCa (14.8%), and that
94.5% of the participating women would prefer a female physician. These findings were
also corroborated by research from Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail
(2011) reporting that 39.4% of the respondent women had a Pap test; likewise, studies by
Metwali, Al Kindi, Shanbleh, Al Akshar, & Sarhan (2015) assessing women in the United
Arab Emirates, discovered that amongst 212 participating women, 37.2% had a Pap test.

Q10 If you had a Pap test before, when was it performed?
Percent Response Rate: 34.7%, from 104 of 300 surveys. Table 12 and Figure 6 represent the
distribution of responses from all respondents for Q10, also stratified by Gender. Table 19
represents the bivariate analyses conducted and matrices of p-values.
These data produced one statistically significant association with 1 Category 1
variable reflecting Socio-demographics: Marriage duration (p=0.03648). However, as
Marriage duration is a potential limitation in this study this association needs to be
considered cautiously.
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Remarks:
From 104 respondents, 74 (71.1%) indicated having a Pap test in the preceding 13 years; whereas, 21 (20.2%) of respondents had a Pap test in the preceding 4-6 years,
and 9 (8.70%) over 6 years prior. Of the genders, 82.0% of the respondents were women;
whereas, 71.9% of which had a Pap test within 1-3 years, 20.7% within 4-6 years, and
7.32% over 6 years prior.
The relatively low Response Rate for this survey question reflected the responses
predominantly from women. As such, that 71.9% of women that have had a Pap test had
it in the preceding 1-3 years correlated with the currently-enforced guidelines by the
QMoPH recommending that women aged 25-49 years should be screened every 3 years
(QMoPH National Cancer Program, 20161).
Relevant Research:
Survey-based research by Alali et al., (2016), assessing women employed in
PHCC centers in Qatar, reported that 9.0% had adequate knowledge of their eligibility
for Pap test sampling and an awareness of the recommended screening intervals as
endorsed by the QMoPH.
Similar survey-based research by Fernandez et al., (2009) studied the relationship
between self-efficacy and Pap test uptakes in low-income Mexican American women.
Their study reported that higher self-efficacy correlated with the likelihood of recent Pap
testing amongst these women. In contrast, research by Denny & Wright (2009) reported
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a 4.22-fold increase in the risk for developing CxCa in women that had a preceding Pap
test greater than 4-6 years prior.

Q11 Did you, or any member of your family have cervical cancer before?
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 12 and Figure 6 represent the
distribution of responses from all respondents for Q11, also stratified by Gender. Table 19
represents the bivariate analyses conducted and matrices of p-values.
These data produced no statistically significant associations with Category 1
variables reflecting Socio-demographics.
Remarks:
From 286 respondents, 10 (3.49%) indicated having a family history of CxCa;
whereas, 266 (93.0%) of respondents indicated no family history, and 10 (3.49%) did not
know. That 93.0% of respondents claimed no family history of CxCa likely reflected the
low prevalence of this disease as published for the clinical setting of the State of Qatar,
or, arguably, a lacking awareness of the disease. However, another limitation in this
study is possible under-estimation of CxCa incidence in Qatar, which may impact public
perceptions of extent of disease at large.
Relevant Research:
No pertinent research pertaining to this question could be identified arising from
Qatar.
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Interpretation Of Health Literacy Research Data (Questions: 12-20)
Q12 Cervical cancer may be preventable.
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 12 and Figure 7 represent the
distribution of responses from all respondents for Q12, also stratified by Gender. Table 20
represents the bivariate analyses conducted and matrices of p-values.
These data produced 1 statistically significant association with Category 1
variables reflecting Socio-demographics: Employment in the healthcare sector
(p=0.0001159).
These overall findings suggest that statistically significant differences exist
between respondents based on CxCa being possibly preventable, amongst survey
participants employed in the healthcare sector, or otherwise. However, as employment
in the healthcare sector is a potential limitation in this study, this association may be
potentially unreliable.
Remarks:
From 288 respondents, 242 (84.0%) indicated that CxCa may be preventable;
whereas, 3 (1.00%) of respondents said no, and 43 (15.0%) did not know. That 84.0% of
respondents claimed that CxCa may be preventable may reflect adequate awareness of
CxCa. However, that 15% of respondents did not know suggested insufficient
knowledge of CxCa preventability.
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Relevant Research:
In survey-based research in Qatar by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, &
Ismail (2011), they asked a related question: “Is it possible to detect CxCa with the Pap
test smear before symptoms appear?” Their study revealed that 62.4% of the
participating women agreed that the Pap test may detect CxCa early, compared to 37.6%
that disagreed.

Q13 You are aware of the Pap test smear cytologic method.
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 12 and Figure 7 represent the
distribution of responses from all respondents for Q13, also stratified by Gender. Table 20
represents the bivariate analyses conducted and matrices of p-values.
These data produced 4 statistically significant associations with Category 1
variables reflecting Socio-demographics: Nationality (p=0.03766); Gender (p=0.009553);
Health insurance coverage (p=0.004242); and Employment in the healthcare sector
(p=0.0000065).
These overall findings suggest that statistically significant differences exist
between respondents based on awareness of the cytologic method, in Health Services
(Q9-11).
Remarks:
From 288 respondents, 191 (66.3%) indicated awareness of the cytologic method;
whereas, 97 (33.7%) of respondents indicated no awareness. That 33.7% of respondents
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indicated not having an awareness of the Pap test cytologic method is relevant to the
hypotheses in this dissertation. These findings suggest insufficient knowledge of the
cytologic Pap test method overall; accordingly, 27.6% of women respondents indicated
no knowledge of the Pap test cytologic method. Furthermore, this variable revealed a
statistically significant association between women’s nationality, health insurance
coverage, and whether employed in the healthcare sector or not.
Relevant Research:
These data are consistent with research outcomes from work by Al-Meer, Aseel,
Al-Khalaf, Al-Kuwari, & Ismail (2011). Their research revealed that 76% of surveyed
women in Qatar indicated having adequate knowledge of the Pap test smear method;
although, levels of health literacy decreased significantly in women recently married, in
those under age 30, and in those with lower education levels. Their findings are
corroborated by research conducted in the United Arab Emirates by Metwali, Al Kindi,
Shanbleh, Al Akshar, & Sarhan (2015). Their work concluded that of 212 women
surveyed, 74.5% knew of the Pap test.

Q14 Where did you hear of the Pap test smear cytologic method for the first time?
Percent Response Rate: 93.3%, from 280 of 300 surveys. Table 13 and Figure 8 represent the
distribution of responses from all respondents for Q14, also stratified by Gender. Table 20
represents the bivariate analyses conducted and matrices of p-values.
These data produced 4 statistically significant associations with Category 1
variables reflecting Socio-demographics: Age group (p=0.04087); Marital status
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(p=0.002733); Marriage duration (p=0.02039); and Employment in the healthcare sector
(p=0.0005167).
These overall findings suggest that statistically significant differences exist
between respondents based on acquisition of knowledge of the Pap test smear method.
Remarks:
From 280 respondents, the largest proportion of responses indicated Gynecologist,
72 (25.7%); followed by Other, 52 (18.6%), and Not applicable, 48 (17.1%). That 26.9% of
women heard of the Pap test from a Gynecologist suggests these women may have had
a Pap test and therefore received medical consultation. However, the second largest
frequency of women’s responses (17.9%) indicated Not applicable. These findings may
also suggest a sub-set of women lacking health literacy for CxCa.
Relevant Research:
Research conducted in Qatar by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail
(2011) revealed a significant finding: That the majority of women respondents obtained
knowledge of CxCa from their social network (i.e., relatives and friends) rather than
from physicians. These outcomes may explain the 17.1% of respondents in this study
that indicated Not applicable for Q14. Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail
(2011) attributed this surprising finding to the absence of a well-organized screening
program in Qatar.
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In another study by Badrinath, Ghazal-Aswad, Osman, Deemas, & McIlvenny
(2004), assessing the knowledge of CxCa amongst female primary care physicians in the
United Arab Emirates, revealed that of the participating 98 physicians, 40.0% reported
ever performing a clinical Pap test procedure on their patients. These findings may not
only reflect insufficient health literacy amongst clinicians, they may also reflect lacking
procedural competencies, and perhaps a lack of Pap test promotion.

Q15 You have knowledge of cervical cancer.
Percent Response Rate: 96.7%, from 290 of 300 surveys. Table 13 and Figure 8 represent the
distribution of responses from all respondents for Q15, also stratified by Gender. Table 20
represents the bivariate analyses conducted and matrices of p-values.
These data produced 4 statistically significant associations with Category 1
variables reflecting Socio-demographics: Nationality (p=0.000022); Gender (p=0.000304);
Health insurance coverage (p=0.03714); and Employment in the healthcare sector
(p=0.0003576).
The overall findings suggest that statistically significant differences between
respondents exist relevant to knowledge of CxCa.
Remarks:
From 290 respondents, the largest proportion of responses indicated knowledge
of CxCa, 203 (70.0%); followed by No knowledge, 87 (30.0%). That 30.0% of respondents
indicated not having knowledge of CxCa is relevant to the hypotheses in this
dissertation. These data further suggest that an impactful relationship may exist
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between nationality, health insurance coverage, and employment in the healthcare
sector between the women and men participants. Given the limitations outlined for this
study, in-depth follow-up research may explore specific parameters in these associations
to facilitate health promotion initiatives in the State of Qatar.
Relevant Research:
Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011)
surveying women in Qatar revealed that over 85% of women participants had heard of
CxCa, and that knowledge of CxCa increased significantly in women in the 30-49 years
age group, in those employed, and in those with a University degree education. Studies
by Metwali, Al Kindi, Shanbleh, Al Akshar, & Sarhan (2015) surveying 212 women in
the United Arab Emirates revealed that 29% of participating women had knowledge of
CxCa.

Q16 Early detection of cervical cancer is important for effective treatment.
Percent Response Rate: 96.7%, from 290 of 300 surveys. Table 13 and Figure 9 represent the
distribution of responses from all respondents for Q16, also stratified by Gender. Table 20
represents the bivariate analyses conducted and matrices of p-values.
These data produced 1 statistically significant association with Category 1
variables reflecting Socio-demographics: Employment in the healthcare sector
(p=0.0004853).
These overall findings suggest that statistically significant differences exist
between respondents based on importance of early detection of CxCa for effective

206

treatment and likely employment in the healthcare sector. However, as employment in
the healthcare sector is a potential limitation in this study, this association may be
unreliable.
Remarks:
From 290 respondents, the largest proportion of responses indicated that early
detection of CxCa is important for effective treatment, 271 (93.4%); followed by No, 1
(0.40%), and Don’t know, 18 (6.20%). That 6.20% of respondents indicated that early
detection of CxCa was not important is relevant to the hypotheses in this dissertation. Of
the women respondents, 7.51% indicated not knowing if early detection of CxCa is
important for effective treatment.
Relevant Research:
Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011)
in Qatar, revealed that 62.4% of participating women agreed that early detection of
CxCa is important for effective treatment; whereas, 37.6% of women disagreed.

Q17 Regular Pap tests may protect you from cervical cancer.
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 14 and Figure 9 represent the
distribution of responses from all respondents for Q17, also stratified by Gender. Table 21
represents the bivariate analyses conducted and matrices of p-values.
These data produced 1 statistically significant association with Category 1
variables reflecting Socio-demographics: Employment in the healthcare sector (p=0.02428).
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These overall findings suggest that statistically significant differences exist
between respondents based on protection through regular Pap tests. However, as
employment in the healthcare sector is a limitation in this study, this association may be
unreliable.
Remarks:
From 286 respondents, the largest proportion of responses indicated that regular
Pap tests may protect from CxCa, 243 (84.9%); followed by No, 8 (2.79%), and Don’t
know, 35 (12.3%). That 12.3% of respondents indicated that regular Pap testing does not
protect from CxCa is relevant to the hypotheses in this dissertation.
Relevant Research:
Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011)
in Qatar, revealed that 64.8% of participating women agreed that the Pap test may
protect them from CxCa; whereas, 35.2% of women disagreed.

Q18 Cervical cancer may be curable.
Percent Response Rate: 96.7%, from 290 of 300 surveys. Table 14 and Figure 10 represent
the distribution of responses from all respondents for Q18, as also stratified by Gender.
Table 21 represents the bivariate analyses conducted and matrices of p-values.
These data produced 3 statistically significant associations with Category 1
variables reflecting Socio-demographics: Nationality (p=0.004244); Employment status
(p=0.01827); and Employment in the healthcare sector (p=0.0000623).
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Remarks:
From 290 respondents, the largest proportion of responses indicated that CxCa,
may be curable, 190 (65.5%); followed by No, 8 (2.70%), and Don’t know, 92 (31.8%). That
31.8% of respondents indicated no knowledge that CxCa may be curable is relevant to
the hypotheses in this dissertation, and considered a significant finding. These findings
may facilitate targeted health promotion initiatives in Qatar.
Relevant Research:
Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011)
in Qatar, revealed that 82.4% of participating women agreed that CxCa may be curable;
whereas, 17.6% of women disagreed.

Q19 Vaccination for the Human Papilloma Virus protects against cervical cancer and
other HPV-associated cancers.
Percent Response Rate: 95.7%, from 287 of 300 surveys. Table 14 and Figure 10 represent
the distribution of responses from all respondents for Q19, also stratified by Gender.
Table 21 represents the bivariate analyses conducted and matrices of p-values.
These data revealed: 4 statistically significant associations with Category 1
variables reflecting Socio-demographics: Nationality (p=0.0000026); Gender (p=0.0002238);
Marriage duration (p=0.0273); and Employment in the healthcare sector (p=0.003599).
These overall findings suggest that statistically significant differences exist
between respondents based on likely protection through HPV vaccination. However,
due to study limitations these associations may be potentially unreliable.
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Remarks:
From 287 respondents, the largest proportion of responses indicated that HPV
vaccination may protect against CxCa, 180 (62.7%); followed by No, 6 (2.10%), and Don’t
know, 101 (35.2%). That 35.2% of respondents indicated no knowledge that HPV
vaccination may protect against CxCa is relevant to the hypotheses in this dissertation,
and perhaps a major finding as HPV vaccination was recently rolled out in the State of
Qatar in February 2018. Of the women respondents, 26.5% indicated no knowledge of
protection against CxCa from HPV vaccination.
Nevertheless, despite the study limitations and the recent introduction of HPV
vaccination in Qatar, it may take numerous years before the impact of this initiative may
be epidemiologically validated. As such, this initiative should not be taken to imply that
Pap testing be diminished. Therefore, health promotion for both Pap testing and for
HPV vaccination ought to be executed in parallel, and their effectiveness would depend
on public awareness and acceptance, and on framing approaches to convey awareness
considering the various nationalities of expatriates residing in Qatar.
Relevant Research:
No pertinent survey-based research pertaining to HPV vaccination could be
identified arising from Qatar. Nevertheless, a literature search was conducted to
uncover studies to correlate with the data generated from this dissertation. That 35.2% of
all respondents in this dissertation indicated having no knowledge of HPV vaccination
is considered a significant health literacy finding.
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Studies by Senapati, Nayak, Kar, & Dwibedi (2017) reported that the risk
associated with the potential development of CxCa is HPV genotype specific, and may
be linked with HPV genotype co-infections, or multiple infections. Therefore, an
awareness of the prevalent HPV genotypes in the Qatar clinical setting would be of
epidemiological value as vaccination programs are being implemented. Jumaan,
Ghanem, Taher, Braikat, Al Awaidy, & Dbaido (2013) studied the likely prospects and
challenges that may arise from HPV vaccination in the EMENA region. Of the barriers
that they uncovered, they reported the most impactful may be the relatively poor
understanding of CxCa and HPV vaccination amongst parents, physicians, and
government officials. Their study concluded that for HPV vaccination to be successful in
the EMENA countries, and as physicians are very influential, it is crucial that clinicians
are well aware of the target practices in order to promote vaccination.
Jumaan, Ghanem, Taher, Braikat, Al Awaidy, & Dbaido (2013) also emphasized
that physicians’ awareness of HPV vaccination in the EMENA region is scarce. In a
study by Saqer, Ghazal, Barqawi, Babi, AlKhafaji, & Elmekresh (2017) to assess
knowledge of HPV vaccination in Sharjah, a United Arab Emirate, revealed that despite
the general public’s lack of knowledge pertaining to HPV vaccination, parents showed a
willingness to vaccinate their daughters if government recommended the practice, and
also provided the vaccine. The prevalence of HPV and CxCa in Qatar was studied by
Afifi, Altaher, & Abushareeda in 2005. Their studies revealed that HPV infections
commenced with early marriage and frequent coitus from early in life, and with
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increasing number of pregnancies, and that these parameters are associated with
cervical carcinogenesis amongst women in Qatar. Moreover, their studies revealed that
older women in Qatar failed to realize that the risk of developing CxCa does not reduce
with age; therefore, it is important that they seek cervical sampling accordingly.
Bansal, Elmi, Skariah, Haddad, Abu-Raddad, Al Hamadi, Mohamed-Nady,
Affifi, Ghedira, Hassen, Al-Thani, Al-Ansari, & Sultan (2014) studied the distribution of
HPV genotypes amongst Arab women in the State of Qatar. Their studies analyzed the
prevailing HPV genotypes depending on cytologic findings. Bansal et al., (2014)
reported that HPV 16 was the prevalent genotype amongst women with normal
cytologic findings, and that HPV 16, 18 and 56 were the most prevalent amongst women
with abnormal cytologic findings. Moreover, Bansal et al., (2014) discovered a high
prevalence of HPV 81 amongst the low-risk HPV lesions. They claimed these findings
are unique to the Arab population in Qatar, and unlike the epidemiology of HPV
infection in western nations.
Work by Leader, Weiner, Kelly, Hornik, & Capella (2009) revealed that women
may be more receptive to HPV vaccination if it is framed as a tool by which to prevent
CxCa, rather than for the prevention for sexually transmitted infections. Moreover, as
HPV vaccination is targeted towards adolescents and young adults, the school and
academic settings may play a significant role in promoting the uptake of HPV
vaccination through improved awareness of CxCa (Desiante, Russo, Giorgino, Caputi,
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Battista, Cipriani, & Conversano, 2017). Such an approach would greatly improve the
overall knowledge base of CxCa and that of the Pap test in the State of Qatar.

Q20 Menopausal women need a Pap test.
Percent Response Rate: 93.7%, from 281 of 300 surveys. Table 15 and Figure 11 represent
the distribution of responses from all respondents for Q20, also stratified by Gender.
Table 21 represents the bivariate analyses conducted and matrices of p-values.
These data produced 2 statistically significant associations with Category 1
variables reflecting Socio-demographics: Nationality (p=0.01045); and Employment in the
healthcare sector (p=0.02444).
These overall findings suggest that statistically significant differences exist
between respondents based on menopausal women needing a Pap test, depending on
nationality and employment in the healthcare sector although such employment is a
potential limitation in the study. As such, the aforementioned associations may be
unreliable.
Remarks:
From 281 respondents, the largest proportion of responses indicated that
menopausal women need a Pap test, 194 (69.0%); followed by No, 8 (2.80%), and Don’t
know, 79 (28.2%). That 28.2% of respondents indicated no knowledge that menopausal
women need a Pap test is relevant to the hypotheses in this dissertation. Of the women
respondents, 23.1% indicated no knowledge that menopausal women need a Pap test.
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It is speculated that such lacking health literacy amongst women may result from
equally lacking perceptions of susceptibility to CxCa development.
Relevant Research:
No pertinent survey-based research pertaining to menopausal women and their
need for Pap testing could be identified arising from Qatar. It is believed that this
dissertation reflects the first such initiative. However, Afifi, Altaher, & Abushareeda
(2005) revealed that older women in Qatar were inadequately aware that their risk of
developing CxCa does not diminish with age; therefore, it is important they seek
cervical sampling accordingly. The data arising from this dissertation are consistent with
such findings.

Interpretation Of Self-Efficacy And Perceptions Research Data (Questions: 2130)
Q21 More information is needed to improve your knowledge of cervical cancer.
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 15 and Figure 11 represent
the distribution of responses from all respondents for Q21, also stratified by Gender.
Table 22 represents the bivariate analyses conducted and matrices of p-values.
These data produced 3 statistically significant associations with Category 1
variables reflecting Socio-demographics: Age group (p=0.04504); Marital status
(p=0.01028); and Marriage duration (p=0.02365).
These overall findings suggest that statistically significant differences exist
between respondents based on need for additional CxCa information, relevant to age
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group, marital status, and marriage duration; although marriage duration is a potential
limitation in this study, hence the association may be unreliable.
Remarks:
From 286 respondents, the largest proportion of responses indicated Strongly
agree, 147 (51.4%); followed by Agree, 117 (40.9%). That 92.3% of respondents indicated
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. Of the women
respondents, 52.7% indicated strong agreement for additional information about CxCa.
Relevant Research:
No pertinent research identified.

Q22 Regular Pap tests are a good health practice.
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 15 and Figure 12 represent
the distribution of responses from all respondents for Q22, also stratified by Gender.
Table 22 represents the bivariate analyses conducted and matrices of p-values.
These data produced no statistically significant associations with Category 1
variables reflecting Socio-demographics.
However, these findings may represent women’s perceptions of beneficial health
protection through regular Pap testing; perhaps Pap test rhythmicity is perceived
positively. Nevertheless, of the women respondents in this study, 4.14% were
undecided. These findings may facilitate targeted health promotion initiatives in Qatar.
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Remarks:
From 286 respondents, the largest proportion of responses indicated Strongly
agree, 196 (68.5%); followed by Agree, 72 (25.1%). That 93.7% of respondents indicated
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. Of the women
respondents, 69.8% indicated strong agreement.
Relevant Research:
Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) posed a related question
in their survey: “Is early detection of CxCa good for treatment outcome?” Their study
reported that 64.8% of the surveyed women agreed with this question, whereas, 35.2%
disagreed.

Q23 Getting a Pap test performed is too difficult.
Percent Response Rate: 94.7%, from 284 of 300 surveys. Table 16 and Figure 12 represent
the distribution of responses from all respondents for Q23, also stratified by Gender.
Table 22 represents the bivariate analyses conducted and matrices of p-values.
These data produced 1 statistically significant association with Category 1
variables reflecting Socio-demographics: Marriage duration (p=0.04028). However,
marriage duration is a limitation in this study and the association may be unreliable.
Remarks:
From 284 respondents, the largest proportion of responses indicated Strongly
disagree, 116 (40.8%); followed by Undecided, 85 (29.9%). That 40.8% of respondents
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indicated Strongly disagree, is relevant to the hypotheses in this dissertation. However, of
the women respondents, 38.1% indicated disagreement, but 6.55% strongly agreed that
getting a Pap test performed is too difficult. These findings may suggest that 6.55% of
women faced overwhelming barriers to Pap test uptakes.
Relevant Research:
Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) posed a related question
in their survey: “If you were told that a Pap test is a simple, painless and good for early
detection of CxCa, would you like to have one?” Their study reported that 85.8% of the
surveyed women agreed with this question, whereas, 14.2% disagreed

Q24 You would recommend a Pap test to your family, friends, and colleagues.
Percent Response Rate: 95.0%, from 285 of 300 surveys. Table 16 and Figure 13 represent
the distribution of responses from all respondents for Q24, also stratified by Gender.
Table 22 represents the bivariate analyses conducted and matrices of p-values.
These data produced 1 statistically significant association with Category 1
variables reflecting Socio-demographics: Employment status (p=0.04067).
These overall findings suggest that employed women, being likely more health
literate of CxCa, may be more willing to recommend the Pap test to other women.
Remarks:
From 285 respondents, the largest proportion of responses indicated Strongly
agree, 177 (62.1%); followed by Agree, 89 (31.6%). Of the women respondents, 64.5%
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strongly agreed to recommend the Pap test to family, friends, and colleagues; however,
5.32% of respondent women were undecided, although none disagreed.
Relevant Research:
No pertinent research identified.

Q25 Getting a Pap test is a valued investment for good healthcare.
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 16 and Figure 13 represent
the distribution of responses from all respondents for Q25, also stratified by Gender.
Table 22 represents the bivariate analyses conducted and matrices of p-values.
These data produced no statistically significant associations with Category 1
variables reflecting Socio-demographics.
Overall findings may suggest positive perceptions amongst women for the likely
investment value in Pap testing.
Remarks:
From 288 respondents, the largest proportion of responses indicated Strongly
agree, 177 (61.5%); followed by Agree, 95 (33.0%). That 94.4% of respondents indicated
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. Of the women
respondents, 61.5% strongly agreed that the Pap test is a valued investment.
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Relevant Research:
No pertinent survey-based research pertaining to value of investment in a Pap
test could be identified arising from Qatar. It is believed that this dissertation reflects the
first such initiative.

Q26 You would support a Pap test screening program for cervical cancer.
Percent Response Rate: 95.7%, from 287 of 300 surveys. Table 17 and Figure 14 represent
the distribution of responses from all respondents for Q26, also stratified by Gender.
Table 23 represents the bivariate analyses conducted and matrices of p-values.
These data produced no statistically significant associations with Category 1
variables reflecting Socio-demographics.
These overall findings suggest equivalent perceptions of screening practice for
CxCa amongst women and men in the State of Qatar.
Remarks:
From 287 respondents, the largest proportion of responses indicated Strongly
agree, 196 (68.3%); followed by Agree, 81 (28.2%). That 96.5% of respondents indicated
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. The frequencies
of support for a screening program between women and men respondents were
essentially equal: 69.0% and 67.2% respectively. These findings reflecting public support
may facilitate targeted health promotion initiatives in Qatar.
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Relevant Research:
No pertinent survey-based research pertaining to public support for a Pap test
screening program for CxCa could be identified arising from Qatar. It is believed that
this dissertation reflects the first such initiative and data.

Q27 A formal Pap test screening program for cervical cancer should be established for
all women in the State of Qatar.
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 17 and Figure 14 represent
the distribution of responses from all respondents for Q27, also stratified by Gender.
Table 23 represents the bivariate analyses conducted and matrices of p-values.
These data produced no statistically significant associations with Category 1
variables reflecting Socio-demographics.
These overall findings suggest equivalent perceptions of screening practice for
CxCa amongst women and men in the State of Qatar.
Remarks:
From 286 respondents, the largest proportion of responses indicated Strongly
agree, 193 (67.4%); followed by Agree, 78 (27.2%). That 94.8% of respondents indicated
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. The frequencies
of support for a screening program between women and men respondents were
essentially equal: 69.0% and 65.3% respectively. These findings demonstrated strong
support amongst women and men respondents that the State of Qatar ought to establish
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a formal screening program for all resident women. These findings reflecting public
support may facilitate targeted health promotion initiatives in Qatar.
Relevant Research:
No pertinent survey-based research pertaining to public support for the
establishment of a formal Pap test screening program for CxCa for all women in the
State of Qatar could be identified arising from Qatar. It is believed that this dissertation
reflects the first such initiative and data.

Q28 You know where to go to get a Pap test performed.
Percent Response Rate: 94.0%, from 282 of 300 surveys. Table 17 and Figure 15 represent
the distribution of responses from all respondents for Q28, also stratified by Gender.
Table 23 represents the bivariate analyses conducted and matrices of p-values.
These data produced 1 statistically significant association with Category 1
variables reflecting Socio-demographics: Nationality (p=0.003118).
These overall findings suggest that statistically significant differences exist
between respondents based on Nationality, relevant to knowledge of where to get a Pap
test performed.
Remarks:
From 282 respondents, the largest proportion of responses indicated Strongly
agree, 88 (31.2%); followed by Agree, 84 (29.8%). That 61.0% of respondents indicated
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. However, of the
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women respondents, 16.4% were undecided, 12.7% disagreed, and 6.67% strongly
disagreed to knowing where to get a Pap test performed. These findings likely reflected
inadequacies in healthcare services availability and health literacy in general.
Relevant Research:
Survey-based research by Alali et al., (2016) revealed that 94.5% of respondent
women in Qatar preferred female physicians to male clinicians; and survey research by
Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) revealed that 55.4% of clinical
staff employed in PHCC centers in Qatar would agree to see gynecologists in well
women’s clinics. Nonetheless, data from this dissertation revealed that 16.4% of
respondent women were undecided as to where to get a Pap test performed. This is
regarded a significant finding.

Q29 A Pap test has no value for you.
Percent Response Rate: 94.7%, from 284 of 300 surveys. Table 18 and Figure 15 represent
the distribution of responses from all respondents for Q29, also stratified by Gender.
Table 23 represents the bivariate analyses conducted and matrices of p-values.
These data produced 1 statistically significant association with Category 1
variables reflecting Socio-demographics: Marriage duration (p=0.01878). However,
Marriage duration is a potential limitation in this study and the association may be
unreliable.
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Remarks:
From 284 respondents, the largest proportion of responses indicated Strongly
disagree, 138 (48.5%); followed by Disagree, 103 (36.3%). That 84.9% of respondents
indicated Strongly disagree + Disagree, is relevant to the hypotheses in this dissertation. Of
the women respondents, 54.5% indicated strong disagreement; however, 6.58% were
undecided. These overall findings likely reflect inadequacies in Self-efficacy &
Perceptions, and Health literacy, and may facilitate targeted health promotion initiatives
in Qatar.
Relevant Research:
No pertinent survey-based research pertaining to public perceptions of personal
value gained from a Pap test could be identified arising from Qatar. It is believed that
this dissertation reflects the first such initiative and data. Nonetheless, survey-based
research by Alali et al., (2016) revealed that 57.8% of respondent women in Qatar did not
perceive that they were at risk for developing CxCa therefore a Pap test was not a
priority for them.

Q30 If a self-test for cervical cancer was available you would prefer it?
Percent Response Rate: 94.3%, from 283 of 300 surveys. Table 18 and Figure 16 represent
the distribution of responses from all respondents for Q30, also stratified by Gender.
Table 23 represents the bivariate analyses conducted and matrices of p-values.
These data produced no statistically significant associations with Category 1
variables reflecting Socio-demographics.
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These overall findings may be reflective of cultural norms in a conservative
society as that in the State of Qatar.
Remarks:
From 283 respondents, the largest proportion of responses indicated Strongly
agree, 123 (43.4%); followed by Agree, 88 (31.0%). That 74.6% of respondents indicated
Strongly agree + Agree for a preference for self-testing for CxCa is an important finding.
Of the women respondents, 43.5% strongly agreed, and 29.2% agreed. These findings led
to a combined 72.6% agreement from women respondents that they would prefer a selfsampling approach if available.
Relevant Research:
No pertinent survey-based research pertaining to self-testing for CxCa could be
identified arising from Qatar. As HPV vaccination was recently rolled out in the State of
Qatar in February 2018, a literature search was conducted to uncover studies to correlate
with the data generated from this dissertation relevant to self-testing
In the US, Des Marais, Zhao, Hobbs, Sivaramam, Barclay, Brewer, & Smith (2018)
studied the likely acceptance of home self-collection of samples for HPV and sexually
transmitted infections. Their studies revealed that most participants (93.6%) indicated
not having difficulties in understanding the method and purpose of self-collection, and
that 96.3% of the participating women showed a willingness to apply this method.
Related cross-sectional studies by Chen, Hsieh, Chou, & Tzeng (2014) attempted to
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determine likelihood of women in Taiwan to apply self-sampling methods for HPV to
screen for CxCa. Their studies concluded that outreach efforts to promote self-sampling
for HPV ought to target women that have had a Pap test, who perceive themselves as
being susceptible to both HPV infection and CxCa, and women who declare a
willingness to apply the method.
Gupta, Palmer, Bik, Cardenas, Nunez, Kraal, Bird, Bowers, Smith, Walton,
Goddard, Almonacid, Zneimer, Richman, & Apte (2018) concluded that self-sampling
for HPV is a method potentially well suited to mitigate barriers such as embarrassment,
and particularly for women not participating in screening programs. It is surmised that
in the clinical setting of Qatar, self-testing methods may overcome various barriers to
Pap test sampling either perceived or experienced by women. Bais, van Kemenade,
Berkhof, Verheijen, Snijders, Voorhorst, Babovic, van Ballegooijen, Helmerhorst, &
Meijer (2006) concluded that cervicovaginal self-sampling using brushes may be an
effective alternative method to protect women that may not respond to calls for Pap test
sampling.

Particular Consideration: Sub-Set Of Married Women In The State Of Qatar
Never Before Having A Pap Test
The highly statistically significant association (p=0.000000008) revealed from this
research between the variables: Age group (Q3) and Had a Pap test before? (Q9) warranted
particular consideration and critical analysis. This association defined a sentinel group
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of women respondents that had never had a Pap test. An effort was launched to filter
through the data to uncover the likely barriers, and potential epidemiological impact.
This sub-set of women respondents that claimed never before having a Pap test
was particularly relevant to the basis of this research work. As such, the aforementioned
association was regarded as being epidemiologically significant and likely to yield
impactful insights relative to the hypotheses posed through this dissertation.
To explore this association in greater detail, categorical data captured specifically
from these women respondents were sorted and analyzed to initially determine their
ages. From the total of 173 women that participated in this study (Table 10), 79 (45.7%)
claimed never to have had a Pap test. This group of women produced a primary age
group of 20-29 years (53.2%), followed by a secondary age group of 30-39 years (30.4%).
For practicality, combined, these women formed a sub-set of respondents accounting for
45.7% of all the women that participated in this survey-based research.
The age range of this sub-set of women may be epidemiologically significant
particularly in the clinical setting of the State of Qatar. As the bimodal peak ages of
CxCa cases presenting with Stage II/III disease in Qatar in 2014 were 40-44 and 60-64
years respectively (QMoPH National Cancer Program, 2014), this sub-set of respondent
women that never had a Pap test may represent a cohort of women with preclinical
CxCa; whereby, their progressing cervical pathobiology may be asymptomatic, and
therefore not clinically suspected. In theory, based on the discussions in Chapter 3, such
women may align clinically with the one million women globally that are unaware of
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their cervical disease as estimated by the WHO (World Health Organization, 2014).
Thus, it may be these very women that would benefit the most from optimized Pap test
screening practices in the State of Qatar. Likewise, an increased sense of disease
susceptibility through targeted health promotion may also encourage these women
particularly to actively seek medical care, as was concluded by the Memphis and Shelby
County trial in 1951.
Analysis of additional categorical data specifically sorted from this sub-set of
respondent women revealed the following parameters; that: 82.2% had a University
level education; 83.5% had health insurance coverage; and, that their nationalities were
Asian, African, and Qatari by decreasing frequencies (i.e., 48.1%, 18.9% and 12.7%
respectively).
More importantly, however, of these 79 women, 35 (44.3%) were married, and 42
(53.2%) were never married. When analyzed in greater detail, this differential produced
valuable epidemiological insights.
The 53.2% of these 79 women that were neither married nor Pap test screened
correlated with the clinical recommendations enforced in the State of Qatar. Currently, it
is recommended that Pap test services be made available to women aged 25 to 64, and
when sexually active, according to the Guidelines For Cervical Cancer Screening In The State
of Qatar (QMoPH National Cancer Program, 20161) (Appendix F). Therefore, Pap testing
in these unmarried women would be discouraged by the medical establishment, unless
they are symptomatic, reflecting the hallmarks of opportunistic screening.
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However, the 44.3% of these 79 respondent women that were married and
sexually active and not Pap tested, posed a unique opportunity for methodical review.
These married women may be at greater risk for developing CxCa than the women
never married. This presumption may be valid as these women could have been Pap test
screened given the current guidelines, but were not. It was prudent to conduct a
methodical data analysis to explore the responses arising from this specific sub-set of 35
respondent women.
The analysis revealed the following categorical data reflecting Healthcare
services, Health literacy, and Self-efficacy & Perceptions, as indicated by the respondent
35 women:


20.0% had no health insurance coverage (Q8);



31.4% had no awareness of the Pap test cytologic method (Q13);



22.9% had no knowledge of CxCa (Q15);



11.4% had no knowledge that early detection of CxCa is important for
effective treatment (Q16);



14.2% had no knowledge that regular Pap tests may protect for CxCa (Q17);



28.6% did not know that CxCa may be curable (Q18);



31.4% did not know that HPV vaccination may protect against CxCa (Q19);



48.5% strongly agreed to needing additional information of CxCa (Q21);



17.1% agreed that getting a Pap test is too difficult (Q23);
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85.7% strongly agreed + agreed that a formal screening program be
established in the State of Qatar for all women (Q27);



34.2% agreed to knowing where to go to get a Pap test performed (Q28);



42.9% strongly disagreed that a Pap test has no value for them (Q29);



77.1% strongly agreed + agreed that they would prefer a self-test for CxCa if
this option was available.

If the frequencies revealed from this sub-set of women respondents may be taken
as being representative, then their extrapolation onto the entire population of women in
the State of Qatar in 2018, may potentially reflect 45.7% of 676,137 women, equating to
308,994 women in Qatar never before having a Pap test (World Population Review,
20181). And similarly, 44.3% of these 308,994 women may potentially equate to 136,884
women in Qatar that may be married, eligible to receive a Pap test, but not being Pap
test screened unless symptomatic. Such plausible realities may also explain, at least
partially, the purportedly relatively low prevalence of CxCa in the State of Qatar largely
due to opportunistic screening practice.
From the remarkable data that emerged reflecting this specific sub-set of
respondent women, preliminary findings arising from this research were described in an
Abstract/ePoster, and submitted for publication and presentation in the International
Academy of Cytology Congress in Sydney, Australia, May 5-9, 2019 (Appendix M).
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Conclusions Arising From Dissertation Aims
In this section, salient data and figures are converged in an effort to support the
hypotheses raised in this dissertation; and based on this discussion, to propose
Opportunities for Improvement with relevance to the clinical setting in the State of
Qatar.

Dissertation Aim 1
Dissertation Aim 1 proposed an evaluation of the degree of health literacy in
women and men in the State of Qatar of CxCa; of Pap test screening and of its benefits
and uptakes; and, of HPV vaccination. Based on Dissertation Aim 1, it was hypothesized
that:
The majority of women and men in the State of Qatar have adequate health
literacy of CxCa; however, they lack commensurate awareness of the disease
prevention benefits possible through Pap test screening and HPV vaccination.
The overall data captured from this needs-assessment research upheld the
hypothesis put forward. From the entire data set reflecting the views of women and
men, the following was revealed relevant to Hypothesis 1:

Health Literacy Of Cervical Cancer:


Q12 (CxCa may be preventable): Yes (84%), Don’t know (15%) (Table 12, Figure
7)



Q15 (You have knowledge of CxCa): Yes (70%), No (30%) (Table 13, Figure 8)
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Q16 (Early detection of CxCa is important for treatment): Yes (93.4%), Don’t
know (6.2%) (Table 13, Figure 9)



Q18 (CxCa may be curable): Yes (65.5%), Don’t know (31.8%) (Table 14, Figure
10)



Q21 (More information is needed about CxCa): Strongly agree (51.4%) (Table 15,
Figure 11)

Health Literacy Of Pap Test Screening:


Q13 (You are aware of the Pap test cytologic method): Yes (66.3%), No (33.7%)
(Table 12, Figure 7)



Q17 (Regular Pap test may protect you against CxCa): Yes (84.9), Don’t know
(12.2%) (Table 14, Figure 9)



Q20 (Menopausal women need a Pap test): Yes (69%), Don’t know (28.2%) (Table
15, Figure 11)



Q22 (Regular Pap tests are a good health practice): Strongly agree (68.5%) (Table
15, Figure 12)



Q25 (Getting a Pap test is a valued investment): Strongly agree (61.5%) (Table 16,
Figure 13)



Q28 (Know where to get a Pap test done): Strongly agree (31.2%) (Table 17,
Figure 15)
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Health Literacy Of HPV Vaccination:


Q19 (HPV vaccination may protect against CxCa): Yes (62.7%), Don’t know
(35.2%) (Table 14, Figure 10)

Of the aforementioned 12 survey questions, 8 revealed statistically significant
associations with respondents’ likely employment in the healthcare sector. These
findings emphasized the impact of differences in health literacy between individuals
that work in healthcare, arguably more medically literate, compared to those that did
not. Overall, the data suggests that women and men in the State of Qatar are generally
aware of CxCa (70% of all respondents indicated Yes); however, a commensurate
awareness of the disease prevention benefits possible through Pap test screening and
HPV vaccination was relatively lower; whereas, 66.3% of respondents indicated an
awareness of the Pap test cytologic method; and 62.7% of respondents indicated an
awareness of HPV vaccination benefits. Nevertheless, while these frequencies reflecting
awareness may appear relatively similar, the indications by respondents reflecting no
awareness are more significant; whereas, 31.8% of respondents did not know that CxCa
may be curable, as compared with 33.7% of respondents that did not know of the Pap
test; and 35.2% of respondents that did not know HPV vaccination may protect against
CxCa.
Therefore, if indeed 33.7% of the general public in Qatar has no awareness of the
Pap test, then this may translate to essentially 1/3 of the female population at risk for
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developing CxCa also not knowing the benefits of Pap test sampling. This reality may be
deemed alarming.
These differences in awareness may be explained by the relatively high degree of
academic literacy amongst the public in Qatar and the astonishing initiatives by the
QMoPH and the QCS to raise awareness of CxCa overall, and, by the lack of organized
screening in Qatar. As Pap test screening is neither endorsed as a population-based
disease prevention tool, nor recommended equivalently for all women deemed at risk
for developing this disease, a differential of awareness potentially exists between the
public’s knowledge of the disease, and its knowledge of the methods through which to
detect it and protect one’s self from it.
Relative to Dissertation Aim 1, and the arising hypothesis, another remarkable
finding was the identification of the sub-set of married women that never had a Pap test.
Given their specific ages ranging between 20 and 39 years of age, these women likely
comprise a cohort at highest risk for developing CxCa. This research revealed that of
these specific women: 22.9% indicated no knowledge of CxCa; compared with 31.4%
that indicated no awareness of the Pap test; and, also 31.4% that indicated no awareness
of the disease prevention benefits possible through HPV vaccination. Moreover, 48.5%
of these specific women indicated a need to acquire additional knowledge of CxCa.
Therefore, while this dissertation demonstrated adequate health literacy amongst
women and men in Qatar for CxCa, it also revealed relatively lacking commensurate
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health literacy for disease prevention benefits possible through Pap test cytopathology
and HPV vaccination.

Dissertation Aim 2
Dissertation Aim 2 proposed an evaluation of the degree of support in women
and men in the State of Qatar for the establishment of a formal Pap test screening
program for all women. Based on Dissertation Aim 2, it was hypothesized that:
The establishment of a formal Pap test screening program for CxCa for all
women in the State of Qatar is strongly supported by women and men.
The overall data captured from the needs-assessment research upheld the
hypothesis put forward. From the entire data set reflecting the views of women and
men, the following was revealed relevant to Hypothesis 2:

Support For Population-Based Cervical Cancer Screening In The State Of Qatar:


Q26 (You would support a Pap test screening program): Strongly agree (68.3%),
Strongly disagree (0.00%) (Table 17, Figure 14)



Q27 (A formal Pap test screening program for cervical cancer should be established
for all women in the State of Qatar): Strongly agree (67.4%), Strongly disagree
(0.00%) (Table 17, Figure 14)

Although neither of the aforementioned questions revealed notable statistically
significant dependencies with other variables, the data suggests that women and men in
the State of Qatar strongly support the establishment of a formal CxCa screening
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program for all women. Of all respondents, 67.4% strongly agreed with this proposition.
In contrast, from the sub-set of married women that had never before had a Pap test,
85.7% strongly agreed + agreed to the establishment of a formal screening program.
Therefore, this dissertation demonstrated strong support by women and men
respondents for the establishment of a formal Pap test screening program for CxCa for
all women in the State of Qatar.

Dissertation Aim 3
Dissertation Aim 3 proposed an evaluation of possible similarities of extent of
CxCa at presentation and diagnosis between the contemporary Qatar experience and the
historical experience in the US prior to the introduction of clinical population-based Pap
test screening in 1957. Based on Dissertation Aim 3, it was hypothesized that:
The extent of CxCa at presentation and diagnosis in the historical US experience,
prior to the introduction of clinical population-based Pap test screening in 1957,
bears similarities with the current experience of CxCa presentation in the State of
Qatar mainly due to opportunistic Pap test uptakes.
The data that was reviewed and correlated relevant to Dissertation Aim 3,
revealed various parallels between the historical experience in the US and the
contemporary experience in the State of Qatar pertaining to CxCa management, and
upheld the hypothesis put forward.
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Opportunistic Cervical Sampling:
Arguably, the detection of CxCa during the 1920s and 1930s in the US, and in the
modern Qatar setting, aligned with opportunistic cervical sampling. In the US,
symptomatic women received a reflex biopsy; in Qatar they received a reflex Pap test. In
either situation, disease identification was prompted by clinical symptoms raising the
suspicion of CxCa. However, what is unique from this parallel between the US and the
Qatar experiences is that the potential benefits from systematic Pap test screening were
unknown in the 1920s and 1930s.

Advanced-Stage Cervical Cancer At Presentation:
The alarming priorities due to CxCa experienced in contemporary developing
regions are not unlike the presentation and burden of disease experienced in the US
prior to formalization of Pap test screening in the late-1950s. A striking parallel between
the historical experience in the US and the contemporary Qatar experience was the 60%
of inoperable CxCa cases at presentation and diagnosis during the mid-1940s in the US
(Meigs, Graham, Fremont-Smith, Kapnick, & Rawson, 1943). Those outcomes were
remarkably similar with the 60% of cases presenting with Stage II/III CxCa in Qatar
primarily because of opportunistic screening in 2014 (QMoPH National Cancer
Program, 2014).
Also, Meigs, Graham, Fremont-Smith, Janzen, & Nelson (1945) reported that
despite best practice in 1945, the possible cure rate for CxCa was 40%; implying, that the
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death rate would likely have been essentially 60%. These findings form another possible
parallel with the contemporary Qatar experience of advanced disease at presentation.

Death Rates Due To Cervical Cancer:
Despite the aforementioned likely death rates from CxCa in the mid-1940s in the
US, the death rate in modern practice as a result of Pap test screening practices has fallen
to a 32.2% US-specific death rate according to the ACS (American Cancer Society, 2018).
Currently in Qatar, from the 15 CxCa cases estimated annually by the ICO, the estimated
death rate from CxCa is at 26.7% (Institut Catala d’Oncologica, 20172). The literature
reviews conducted for this dissertation did not reveal a plausible scenario to explain this
parallel; however, as 72% of the CxCa cases in Qatar are seen typically in expatriate
women, it is likely that these women repatriate to their homelands post-diagnosis for
treatment, and may be therefore lost to follow-up.

Cervical Cancer Case Registries:
In 1914, the ASCC collaborated with the Department Of Commerce, United States of
America, Bureau Of The Census, to produce a detailed registry of deaths throughout the
US based on estimated population growth; cancer type; patient age group; gender; and,
State of residence. This initiative produced a mammoth publication listing numbers of
deaths; it was essentially a death registry. However, it was not until 1952, and
henceforth, that the American Cancer Society published Cancer Facts And Figures
annually to include data for CxCa (Thun, Calle, Rodriguez, & Wingo, 2000). This was
prompted by the Memphis trial that recommended tracking of CIS. The ACS’s Cancer
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Facts And Figures not only tracked death rates, it also tracked actual incidence rates
based on robust data collection and analysis.
Currently in Qatar, the National Cancer Registry initiative was launched at HMC
in 2012 to record prevalence statistics from cancer cases (A.A. Hmaidan; personal
communication, March 21, 2016). Prevalence statistics prior to 2012 were computed from
case studies based on treatment course and outcomes, hence regarded potentially
inaccurate. As such, epidemiologically-accurate cancer statistics became available in
Qatar from 2012 henceforth through the National Cancer Program. Hence a major part of
historical case and death statistics due to CxCa is unavailable. These realities form
another parallel between the US and Qatari experiences.
Therefore, epidemiological data reviews and correlations conducted for this
dissertation demonstrated various parallels between the historical US experience and
the contemporary experience arising from CxCa management in the State of Qatar. It is
concluded that these parallels stemmed from the commonality of opportunistic cervical
sampling.

Opportunities For Improvement
In this section, the author proposes opportunities for improvement in an effort to
optimize existing Pap test cervical sampling practices in the State of Qatar. The belowmentioned proposals arise based on the research outcomes herein described. It is once
again prudent to emphasize the remarkable investments allocated towards
cytopathology services and the overall initiatives conducted to raise awareness of CxCa

238

in Qatar. However, data arising from this dissertation revealed major gaps in Health
Literacy and in the public’s sense of Self-efficacy & Perceptions towards the uptake of
Pap test services and HPV vaccination.

Tumor Registry:
Proposed is the development and implementation of a robust Tumor Registry in
the State of Qatar for CxCa.
The likely benefits may be potentially significant. Habbema, De Kok, & Brown
(2012) described the impact of such a system in the burgeoning screening systems for
CxCa in the Netherlands. A Tumor Registry designed to track all cases may also suffice
as a registry of all women residing in Qatar age 15 and older, and therefore those
women deemed at risk for developing CxCa. As all residents in Qatar have a QID
residency number, the Tumor Registry may track all women using the QID system. Such
a Registry may also form the platform for organized screening by registering initial call
to screening, by tracking adherence to rescreening recommendations based on
cytopathologic findings, and by monitoring the follow-up timelines and surgical
pathology outcomes arising from pathologic cases.
Such a Tumor Registry would better track intraepithelial and invasive disease,
and therefore result in accurate epidemiological statistics inclusive of CIS and invasive
CxCa, leading to reliable statistics by which to assess incidence, prevalence, and
treatment effectiveness. A Tumor Registry would also track women regardless of
transience. It is inevitable that with the large population of expatriate residents in Qatar,
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women that may be lost to follow-up would pose a significant limitation in the
calculation of actual incidence of CxCa in this small clinical setting. Ultimately, a
potential decision to implement systematic Pap test screening in Qatar would rest upon
accurate prevalence data. Therefore, a Tumor Registry may prove to be a most
significant prerequisite infrastructure for system optimization.
Another potential benefit from a Tumor Registry would be the standardization of
diagnostic and therapeutic practices conducted in Qatar between the private and public
healthcare providers. Alignment of these disciplines may produce substantial
information upon which to consider cervical sampling methods that would be tailored
to this clinical environment (Al-Naggar, 2012, Khan & Woolhead, 2015).
A Tumor Registry may also facilitate targeted health literacy through specific
apps disseminated throughout the extensive mobile phone networks in Qatar, based on
age-group, nationality, and mother language.

Implementation Of Population-Based Screening For All Women:
Data revealed through this dissertation research amply support the design and
implementation of population-based Pap test screening in Qatar.
The survey-based research conducted by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari,
& Ismail (2011) formed the closest study to the intents and purposes of this dissertation.
Their report concluded that the gaps in health literacy that they uncovered were
attributable to the lack of organized Pap test screening in Qatar. As such, based on the
health literacy gaps revealed through this research, and the overwhelming public

240

support for such a system as evidenced by the survey respondents, population-based
screening ought to be formally considered and implemented.
Another significant justification for Pap test population-based screening in Qatar
is the recent implementation of HPV vaccination in this nation. Given the health literacy
gaps pertaining to the awareness of HPV vaccination amongst the general public as
represented by the respondents in this research, the impact of vaccination may not be
fully realized for some time.
Another epidemiological determinant may be the unique prevalence of HPV
genotypes in this clinical setting as reported by Bansal, Elmi, Skariah, Haddad, AbuRaddad, Al Hamadi, Mohamed-Nady, Affifi, Ghedira, Hassen, Al-Thani, Al-Ansari, &
Sultan (2014). As HPV 16 was shown to be prevalent in women in Qatar even with
normal cytologic findings, continuous Pap test screening may be appropriate to track
likely progressive cervical disease.
Whereas the Pap test may not prevent the biological initiation of cervical
neoplasia, it may effectively prevent its progression to infiltrating disease by facilitating
early detection, leading to timely surgical intervention and effective ablation.
Furthermore, HPV vaccination may not protect women already infected, and which are
therefore at risk for developing cervical cancer. Therefore, despite the potential for
primary disease prevention through HPV vaccination in Qatar, systematic Pap test
screening practices seem prudent to provide outreach and coverage for all women
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deemed at risk for developing this disease as it may require decades of surveillance
before the effect of vaccination is realized in this nation.

Managing Reallocation Of Financial Resources:
It is speculated that with a potential reduction in CxCa cases in the State of Qatar
that may arise due to systematic screening, reallocation of saved financial resources may
support expanded and financially sustainable Pap test screening (Goldie, Gaffikin,
Goldhaber-Fiebert, Gordillo-Tobar, Levin, Mahe & Wright, 2005; Kim, Sharma, O’Shea,
Sweet, Diaz, Sancho-Garnier, & Seoud, 2013). Based on studies by Pendrith, Thind,
Zaric, & Sarma (2016), mitigation of the 18 cases of advanced CxCa that were reported in
2014 in Qatar, and the associated costs for treatment and follow-up, may have translated
into an, albeit conservative, saving of 1.75 million Riyals. Such savings, possible through
Pap test screening, and assuming the cost for a Pap test to be 200 Qatari Riyals (i.e.,
$54.79 USD), may have supported reallocation of funds to support 8,750 Pap tests.
Although 83.5% of the 170 respondent women that participated in this research
indicated having healthcare insurance, the remainder 16.5% of women claimed that they
did not. Therefore, a relatively significant proportion of women in the State of Qatar
may be facing financial obstacles in seeking and actually getting a Pap test performed.
Based on the overall discussions in Chapter 6, the converged survey-based data
and conclusions arising from this dissertation, optimization and transformation of
current opportunistic Pap test screening practices to systematic screening for CxCa in
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the State of Qatar may be feasible, and particularly given the advanced cytopathology
services already in operation at Sidra Medicine and HMC in this small clinical setting.
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CHAPTER 7: EPILOGUE

It is an unfortunate contradiction that in the clinical setting of opportunistic
screening, any woman ought to present with classical symptoms of invasive disease
before the Pap test may have an opportunity to forewarn that she has cervical cancer. It
is equally perplexing that in the modern epoch of unprecedented medical experience of
cervical cancer and near-complete epigenetic and molecular characterization of this
dreaded disease that any woman globally may not be able to undergo at least one
episode of cervical sampling to test for likely preclinical disease.
Cervical sampling may take various forms: It may be a classic Pap test, a
molecular HPV test, a self-test for HPV, or, simply, visualization of the uterine cervix to
inspect for anatomical aberrations through the Schiller’s iodine or acetic acid method.
Options for secondary prevention of cervical cancer both basic and sophisticated are
abound. HPV vaccination for primary prevention of the disease is also available but
requires time to mature, to yield clinical results. However, every effort is ethically
required by the medical establishment to avoid the need for tertiary prevention: The
radical methods oftentimes necessary to treat advanced cervical cancer, largely resulting
from underperforming diagnostic screening practices in preventive and societal
medicine.
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The author has witnessed the impact of systematic cervical cancer screening in
the backdrop of opportunistic screening vividly and definitively through specific career
phases in the EMENA region.
After a 14-year career phase at the Health Sciences Center in Winnipeg, Canada,
applying North American practices to manage cervical cancer, the author relocated to
the King Faisal Specialist Hospital & Research Center (KFSH&RC) in Riyadh, Saudi
Arabia, in December 1994. The KFSH&RC catered to the Royal family and employed
6,500 staff. The KFSH&RC had an outreach for nearly 25,000 individuals eligible to avail
its medical services. The cytopathology service at KFSH&RC analyzed 8,000 Pap test
cases annually. By applying systematic screening practices stipulated through CAP
accreditation, none of the women with detected intraepithelial cervical disease
developed invasive cancer. Yet, nearly 10 cases of advanced cervical cancer were
experienced annually. These women presented to Emergency seeking much delayed
care, and originated from outside the cervical sampling outreach of the KFSH&RC.
Subsequently, at King Abdulaziz Medical City hospital, in Riyadh, Saudi Arabia,
where the service outreach expanded to over 54,000 individuals, predominantly military
personnel and their extended families, intraepithelial disease was likewise managed,
and development of invasive cervical cancer was negated successfully. Nevertheless,
annually, nearly 12 cases of advanced cervical cancer were experienced; and, none of
those women had ever had a Pap test, of any form.
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These tertiary hospital experiences clearly distinguished the demarcations
between opportunistic and systematic screening practices for cervical cancer. In essence,
the screening outreach orbits of these two impressive medical institutions formed
pockets of organized screening superimposed, not unlike islands, upon a greater
landscape characterized as a sea of opportunistic screening throughout the vast Saudi
Arabian heartland. Arguably, incremental expansion of the organized screening orbits
would gradually phase out the opportunistic screening landscape; such a scenario
would mirror the clinical screening experience in the US that has formed since 1957.
Most of those diseased women that presented to cytopathology declined
treatment despite, oftentimes, favorable prognoses depending on disease-stage at
diagnosis. The societal impact of cervical cancer in this conservative, matriarchicallystructured culture is not only devastating it is also incalculable, due to its compounding
ripple effect throughout all strata of society.
At the onset of this research work, it was merely hoped that the uncovered
insights, data, and conclusions drawn, may possibly serve to optimize screening practice
in the State of Qatar. With composition of this Epilogue, it is essentially assured that
indeed, they may.
In the midst of this experience, insofar as cervical cancer is concerned, there is
ample opportunity for political commitment, for revision of clinical philosophies, and
for execution of optimized screening practices supported by strategic health promotion
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initiatives. And, in the opinion of the author, these convictions have a global relevance,
not just for the State of Qatar.
In closing, the author expresses utmost gratitude and extends sincere thanks to
the University of Nebraska Medical Center for seeing merit in this scientific work in
Preventive and Societal Medicine.

Nikolaos Chantziantoniou
May 7, 2019
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APPENDICIES

Appendix A: National Cancer Program, Qatar National Cancer Registry 2014
report published by the Qatar Ministry of Public Health.
[http://www.sidra.org/sidra-marks-international-pathology-day/]
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Appendix B: Needs-Assessment Survey (English version) [Protocol: MoPHSidra-IRB-099].

AWARENESS, KNOWLEDGE, AND PERCEPTIONS OF
SCREENING FOR CERVICAL CANCER, AND HUMAN
PAPILLOMAVIRUS VACCINATION IN QATAR
Respondent Number:

ANONYMOUS SURVEY FOR MEN AND WOMEN
Questions (English)
1 Nationality
o
o
o
o
o
o
o
o

Qatari
Middle Eastern
Asian
European
North American
South American
African
Other

2 Gender
o
o

Female
Male
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3 Age group (Years)
o
o
o
o
o
o

Under 20
20-29
30-39
40-49
50-59
Over 60

4 Highest education level
o
o
o
o

Middle School
High School
University
Other

5 Marital status
o
o
o
o

Never married
Married
Divorced
Widowed

6 Marriage duration (Years)
o
o
o
o
o

Under 5
5-10
10-20
Over 20
Not applicable

7 Employment status
o
o
o

Employed
Unemployed
Other

8 You have health insurance coverage
o
o

Yes
No
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9 You had a Pap test before
o
o
o

Yes
No
Not applicable

10 If you had a Pap test before, when was it
performed
o
o
o

1-3 years ago
4-6 years ago
Over 6 years ago

11 Did you, or any member of your family
have cervical cancer before
o
o
o

Yes
No
Don’t know

12 Cervical cancer may be preventable
o
o
o

Yes
No
Don’t know

13 You are aware of the Pap test smear
cytologic method
o
o

Yes
No
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14 Where did you hear of the Pap test smear
cytologic method for the first time
o
o
o
o
o
o
o

Relatives, friends
Gynecologist
Mass media (newspaper, internet,
television)
Family physician
Nurse
Other
Not applicable

15 You have knowledge of cervical cancer
o
o

Yes
No

16 Early detection of cervical cancer is
important for effective treatment
o
o
o

Yes
No
Don’t know

17 Regular Pap tests may protect you from
cervical cancer
o
o
o

Yes
No
Don’t know

18 Cervical cancer may be curable
o
o
o

Yes
No
Don’t know
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19 Vaccination for the Human Papilloma
Virus protects against cervical cancer and
other HPV-associated cancers
o
o
o

Yes
No
Don’t know

20 Menopausal women need a Pap test
o
o
o

Yes
No
Don’t know

21 More information is needed to improve
your knowledge of cervical cancer
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

22 Regular Pap tests are a good health
practice
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

23 Getting a Pap test performed is too
difficult
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree
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24 You would recommend a Pap test to your
family, friends, and colleagues
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

25 Getting a Pap test is a valued investment
for good healthcare
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

26 You would support a Pap test screening
program for cervical cancer
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

27 A formal Pap test screening program for
cervical cancer should be established for all
women in the State of Qatar
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree
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28 You know where to go to get a Pap test
performed
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

29 A Pap test has no value for you
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

30 If a self-test for cervical cancer was
available you would prefer it
o
o
o
o
o

Strongly agree
Agree
Undecided
Disagree
Strongly disagree

31 If employed, are you employed in the
healthcare sector?
o
o

Yes
No

Thank you for your participation
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Appendix C: Symposium Compendium (The 1st Century Of Gynecological
Cytopathology, The Pap test – Then, Now And The Future), conducted
December 7, 2014. [https://www.sidra.org/media/newsroom/2014/december/sidra-medical-and-research-center-hosts-symposiu/]
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Appendix D: Symposium Goals and Objectives (The 1st Century Of
Gynecological Cytopathology, The Pap test – Then, Now And The Future),
conducted December 7, 2014. [https://www.sidra.org/media/newsroom/2014/december/sidra-medical-and-research-center-hosts-symposiu/]
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Appendix E: Symposium Program Schedule (The 1st Century Of Gynecological
Cytopathology, The Pap test – Then, Now And The Future), conducted
December 7, 2014. [https://www.sidra.org/media/newsroom/2014/december/sidra-medical-and-research-center-hosts-symposiu/]
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Appendix F: National Cancer Program, Guidelines For Cervical Cancer
Screening In The State Of Qatar report (2016) published by the Qatar Ministry
of Public Health.
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Appendix G: National Cancer Program, Guideline For Suspected Cancer
Referral In The State Of Qatar report (2016) published by the Qatar Ministry of
Public Health. [https://www.moph.gov.qa/healthstrategies/Documents/MOPH_%20Suspected%20Cancer%20Referral%20Guide
line%20for%20the%20State%20of%20Qatar_V1_2016.pdf]
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Appendix H: Cervical cancer health literacy campaign: “Be Well”, produced by
the Qatar Cancer Society (2017). [http://www.qatarisbooming.com/article/qcsurges-women-go-cervical-cancer-screening]
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Appendix I: The National Health Strategy 2018-2022; Our Health Our Future
(2018), published by the Qatar Ministry of Public Health.
[https://www.moph.gov.qa/HSF/Documents/short%20report%20eng%2020.03.2
018.pdf]
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Appendix J: The National Clinical Guidelines For The State Of Qatar (2nd
Edition, 2017), published by the Qatar Ministry of Public Health.
[https://www.moph.gov.qa/healthstrategies/Documents/April%202017%20clinical%20guidline%20en.pdf]
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Appendix K(a): Infographic, What Is Cervical Cancer; a 2-page fold-out
brochure produced by the Ministry of Public Health, State of Qatar (Front and
Back covers). [www.moph.gov.qa]

285

Appendix K(b): Infographic, What Is Cervical Cancer; a 2-page fold-out
brochure produced by the Ministry of Public Health, State of Qatar (Pages 2
and 3). [www.moph.gov.qa]
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Appendix L: The National Cancer Framework – Achieving Excellence In Cancer
Care: A Vision for 2022, published by the Qatar Ministry of Public Health.
[https://www.moph.gov.qa/publications/Documents/Health%20Publications/National
%20Cancer%20Framework%20English.pdf]
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Appendix M: Abstract/ePoster, International Academy of Cytology Congress,
Sydney, Australia, May 5-9, 2019
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